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CHAPTER 1
General Introduction
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1. Autosomal Dominant Polycystic Kidney Disease
Autosomal	Dominant	Polycystic	Kidney	Disease	(ADPKD)	is	a	heritable	genetic	disorder	with	
a	prevalence	of	<5/10.000	 in	 the	European	Union1.	 The	major	hallmark	of	ADPKD	 is	 the	
formation	of	many	fluid-filled	cysts	in	the	kidneys,	which	ultimately	impairs	the	normal	renal	
structure	and	function,	leading	to	end-stage	renal	disease	(ESRD)2,3.	Additionally,	extrarenal	
manifestations	such	as	liver	and	pancreas	cysts	and	cardiovascular	abnormalities	are	also	
present2.
In	the	majority	of	the	cases,	ADPKD	is	caused	by	a	mutation	in	either	of	two	genes:	PKD1 
in	85%	of	the	case;	PKD2	in	15%	of	the	cases.	PKD1/2	genes	encode	for	Polycystin	1	(PC1)	
and	Polycystin	2	(PC2),	respectively2.	PC1	is	a	very	large	membrane	protein	of	4303	amino	
acids,	with	a	 long	extracellular	N-terminal,	 eleven	 transmembrane	domains,	 and	a	 small	
intracellular C-terminal4.	PC2	is	a	much	smaller	transmembrane	protein	of	968	amino	acids,	
with	six	transmembrane	domains,	and	intracellular	N-	and	C-terminal5.	The	polycystins	are	
localised	at	various	location	in	a	renal	epithelial	cell.	Particularly,	PC1	expression	has	been	
observed	at	the	apical	and	basal	side	of	the	epithelial	cells,	the	primary	cilium,	and	several	
lateral	junctions.	PC2,	instead,	have	been	observed	mainly	at	the	primary	cilium,	basolateral	
membrane	 and	 endoplasmic	 reticulum6.	 The	 exact	 functions	 of	 these	 two	 proteins	 are	
still	not	completely	understood.	PC1	may	function	as	a	receptor	able	to	respond	to	both	
mechanical	and	chemical	signals	and	transducing	them	to	downstream	signalling.	Indeed,	
the	intracellular	portion	of	the	protein	can	be	cleaved	and	translocate	to	the	nucleus	where	
it	interacts	with	several	transcription	factors	like	β-catenin	and	STATs7-10.	PC2	seems	to	be	a	
non-selective	cation	channel	and	might	be	regulating	the	intracellular	Ca2+	concentration,	
influencing	 several	 signalling	 pathways4,6.	 However,	 the	molecular	mechanisms	 that	 lead	
to	 cyst	 initiation	and	progression	after	 the	 loss	of	 functional	 levels	of	PC1/2	are	 still	not	
understood.
Conversely,	 the	 pathophysiology	 of	 the	 disease	 progression	 is	 mainly	 known	 (Figure	 1).	
In	most	cases,	ADPKD	patients	carry	a	germline	mutation	 in	one	allele	of	PKD1/2	 genes.	
Throughout	life,	due	to	somatic	mutations	in	the	unaffected	allele	(second	hit	mutations)	
or	to	stochastic	fluctuations	in	the	gene	dosage	of	PKD1/2	(haploinsufficiency),	the	level	of	
expression	of	PC1/2	drops	below	a	critical	threshold11.	As	a	consequence,	renal	epithelial	
cells	are	more	prone	to	cyst	formation.	Interestingly,	the	time	between	the	critical	reduction	
of	PC1/2	and	cyst	 initiation	can	be	 influenced	by	the	biological	context.	As	evidenced	by	
several	 studies,	 differences	 in	 timing	 and	 location	 of	 gene	 inactivation,	 the	 metabolic	
status,	the	genetic	context	and	introduction	of	renal	injury	can	influence	cyst	formation	and	
progression12.	Once	 cysts	 have	 been	 formed,	 proliferation	 and	 fluid	 secretion	 contribute	
to	the	cyst	size	increase,	which	eventually	cause	stress	on	the	surrounding	tissue	resulting	
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in	 local	 injury	 and	 fibrosis13.	 In	 the	 advanced	 stages	 of	 the	 disease,	 cystic	 kidneys	 are	
characterised	by	 local	 injury,	production	of	growth	factors	and	cytokines,	 infiltrating	cells	
and	progressive	fibrosis,	which	ultimately	lead	to	loss	of	renal	function11.
Figure 1. Disease progression in ADPKD
A single PKD1 or PKD2	allelic	mutation	is	inherited	in	patients	affected	with	ADPKD.	Later	in	life,	due	to	a	second	
hit	mutation	in	the	unaffected	allele	or	to	stochastic	variation	in	gene	expression,	the	level	of	PC1/2	expression	
drops	under	a	critical	threshold.	As	a	result,	epithelial	cells	are	more	prone	to	 initiate	cyst	formation.	The	time	
between	the	critical	reduction	of	PC1/2	levels	and	the	initiation	of	the	cysts	is	variable	and	can	be	influenced	by	
other	events,	 for	example,	 renal	 injury.	After	 injury,	 the	 tissue	 repair	occurs	 in	 the	absence	of	 sufficient	 levels	
of	PC1/2	resulting	in	an	abnormal	tubular	epithelium.	The	structurally	altered	epithelial	cells	are	more	prone	to	
cyst	formation,	accelerating	disease	progression.	After	cysts	are	formed,	increased	proliferation	and	altered	fluid	
secretion	help	 the	cyst	 to	grow	and	expand,	compressing	 the	surrounding	 tissue.	Mechanical	 stress,	as	well	as	
secretion	of	cytokines	and	growth	factors,	generate	additional	injury	locally,	which	contributes	to	cyst	formation	
and	fibrosis	deposition.	In	the	more	advanced	stages	of	the	disease,	the	tissue	is	increasingly	fibrotic,	with	visible	
cellular	infiltrates	and	loss	of	normal	parenchyma.	Image	from	Happé	et al. 11
2. Renal injury and repair mechanisms 
Following	a	renal	 insult,	 the	kidneys	are	able	to	repair	 the	 injury	themselves	by	 inducing	
proliferation	of	surviving	tubular	epithelial	cells14.	During	this	regeneration	phase,	tubular	
epithelial	 cells	 are	 lost	 or	 show	an	 aberrant	morphology	 (e.g.,	 loss	 of	 brush	 border	 and	
flattening	 of	 proximal	 tubular	 epithelial	 cells).	 Also,	 infiltration	 of	 inflammatory	 cells	
is	observed15.	All	 these	events	ensure	a	proper	 repair	of	 kidney	 structures	and	 function.	
However,	 in	some	cases	the	damage	is	too	extensive,	or	the	 injury	 insult	persists	 leading	
to	tissue	remodelling,	progressive	fibrosis	and	loss	of	renal	function.	This	fibrotic	phase	is	
characterised	 by	 chronic	 inflammation,	 expansion	 of	 alpha-smooth	muscle	 actin	 (αSMA)	
positive	cells,	capillary	rarefaction	and	hypoxia,	which	fuel	the	deposition	of	extracellular	
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matrix	(ECM)	and,	at	the	same	time,	perpetuate	local	injury	leading	eventually	to	chronic	
kidney	injury	(CKD)	and	ESRD16	(Figure	2a).
3. Renal injury and progression of ADPKD 
The	link	between	cyst	progression	and	injury	has	been	already	suggested	by	Weimbs,	who	
postulated	that	a	possible	role	for	PC1	is	to	sense	renal	injury	via	changes	in	luminal	fluid	
flow.	As	a	result,	PC1	activates	molecular	pathway	transducers,	such	as	mTOR	and	STAT6,	
leading	to	increased	proliferation	and	repair	of	the	injured	kidney	tissue.	In	ADPKD,	reduced	
levels	 of	 PC1	might	 trigger	 the	 activation	 of	 proliferation	 even	 in	 the	 absence	 of	 injury,	
resulting	 in	 cyst	 growth	 and	 expansion17.	 However,	 especially	 in	 adult	 kidneys,	 deletion	
of Pkd1	 alone	does	not	 immediately	 translate	 in	 cyst	 formation,	which	occurs	only	 after	
a	 lag	period.	Another	event,	such	as	renal	 injury,	must	occur	to	start	cyst	 formation17.	 In	
line	with	this	idea,	several	research	groups	employing	different	kinds	of	renal	injury	(e.g.,	
nephrotoxic	 compound,	 ischemia-reperfusion	 or	 unilateral	 nephrectomy)	 demonstrated	
how	 acute	 kidney	 injury	 (AKI)	 was	 able	 to	 speed-up	 cyst	 progression	 in	 mice18-22.	
Additionally,	cyst	expansion	causes	mechanical	stress	to	the	surrounding	tissue	and	vessels	
together	with	the	secretion	of	cytokines	and	growth	factors,	activating	pathways	involved	
in	cyst	progression	and	resulting	in	a	snowball	effect	that	supports	more	cyst	formation13.	
Interestingly,	 various	mechanisms	normally	 active	during	 the	 injury-repair	 phase	 such	as	
proliferation,	inflammation,	cell	differentiation,	cytokines	and	growth	factors	secretion,	are	
also	 activated	during	 PKD	progression,	 and	 largely	 overlap	with	 the	mechanisms	 at	 play	
during	renal	development17,22-24.	In	fact,	renal	epithelial	cells	in	ADPKD	kidneys	often	appear	
“dedifferentiated”	with	 reduced	 expression	of	 the	 epithelial	marker	 E-cadherin,	which	 is	
compensated	by	increased	expression	of	the	mesenchymal	marker	N-cadherin.	The	switch	in	
cadherins	seems	to	be	a	direct	effect	of	the	missing	interaction	of	PC1/2	with	the	E-cadherins	
at	the	adherens	junctions.	As	a	consequence,	the	cells	lose	the	proper	polarisation	resulting	
in	a	less	differentiated	phenotype	and	alterations	in	cellular	functions25,26.	Moreover,	ADPKD	
cells	re-express	genes	normally	expressed	during	developmental	stages	and	silenced	in	adult	
tissues,	 in	 line	with	 the	partial	 dedifferentiated	phenotype	observed27.	 Altogether,	 these	
events	can	ultimately	contribute	to	disease	progression.	In	a	normal	situation,	reactivation	
of	 the	 aforementioned	 pathways	 following	 renal	 injury	 allows	 remodelling	 of	 the	 tissue	
and	a	proper	organ	repair.	Instead,	in	a	context	of	PKD-related	gene	mutations,	aberrant	or	
chronic	activation	of	 these	developmental	pathways	and	repair/remodelling	mechanisms	
results	in	exacerbation	of	the	disease	(Figure	2b).	
In	 the	 following	paragraphs,	 I	will	discuss	some	of	 the	main	pathways	 involved	 in	 injury-
repair	and	ADPKD.
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Figure 2. The evolution of injury in normal and Pkd1 deficient kidneys 
a)	After	injury,	the	renal	epithelium	can	regenerate	the	damaged	and	lost	tissue.	This	phase	is	characterised	by	the	
dedifferentiation	and	proliferation	of	epithelial	cells,	as	well	as	the	recruitment	of	leucocytes	and	the	activation	
of	 fibroblasts	 in	 myofibroblasts.	When	 all	 these	 processes	 work	 harmoniously,	 the	 tissue	 is	 restored	 and	 the	
injury	 resolved.	 The	 infiltrating	macrophages	 undergo	 an	M1-like	 to	M2-like	 switch	 and	 help	 in	 the	 resolution	
of	the	inflammatory	response	and	renal	growth.	However,	in	case	of	severe	damage	or	chronic	activation	of	the	
inflammatory	signalling,	it	is	possible	to	have	maladaptive	repair.	Proliferating	cells	may	arrest	in	G2/M	phase	and	
start	to	produce	pro-inflammatory	and	pro-fibrotic	molecules	that	fuel	a	chronic	 inflammation	with	progressive	
collagen	deposition	and	loss	of	the	normal	parenchymal	structure,	leading	to	chronic	kidney	disease	(CKD).	b)	After	
injury,	Pkd1	deficient	kidneys	can	repair	the	tissue	damage	or	can	develop	cysts,	depending	on	how	intense	the	
injury	insult	was,	and/or	the	genetic	makeup	of	the	organism.	However,	even	in	case	of	tissue	repair,	Pkd1	deficient	
kidneys	show	aberrant	repair	with	altered	cell	polarity	and	cell	differentiation,	providing	a	potential	explanation	for	
the	increased	speed	of	cyst	formation	observed	after	injury.
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3.1 Injury-repair and fibrosis
3.1.1 Renal injury
Repair	after	 renal	 injury	 relies	on	 the	surviving	epithelial	 cells,	which	can	dedifferentiate	
to	 be	 able	 to	 spread	 and	migrate	 to	 cover	 exposed	 tubular	 tracts	 and	 to	 proliferate	 in	
order	to	restore	the	integrity	of	the	tissue.	Indeed,	injured	kidneys	are	strongly	positive	for	
proliferation	markers	such	as	Ki67	and	proliferative	cell	nuclear	antigen	(PCNA)28,29.	Once	
the	 integrity	of	 the	 tubules	 is	 restored,	 cells	need	 to	differentiate	back	 into	 fully	mature	
epithelial	 cells	 to	 re-establish	 the	 proper	 function	 of	 the	 organ.	 It	 has	 been	 proposed	
that	 laminin-integrin	 interactions	 might	 drive	 re-differentiation	 of	 the	 epithelium.	 In	
particular,	 laminin-5	 and	 α3β1-integrin	 expression	 are	 increased	 after	 ischemic	 kidney	
injury30.	Interestingly,	laminin-5	expression	is	also	increased	in	the	ECM	of	ADPKD	kidneys.	
Stimulation	with	 purified	 laminin-5	 can	 activate	 the	 extracellular-signal-regulated	 kinase	
(ERK)	in	traditional	cell	cultures	and	can	stimulate	proliferation	and	cyst	formation	in	three-
dimensional cultures31.	Moreover,	a	hypomorphic	mutation	in	laminin-5	in	mice	causes	cyst	
formation,	both	in	the	cortex	and	medulla,	showing	that	defects	in	ECM	components	are	
sufficient	to	cause	PKD32.
After	renal	injury,	expression	levels	and	activity	of	transforming	growth	factor-beta	(TGF-β)	
are	increased	and	play	a	role	in	maintaining	the	injured	tubule	in	a	dedifferentiated	state.	
This	 is	 necessary	 for	 cell	 proliferation	 and	 repair	 of	 the	 tubule33.	 The	 TGF-β	 superfamily	
of	proteins	comprises	a	group	of	highly	conserved	secreted	morphogens,	which	regulate	
a	 variety	 of	 developmental	 and	 homeostatic	 processes.	 Upon	 binding	 of	 the	 TGF-β	
family	members	to	their	receptors,	a	series	of	phosphorylation	events	are	triggered.	The	
signalling	 cascade	 ends	 up	 with	 the	 phosphorylation	 and	 subsequent	 activation	 of	 the	
SMAD	transcription	 factors,	which	 translocate	 to	 the	nucleus	where	 they	can	drive	gene	
expression34.	Thus,	TGF-β	can	suppress	 the	expression	of	epithelial	markers	and	 increase	
the	expression	of	mesenchymal	markers,	 such	 as	αSMA	and	 vimentin,	 leading	 to	partial	
dedifferentiation,	 i.e.	 epithelial-to-mesenchymal	 transition	 (EMT).	 Although	 EMT	 is	 a	
physiological	 event	 during	 renal	 development	 and	 useful	 adaptive	 response	 to	 injury,	
sustained	 EMT	 can	 result	 in	 increased	 matrix	 deposition	 and	 cytokine	 production	 that	
lead	 to	 CKD.	 Moreover,	 TGF-β	 can	 stimulate	 ECM	 deposition	 by	 acting	 directly	 on	 the	
transcription	of	fibronectin,	proteoglycans,	collagens	and	integrins.	At	the	same	time,	TGF-β	
antagonises	matrix	degradation	by	stimulating	proteases	inhibitors	production35.	In	line	with	
these	findings,	several	in vivo and in vitro	experiments	have	shown	that	TGF-β	might	be	the	
mediator	of	AKI-to-CKD	progression36.	
3.1.2 PKD
EMT	 and	 excessive	 ECM	 deposition	 are	 also	 characteristic	 features	 of	 ADPKD.	
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Immunohistochemical	 analyses	 of	 human	 kidneys	 in	 advanced	 stages	 of	 ADPKD	 showed	
increased	αSMA+	myofibroblast	and	interstitial	fibrosis,	loss	of	epithelial	markers	in	favour	
of	mesenchymal	ones	in	tubules,	and	increased	TGF-β-SMAD	signalling37.	All	these	events	
suggest	that	local	injury	and	TGF-β	regulated	EMT	might	play	a	role	in	ADPKD	progression.	
Increased	 TGF-β	 and	 nuclear	 phospho-SMAD2	 staining	 are	 often	 observed	 in	 cyst-lining	
epithelium	and	interstitial	cells	surrounding	cysts,	both	in	mice	and	humans38.	Shear	stress,	
induced	by	fluid	flow,	on	wildtype	and	Pkd1-/- tubular	epithelial	cell	cultures	activates	the	
TGF-β	 downstream	 targets	 SMAD2/3,	 which	 is	 prevented	 by	 administration	 of	 TGF-β-
neutralizing	antibodies	and	by	inhibitors	of	the	TGF-β-binding	type-I-receptor	ALK5	(activin	
receptor-like	kinase	5).	This	indicates	that	autocrine	TGF-β	signalling	is	activated	upon	shear	
stress	in	renal	epithelial	cells39-41.	This	response	was	higher	in	Pkd1-/-	cells	because	of	more	
TGF-β-production.	In	addition,	it	has	been	shown	that	TGF-β	can	restrict	cystogenesis	in	a	
three-dimensional	culture	of	both	murine	and	human	cells42,43.	 However,	in	mice,	conditional	
ablation	of	Alk5	together	with	Pkd1	in	renal	epithelium	did	not	result	in	amelioration	of	PKD	
progression,	while	sequestering	of	activin	A	and	B,		other	members	of	the	TGF-β	family,	via	
administration	of	the	soluble	activin	receptor	IIB,	lead	to	amelioration	of	PKD	progression	in	
three	different	mouse	models44.	Paracrine	effects	on	interstitial	cells,	rather	than	autocrine	
effects	might	be	critical	in	PKD,	and	it	seems	that	there	is	context-dependent	effect	of	TGF-β	
family	members.	Indeed,	it	is	known	that	TGF-β	can	both	inhibit	and	promote	cell	growth,	
drive	differentiation	but	also	dedifferentiation	of	cells,	and	can	be	helpful	in	injury	but	can	
also	be	the	major	driver	of	fibrosis.	Although	the	signalling	process	is	essentially	the	same,	
the	context,	 cell	 types	and	 the	cofactors	 involved	 shape	 the	outcome	of	 the	 signalling34.	
Hence,	further	studies	to	investigate	the	role	and	the	possible	use	of	TGF-β	as	a	therapeutic	
target	in	ADPKD	are	needed.
The	 cells	mostly	 responsible	 for	 ECM	deposition,	 are	myofibroblasts.	Myofibroblasts	 can	
originate	from	different	precursor	cells,	but	the	most	important	seem	to	be	renal	fibroblasts,	
resident	macrophages	and	other	cells	of	hematopoietic	origin	that	migrate	into	the	kidney45.	
These	cellular	transitions,	together	with	direct	injury-induced	damage	to	the	vasculature,	can	
contribute	to	the	loss	of	capillaries	surrounding	the	renal	tubules	resulting	in	local	hypoxia,	
a	 known	driver	of	fibrotic	 response	 in	CKD46.	 In	ADPKD,	 cyst	 formation	and	expansion	 is	
associated	with	 altered	 vascular	 architecture.	 In	 particular,	 peritubular	microvasculature	
shows	signs	of	regression	of	larger	capillaries	together	with	flattened	arterioles	and	atresic	
venules.	 At	 the	 same	 time,	 cysts	 are	 surrounded	 by	 a	 dense	 but	 disorganised	 capillary	
network,	which	forms	a	sort	of	“vascular	capsule”47.	The	observed	vascular	alteration	can	
be	the	result	of	expanding	cysts,	exerting	mechanical	compression	of	intrarenal	vasculature	
and	impairing	its	function.	This	could	also	be	directly	related	to	reduced	expression	of	the	
polycystins	 in	 the	 vasculature	where	 they	 have	 crucial	 roles	 in	mechanosensation,	 fluid-
shear stress sensing, signalling and maintaining structural integrity48-52.	 Regardless	 of	
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the	 primary	mechanism,	 a	 final	 common	 outcome	 is	 the	 development	 of	 local	 hypoxia,	
which	in	turn	induces	expression	of	hypoxia-inducible	factor-1	alpha	(HIF-1α)	in	the	cystic	
epithelium,	and	HIF-2α	in	interstitial	cells53	(Figure	3).	Particularly,	HIF-1α	seems	to	have	a	
central	role	in	cyst	growth	in vivo,	because	deletion	of	Hif1a	in	a	conditional	kidney-specific	
Pkd1	 mutant	mouse	model	 was	 able	 to	 reduce	 fibrosis	 and	 improve	 PKD	 progression54.	
Additionally,	gene	expression	studies	of	renal	cells	from	cystic	human	and	murine	kidneys	
found	a	consistent	hypoxia	gene	expression	profile	suggesting	that	hypoxia	has	an	important	
role	in	ADPKD	progression23,55.	 In	fact,	on	one	hand,	hypoxia	in	ADPKD	contributes	to	the	
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Figure 3. Effect of cyst expansion on the surrounding tissues 
Cyst	expansion	causes	mechanical	stress	to	the	surrounding	tissue	and	vessels.	As	a	result,	injury-related	mechanisms	
are	activated,	and	cytokines	and	growth	factors	are	secreted	in	the	renal	tubules	and	the	surrounding	interstitium.	
TGF-β	secretion	drives	tubular	cell	dedifferentiation,	recruitment	of	infiltrating	cells	to	the	cyst	site,	and	activation	
of	αSMA+	myofibroblasts	with	increased	extracellular	matrix	deposition.	M2-like	macrophages	accumulate	around	
the	cysts	where	they	secrete	anti-inflammatory	and	pro-fibrotic	molecules	that	stimulate	tubular	cells	proliferation	
and	myofibroblasts	activation.	Pro-inflammatory	stimuli	and	accumulation	of	fibrosis	lead	to	pericyte	dissociation	
resulting	in	microvasculature	rarefaction	and	local	hypoxia,	which	exacerbates	the	fibrotic	response.	Inflammatory	
cytokines,	such	as	TNF-α,	IL-1β	and	INF-γ,	as	well	as	the	deletion	of	PC1,	activate	two	major	inflammatory	pathways	
in	renal	epithelial	cells:	NF-κB	and	JAK-STAT.	As	a	result,	pro-inflammatory	molecules	are	produced	and	released,	
attracting	and	activating	even	more	infiltrating	cells,	which	aggravate	the	local	injury	and	ultimately	contribute	to	
cyst	progression.
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hypervascularisation	of	 cysts,	 increasing	 the	 cysts’	 nutrient	 intake,	which	 is	 necessary	 to	
sustain	their	growth.	On	the	other	hand,	it	contributes	to	interstitial	fibrosis	by	driving	pro-
fibrotic	responses,	ultimately	leading	to	organ	failure	and	contributing	to	ADPKD	progression.
3.2 Inflammation
3.2.1 Renal injury
Following	renal	 injury,	both	innate	and	adaptive	immune	responses	intervene	to	respond	
to	 the	tissue	damage.	 Injured	 tubular	epithelial	 cells	 release	pro-inflammatory	 cytokines	
and	 chemokines,	 growth	 factors	 and	 adhesion	 molecules,	 such	 as	 interleukin-1	 (IL-1),	
tumour	necrosis	 factor-alpha	 (TNF-α),	monocyte	 chemoattractant	protein-1	 (MCP-1)	 and	
TGF-β,	which	help	with	 the	 recruitment	and	activation	of	 immune	cells15.	This	early	pro-
inflammatory	response	is	crucial	to	clear	the	tissue	from	dead	cells	and	cellular	debris.	At	
the	same	time,	immune	cells	also	secrete	chemoattractant	cytokines	and	growth	factors	in	
a	self-perpetuating	feedback	loop	that	recruits	and	activates	surrounding	cells,	stimulates	
angiogenesis	 and	 contributes	 further	 to	 the	 injury	 response.	 Two	 important	 pathways	
activated	by	this	response	are	the	nuclear	factor-κB	(NF-κB)	pathway	and	the	Janus	kinase	
(JAK)-signal	 transducer	and	activator	of	 transcription	(STAT)	pathway.	The	NF-κB	pathway	
is	activated	by	the	pro-inflammatory	cytokines	secreted	after	 injury	(e.g.,	TNF-α,	MCP-1),	
which	bind	to	their	specific	ligands	on	the	tubular	cells	resulting	in	the	phosphorylation	of	
the NF-κB	inhibitor,	IκB,	and	subsequent	nuclear	translocation	of	NF-κB	complex56.	Also	JAK-
STAT	pathway	is	activated	by	pro-inflammatory	cytokines	(e.g.,	IL-6	and	interferon-gamma/
INF-γ),	which	activate	JAK	that	in	turn,	activates	STAT	proteins	leading	to	their	translocation	
into the nucleus57.	The	final	effect	of	the	activation	of	these	two	pathways	is	the	transient	
transcription	 of	 pro-inflammatory	 genes	 that	 encodes	 for	 cytokines	 and	 growth	 factors,	
which	 sustain	 the	 recruitment	of	 leucocytes	 to	 the	 site	of	 injury.	 To	 counterbalance	 this	
first	inflammatory	phase,	infiltrating	leucocytes	can	also	secrete	anti-inflammatory	and	pro-
fibrotic	factors	that	lead	to	activation	of	myofibroblasts	and	ECM	deposition.	When	these	
processes	occur	harmoniously	together,	and	 in	collaboration	with	tubular	epithelial	cells,	
the	injury	can	be	successfully	healed.	Conversely,	in	case	of	persistent	or	extensive	injury,	
chronic	activation	of	this	pro-inflammatory	response	together	with	the	chronic	production	of	
anti-inflammatory	and	pro-fibrotic	factors	can	result	in	a	maladaptive	repair	and	progressive	
fibrotic	renal	disease58.
3.2.2 PKD
ADPKD	cannot	be	defined	as	an	 inflammatory	disorder.	However,	renal	histology	analysis	
of	 patients	 with	 ADPKD	 showed	 apparent	 interstitial	 inflammation	 and	 fibrosis	 in	 both	
minimally	and	severely	cystic	kidneys59,60.	Also,	pro-inflammatory	molecules,	such	as	TNF-α, 
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MCP-1,	osteopontin	and	IL-1β	can	be	found	in	the	urine	and	cyst	fluid	of	human	patients61-63.	
Moreover,	several	studies	described	the	accumulation	of	infiltrating	inflammatory	cells,	such	
as	macrophages	and		T	cells,	in	the	renal	interstitium	and	urine	of	ADPKD	patients59,64,65	(Figure	
3).	Particularly,	macrophages	 seem	to	have	a	key	 role	 in	 cyst	progression.	Transcriptome	
analysis	in	the	congenital	polycystic	kidney	(cpk)	mutant	mice	(non-orthologous	mice	with	a	
mutation	in	the	Cys1	gene),	which	are	a	model	of	cystic	renal	disease,	showed	that	the	most	
upregulated	genes	in	the	more	progressive	stages	of	disease	were	associated	with	the	innate	
immune	system,	and	particularly	with	the	alternative	macrophage	activation	pathway	(M2-
like	macrophages)66.	Furthermore,	accumulation	of	M2-like	macrophages	around	cyst	was	
observed	in	several	orthologous	animal	models	for	ADPKD67,68.	Interestingly,	accumulation	
of	macrophages	could	already	be	observed	at	early	stages	and	specifically	around	PC1	and	
PC2	deficient	tubules13,68.	Depletion	of	macrophages	leads	to	the	reduction	of	cyst-lining	cell	
proliferation,	lower	cystic-index	(percent	of	kidney	occupied	by	cysts)	and	improved	renal	
function	 in	 different	 mouse	 models67,68.	 Additionally,	 deletion	 of	 macrophage	 migration	
inhibitory	 factor	 (Mif)	or	pharmacological	 inhibition	of	MIF,	which	 is	upregulated	 in	cyst-
lining	 cells	 and	 is	 responsible	 for	 macrophage	 recruitment,	 resulted	 in	 reduced	MCP-1-
dependent	macrophage	accumulation	 in	 the	cystic	kidneys	and	subsequent	delay	of	cyst	
growth	 in	 several	PKD	mouse	models69.	 Since	comparable	 results	were	observed	 in	both	
orthologous	(with	a	Pkd1/2	mutant	gene)	and	non-orthologous	models	(with	mutations	in	
genes other than Pkd1/2),	 it	 is	plausible	 that	M2-like	macrophages	have	a	 common	 role	
in	cyst	development	regardless	of	the	genetic	mutation	that	is	causing	it.	Indeed,	M2-like	
macrophages	are	able	to	stimulate	tubular	cells	proliferation	after	injury,	promoting	tissue	
repair70.	However,	 in vitro	M2-like	macrophages	stimulated	formation	and	proliferation	of	
microcysts, and in vivo	they	might	have	increased	the	tubular	proliferation	observed	after	
injury	 in	 a	 model	 of	 adult-induced	 cyst	 formation68,71.	 These	 results	 imply	 that	 M2-like	
macrophages	in	PKD	have	a	detrimental	role	more	than	a	protective	one;	thus,	therapies	
that	can	target	specifically	this	population	in	ADPKD	patients	might	be	beneficial.
3.2.2.1 Inflammatory cytokines
Among	all	the	different	inflammatory	cytokines,	TNF-α	seems	to	have	a	particularly	relevant	
role	in	cyst	formation.	High	levels	of	TNF-α	are	found	in	cysts’	fluids	of	ADPKD	patients,	and	
gene	expression	is	increased	in	murine	cystic	kidneys,	where	it	positively	correlates	with	age	
and	cyst	size61,72,73.	In vitro,	stimulation	of	inner	medullary	collecting	duct	cells	with	TNF-α	
was	accompanied	with	the	altered	subcellular	localisation	of	PC2	and	disruption	of	PC1-PC2	
interaction.	Moreover,	both	wild-type	and	Pkd2+/-	embryonic	kidney	explants	treated	with	
TNF-α	 developed	 several	 cyst-like	 structures.	 In vivo,	 intraperitoneal	 injections	 of	 TNF-α	
increased	the	incidence	of	cyst	formation	in	Pkd2+/-	mice	of	8.5	weeks	of	age.	Additionally,	
also TNF-α	receptor	-I	and	-II,	and	TNF-α	converting	enzyme	(TACE)	are	enriched	in	human	
ADPKD	 cyst	 fluids,	where	 they	 contribute	 to	 accumulation	 and	 stabilisation	 of	 bioactive	
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TNF-α74,75.	In	fact,	inhibition	of	TACE	in	bpk	mice	(non-orthologous	model	with	mutation	in	
the Bicc1	gene)	resulted	in	amelioration	of	PKD76.
Another	 important	 inflammatory	 chemokine	 in	ADPKD	progression	 is	MCP-1.	MCP-1	 is	 a	
pro-inflammatory	cytokine	that	attracts	monocytes	at	 the	site	of	 injury77.	Expression	and	
urinary	excretion	of	MCP-1	is	increased	already	at	early	stages	of	the	disease	in	rodent	PKD	
models	and	human	ADPKD	patients62,69,78.	Particularly,	analysis	of	the	urinary	MCP-1	(uMCP-
1)	in	patients	from	the	TEMPO	3:4	trial,	showed	that	uMCP-1	correlated	with	renal	function	
and	that	tolvaptan	treatment	was	able	to	reduce	uMCP-1	 levels79.	Recently,	Cassini et al.	
demonstrated that Mcp-1	expression	is	increased	after	Pkd1/2	deletion	already	in	pre-cystic	
kidneys	and	prior	to	macrophage	infiltration80.	Increased	MCP-1	levels	led	to	the	recruitment	
of	pro-inflammatory	macrophages	(M1-like	macrophages),	which	caused	direct	damage	to	
tubules.	 Subsequently,	 these	macrophages	differentiated	 to	M2-like	macrophages,	which	
stimulate	 tubules	 proliferation	 and	 cyst	 growth80.	 Genetic	 deletion	 of	 Mcp-1 together 
with	Pkd1,	as	well	as	administration	of	an	MCP-1	receptor	inhibitor,	reduced	macrophage	
infiltration,	 cyst	 growth	 and	 improved	 renal	 function	 and	 survival80.	 Therefore,	 targeting	
macrophage	 recruitment	 and	 activation	 might	 be	 a	 promising	 therapeutic	 approach	 in	
ADPKD.	However,	administration	of	an	 inhibitor	of	MCP-1	synthesis	 in	a	non-orthologous	
model	of	PKD	 in	 rats	was	able	 to	 reduce	 interstitial	 inflammation	but	did	not	affect	 cyst	
formation,	questioning	the	importance	of	the	MCP-1-recruited	inflammatory	infiltrates	in	
cysts	initiation81.
3.2.2.2 Inflammatory cytokine related signalling pathways
The	major	inflammatory	pathways	activated	in	PKD	are	NF-κB	and	JAK-STAT.	NF-κB	complex	
proteins	are	regulators	of	transcription	of	several	genes	among	which	inflammatory	genes	
like	TNF-α,	IL-1β	and	MCP-182.	Increased	NF-κB	activity	has	been	described	in	several	rodent	
models	for	PKD	and	human	ADPKD83-85.	Particularly,	the	expression	of	NF-κB	proteins	was	
described	specifically	in	cyst-lining	cells	from	early	stages	until	more	progressive	ones	both	
in	human	and	rodent	PKD	model85.	Interestingly,	in vitro	activation	of	NF-κB	was	observed	
following	overexpression	or	depletion	of	Pkd1 or Pkhd1,	 suggesting	 that	upregulation	of	
the NF-κB	pathway	might	be	an	early	feature	of	ADPKD83,86,87.	Comparison	of	transcription	
profiles	of	AKI	with	those	of	rapidly	progressive	cystic	kidneys	revealed	an	extensive	overlap	
of	genes	between	injury	and	cyst	progression,	with	the	most	enriched	being	NF-κB targets23,88.	
In	 agreement	 with	 these	 findings,	 NF-κB	 pathway	 inhibition	 using	 anti-inflammatory	
compounds	successfully	ameliorated	PKD	progression	in	animal	models,	indicating	that	NF-
κB	 is	a	viable	 target	 for	 therapy60,89-91.	However,	more	studies	are	needed	to	characterise	
the	role	of	 this	pathway	 in	 inflammation	 in	the	context	of	ADPKD.	Another	 link	between	
inflammation	and	ADPKD	is	the	JAK-STAT	pathway.	After	an	injury	in	normal	cells,	changes	
in	fluid	flow	 lead	 to	proteolytic	 cleavage	of	 the	C-terminal	 tail	 of	 PC1,	which	 is	 released	
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from	the	membrane	and	can	translocate	to	the	nucleus7.	Here,	PC1	tail	can	interact	with	
JAK-activated	 STATs	 and	 other	 transcriptional	 coactivators	 (e.g.,	 EBNA2	 coactivator	 P100	
and	STAT6),	participating	 in	gene	regulation	and	transient	activation	of	pro-inflammatory	
cytokines	and	chemokines,	which	in	turn	recruit	leucocyte	to	the	injured	tubules9,10,92.	These	
findings	suggest	that	PC1	regulation	of	STATs	plays	an	important	role	in	the	transduction	of	
mechanical	stimuli	from	the	cilia	to	the	nucleus.	Thus,	in	ADPKD	local	injury	or	defective	ciliary	
signalling	related	to	PC1/2	mutations	interfere	with	the	normal	cilia-to-nucleus	transduction	
and	leads	to	persistent	activation	of	JAK-STAT	signalling.	As	a	consequence,	the	production	
of	 pro-inflammatory	 and	 pro-fibrotic	 mediators	 is	 increased,	 ultimately	 contributing	 to	
driving	cyst	progression.	Indeed,	STAT3	and	STAT6	have	been	described	by	several	groups	
to	be	activated	in	cyst-lining	cells	in	different	PKD	mouse	models,	and	inhibition	of	STAT3	or	
STAT6	was	able	to	ameliorate	the	cystic	phenotype93-96.	Consistent	with	these	results,	gene	
expression	profiling	in	human	and	mouse	cystic	kidneys	found	JAK-STAT	pathway	and	NF-
κB	pathway	among	the	highest	upregulated	signalling	pathways23,55.	Thus,	inhibition	of	the	
inflammatory	response	via	modulation	of	NF-κB	and/or	JAK-STAT	pathways	seems	to	be	a	
promising	therapeutic	strategy	in	PKD.
3.3 Growth factors
3.3.1 Renal injury
Recovery	from	renal	injury	requires	that	the	damaged	tubular	cells	are	replaced	with	new	
ones	ensuring	that	the	structure	and	function	of	the	nephrons	are	restored.	For	this	purpose,	
the	cells	that	participate	in	the	repair	process	produce	growth	factors	(GFs),	which	modulate	
metabolism,	proliferation	and	differentiation,	and	allow	the	tissue	to	adapt	to	the	injury	and	
finally	resolve	it.	Indeed,	there	are	several	lines	of	evidence	showing	that	administration	of	
epidermal	growth	factor	(EGF),	insulin-like	growth	factor	(IGF)	and	hepatocyte	growth	factor	
(HGF)	 ameliorate	 the	outcome	of	 acute	 kidney	 injury,	 although	 for	 some	of	 the	GFs	 the	
evidence	are	still	controversial97-101.	Nevertheless,	once	the	injury	is	repaired,	these	stimuli	
should	stop.	In	the	case	of	maladaptive	repair,	persistent	and/or	aberrant	expression	of	GFs	
can	lead	to	the	development	of	fibrosis.	Several	other	GFs	have	been	implicated	in	fibrosis	
and	CKD	progression,	i.e.	TGF-β1,	TGF-α,	connective	tissue	growth	factor	(CTGF),	vascular	
endothelial	 growth	 factor	 (VEGF),	 platelet-derived	 growth	 factor	 (PDGF)	 and	 fibroblast	
growth	factor	(FGF)35,102-105.	
3.3.2 PKD
Several	of	these	GFs	are	also	upregulated	in	ADPKD.	Probably	the	best	described	are	TGF-β1,	
which	we	already	covered	in	a	previous	paragraph,	and	EGF	(Figure	4).	EGF	and	EGF	family	
ligands	(e.g.,	TGF-α	and	heparin-binding	EGF/HB-EGF)	play	an	important	role	in	renal	cyst	
expansion.	This	 is	based	on	 the	 fact	 that	 cystic	epithelial	 cells	have	higher	expression	of	
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EGF,	 TGF-α	 and	HB-EGF106,107.	 Transgenic	 overexpression	of	Tgf-α in mice resulted in cyst 
formation	 and	 accelerated	 PKD	 progression	 in	 pcy	 mice	 (non-orthologous	 model	 with	
mutation	 in	 the	Nphp3	gene)108,109.	Moreover,	 these	 ligands	are	 found	abundantly	 in	cyst	
fluid	of	ADPKD	patients,	and	stimulation	of	cultured	epithelial	cells	with	cysts	fluid	promotes	
cyst	 formation	and	expansion	 in vitro110.	 Interestingly,	 cystic	epithelial	 cells	 isolated	 from	
ADPKD	patients	are	more	 responsive	 to	 the	proliferative	 stimulus	of	EGF111.	Additionally,	
the	 EGF	 family	 ligands	 receptors	 (EGFR)	 are	 expressed	at	 the	basal	 side	of	 normal	 adult	
tubular	 epithelial	 cells,	 while	 in	 ADPKD	 kidneys,	 they	 are	 also	 localised	 on	 the	 apical	
side112,113.	As	a	consequence,	the	cystic	epithelium	establishes	an	autocrine	loop	where	EGF	
is	synthesised,	released	into	the	cyst	lumen	and	utilised	by	the	same	cyst-lining	epithelial	
cells,	 thereby	driving	their	proliferation	and	cyst	expansion.	Further	evidence	 is	provided	
by	in vivo	experiments.	Orpk	mice	(non-orthologous	model	with	a	mutation	in	Tg737	gene)	
with	 an	 EGFR	mutation	 that	 results	 in	 reduced	 EGFR	 tyrosine	 kinase	 activity	 showed	 a	
significant	 reduction	of	collecting	tubular	cysts	compared	to	mice	without	 this	mutation.	
These	findings	paved	the	road	to	therapies	that	target	the	tyrosine	kinase	activity	of	 the	
EGFR	to	ameliorate	PKD	progression114.	Indeed,	treatment	with	an	inhibitor	of	EGFR	tyrosine	
activity	in	Han:SPRD-Cy/+	rats	(a	non-orthologous	model	with	a	mutation	in	Anks6	gene),	or	
combination	treatment	of	an	EGFR	inhibitor	together	with	the	reduction	of	TGF-α	in a mouse 
model	of	ARPKD	(Autosomal	Recessive	PKD),	were	successful	in	reducing	cyst	formation	and	
increasing survival115,116.	However,	these	molecules	affect	not	only	the	cystic	epithelium	but	
all	the	proliferating	epithelia	with	broad	adverse	effects,	which	are	not	compatible	with	the	
life-long	treatment	necessary	in	ADPKD	where	tolerability	is	a	major	concern.
Also,	other	GFs,	 including	 IGF1,	HGF,	VEGF,	PDGF,	FGF	and	CTGF	have	been	described	 to	
be	 involved	 in	ADPKD.	 Increased	gene	expression	of	 IGF1	and	other	 IGF	 family	members	
is	 observed	 in	 murine	 and	 human	 renal	 cysts	 and	 is	 associated	 with	 hyperproliferation	
of	Pkd1	mutant	cystic	cells55,117.	HGF	and	its	receptor,	the	tyrosine	kinase	receptor	c-Met,	
are	 overexpressed	 in	 cyst-lining	 epithelial	 cells	 in	 human	 ADPKD,	 and	 levels	 of	 HGF	 are	
increased	in	proximal	cysts	fluid118.	In vitro, Pkd1-/-	cells	showed	defective	ubiquitination	of	
c-Met	after	HGF	stimulation	with	a	subsequent	c-Met-dependent	increase	of	the	PI3K/Akt/
mTOR	signalling	pathway119.	This	suggests	that,	as	for	IGF-1,	also	HGF	and	its	receptor	may	
contribute	to	epithelial	cystic	cells	growth	in	an	autocrine	manner.	
For	other	GFs,	the	effect	is	a	bit	broader	and	also	extends	to	the	interstitial	cells.	VEGF	is	an	
angiogenic	cytokine	that	plays	pivotal	roles	in	the	maintenance	of	the	vascular	networks.	In	
rodent	and	human	kidneys,	VEGF	is	lowly	expressed	in	the	epithelium	of	the	glomerulus	and	
in	collecting	ducts120,121.	On	the	contrary,	in	ADPKD	VEGF	and	VEGF	receptor-1	are	expressed	
in	some	of	the	cysts	and	dilated	tubules	epithelial	cells,	which	are	also	able	to	secrete	VEGF	
when	grown	in vitro121,122.	Consistently,	increased	levels	of	VEGF	are	detected	in	serum	and	
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cystic	fluids	of	Cy/+ rats121.	Overexpression	of	VEGF	in	mice	using	a	transgenic	mouse	model	
(Pax8-rtTA/(tetO)7VEGF)	 resulted	 in	 dose-dependent	 cyst	 formation	 and	 activation	 and	
proliferation	of	 interstitial	fibroblasts102.	However,	epithelial	 cells-secreted	VEGF	acts	also	
in	an	autocrine	fashion	on	cell	proliferation.	In	fact,	administration	of	ribozymes	targeting	
mRNA	of	VEGF	receptor	1	and	2	reduced	the	expression	of	the	receptors	in	tubular	cells	with	
subsequent	inhibition	of	proliferation	of	cystic	epithelial	cells121.	Additionally,	administration	
of	VEGFC,	a	member	of	VEGF	family	normally	downregulated	in	PKD,	to	Pkd1nl/nl mice led 
to	the	normalisation	of	the	pericystic	vascular	vessels,	reduction	of	M2-like	macrophages	
infiltration	and,	in	Cys1cpk/cpk	mice,	increase	in	life	span101.	Altogether,	these	results	suggest	
that	tubular	cells	in	ADPKD	aberrantly	express	VEGF,	which	in	turn	stimulates	tubular	cells,	
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Figure 4. Growth factors (GFs) affecting cyst progression 
After	injury,	secretion	of	GFs	helps	to	replace	the	damaged	tubular	cells.	In	ADPKD,	GFs	are	produced	and	secreted	
in	the	lumen	of	the	tubules.	For	example,	EGF	and	other	EGF	family	ligands	are	overexpressed	in	cystic	epithelial	
cells	and	accumulate	 in	the	cystic	 fluids.	At	the	same	time,	EGF	receptors	are	mislocalised	at	the	apical	side	of	
cells	 in	 the	cystic	epithelium.	As	a	 result,	EGF	secreted	 in	 the	 lumen	of	 the	cysts	can	 interact	with	 its	 receptor	
establishing	 an	autocrine	and	paracrine	 loop	 that	drives	proliferation	and	 cyst	 expansion.	Another	well-known	
GF	 in	PKD	 is	TGF-β.	Cystic	epithelial	cells	often	show	increased	TGFβ	expression	and	nuclear	phopspho-SMAD2	
staining.	 TGFβ	 promotes	 dedifferentiation	 of	 epithelial	 cells	 into	 a	 more	 mesenchymal	 type,	 as	 well	 as	 ECM	
deposition	and	activation	of	myofibroblasts,	contributing	to	the	cystic	phenotype.	Some	GFs	 like	CTGF,	but	also	
PDGF	and	FGF,	can	be	secreted	in	the	interstitial	space	surrounding	the	cysts.	Here,	they	can	stimulate	resident	
fibroblasts	to	differentiate	into	active	myofibroblasts,	but	also	sustain	myofibroblasts	proliferation	and	activation,	
with	a	subsequent	extracellular	matrix	deposition,	further	contributing	to	cysts	growth.
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interstitial	 fibroblasts	 and	 endothelial	 cells,	 contributing	 to	 disease	 progression.	 Thus,	
targeting	VEGF	signalling	cascade	in	PKD	seems	to	be	a	viable	therapeutic	option.	However,	
treatment	of	Cy/+	rats	with	an	anti-VEGF-A	antibody	led	to	exacerbation	of	the	cystic	disease	
and	severe	kidney	injury,	highlighting	the	need	for	more	studies	to	better	characterise	the	
role	of	the	different	VEGF	molecules	and	their	receptors	in	kidney	injury	and	cyst	growth123.
Other	GFs	 involved	 in	ADPKD,	 such	as	PDGF,	 FGF	and	CTGF,	 showed	an	effect	mainly	on	
interstitial	 cells	 (Figure	 4).	 PDGF	 expression,	 especially	 PDGF-B,	 was	 found	 in	 cyst-lining	
epithelial	cells	using	immunohistochemistry	in	a	human	ADPKD	kidney124.	However,	PDGF	
did	not	 show	a	mitogenic	effect	on	epithelial	 cells	 in vitro	but	was	able	 to	 stimulate	 the	
proliferation	 of	 ADPKD-derived	 fibroblasts	 in vitro	 more	 effectively	 than	 with	 healthy-
derived	fibroblasts125.	A	 similar	effect	was	observed	upon	FGF	 stimulation,	which	 caused	
ADPKD-derived	fibroblasts	 to	 proliferate	more,	 produce	 and	 release	more	 FGF	 and	elicit	
a	 more	 consistent	 and	 lasting	 tyrosine	 phosphorylation	 signalling	 cascade	 compared	 to	
normal	renal	fibroblasts126.	CTGF	is	most	known	for	its	role	as	a	driver	of	interstitial	fibrosis	
mediating,	 at	 least	 in	 part,	 the	 TGF-β	 pro-fibrotic	 program127.	 In	 normal	 kidneys,	 it	 is	
expressed	mainly	in	the	glomerulus,	but	in	injured	tubules	and	cystic	kidneys,	its	expression	
is	 increased	particularly	at	more	advanced	stages	of	the	disease,	in	areas	of	focal	fibrosis	
and	in	interstitial	cells	surrounding	the	cystic	epithelium128-130.	In	addition	to	its	role	in	renal	
fibrosis,	CTGF	can	also	participate	in	the	recruitment	of	inflammatory	cells	by	activating	the	
NF-κB	pathway131.	Thus,	CTGF	is	a	common	factor	in	renal	fibrosis,	both	in	injury	and	ADPKD,	
and	might	contribute	to	the	progression	of	the	cystic	disease	towards	the	end-stage.	Anti-
CTGF	 therapies	using	 a	human	monoclonal	 antibody	 that	 targets	CTGF	have	 successfully	
improved	 fibrosis	 in	 several	 animal	 models	 and	 have	 been	 tested	 in	 clinical	 trials	 for	
pulmonary	fibrosis,	pancreatic	cancer	and	diabetic	kidney	disease	without	notable	adverse	
effects127.	No	data	is	available	about	a	possible	effect	on	PKD	progression,	but	based	on	its	
positive	effect	on	fibrosis	and	good	tolerability,	it	is	plausible	to	think	that	anti-CTGF	drugs	
might	be	a	useful	adjuvant	therapy	in	ADPKD.
Overall,	 GFs	 secreted	 by	 cystic	 tubular	 epithelial	 cells	 trigger	 surrounding	 epithelial	 and	
interstitial	cells	to	produce	proliferative	and	profibrotic	factors,	which	regulate	cyst	growth	
and	interstitial	fibrosis	observed	in	ADPKD	progression.
3.4 Reactivation of developmental pathways
Gene	expression	analysis	of	human	and	rodent	kidneys	after	injury	and	during	CKD	compared	
to	healthy	control	kidneys	unveiled	aberrant	expression	of	genes	that	belong	to	the	Notch,	
wingless-related	integration	site	(Wnt),	hedgehog	(Hh)	and	Hippo	pathways132-134.	Although	
these	 evolutionarily	 conserved	 pathways	 are	 regulated	 and	 signal	 through	 different	
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routes,	 they	have	 in	common	a	role	 in	renal	development,	and	 illustrate	the	reactivation	
of	 developmental	 pathways	 in	 the	 injury-repair	 response24,135.	 However,	 prolonged	
activation	of	 these	developmental	pathways	due	to	chronic	or	 repetitive	 injury	may	 lead	
to	a	maladaptive	 response	and	CKD136,137.	Also	 in	ADPKD,	gene	expression	analysis	 found	
signs	of	cell	dedifferentiation	and	upregulation	of	developmental	and	mitogenic	signalling	
pathways55.	As	observed	after	injury,	genes	belonging	to	Notch,	Wnt,	Hh	and	Hippo	pathways	
are	upregulated	in	ADPKD,	in	line	with	the	idea	that	injury-repair	and	ADPKD	progression	
share common molecular mechanisms55.
3.4.1 Notch signalling pathway
3.4.1.1 Renal injury
Notch	 pathway	 controls	 cell	 proliferation,	 differentiation	 and	 cell	 fate138.	 During	 renal	
development,	 Notch2	 downregulates	 Six2,	 a	 transcription	 factor	 expressed	 in	 nephron	
progenitor	cells,	by	suppressing	its	upstream	regulator,	Pax2.	This	leads	to	the	reduction	of	
the	progenitor	pools	in	favour	of	the	differentiation	of	proximal	tubular	cells139,140.	Persistent	
activation	of	Notch	signalling	is	associated	with	kidney	fibrosis,	which	is	ameliorated	with	
the	administration	of	Notch	inhibitors141.	Interestingly,	a	well-characterized	Notch	signalling	
partner	is	TGF-β,	a	known	driver	of	fibrosis.	Indeed,	TGF-β	can	directly	regulate	downstream	
targets	 of	Notch,	 and	 the	 targets	Hes and Hey,	 and	 can	 induce	 the	 expression	 of	Notch	
ligand Jag1.	At	the	same	time,	the	increased	level	of	Notch	can	stimulate	TGF-β	expression,	
creating	a	positive-feedback	loop	that	sustains	renal	fibrosis133,142,143.	
3.4.1.2 PKD
Notch	signalling	genes	are	enriched	in	ADPKD,	in	line	with	the	dedifferentiation	and	increased	
proliferation	of	tubular	epithelial	cells144-146.	Protein	expression	analysis	of	Notch	signalling	
components	 in	mouse	and	human	ADPKD	kidneys	revealed	 increased	expression	 in	cysts	
lining	epithelium.	Particularly,	Notch3	activation	was	 increased,	and	 in vitro	 inhibition	of	
Notch	resulted	in	reduced	proliferation	and	cyst	formation	in	3D	culture	of	primary	human	
ADPKD	 cells82.	 Thus,	 modulation	 of	 Notch	 signalling	 may	 be	 an	 interesting	 therapeutic	
approach	 to	 prevent	 fibrosis	 and	 cyst	 growth.	 However,	 there	 is	 evidence	 showing	 that	
reduction	of	Notch	signalling	during	nephrogenesis	leads	to	proximal	tubular	cysts	due	to	
loss	of	oriented	cell	division,	suggesting	that	the	effect	of	this	pathway	on	cyst	progression	
might	be	more	complex145.	
3.4.2 Wnt signalling
3.4.2.1 Renal injury
Wnt	 signalling	 pathways	 regulate	 a	 range	 of	 cellular	 processes	 including	 proliferation,	
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migration	 and	 polarity,	 thereby	 contributing	 to	 organ	 homeostasis.	 They	 are	 normally	
classified	in	canonical,	which	involves	activation	and	nuclear	translocation	of	β-catenin,	and	
noncanonical,	 which	 is	 β-catenin-independent	 and	 includes	 the	Wnt/planar	 cell	 polarity	
(PCP)	 route.	 In	 kidney	 morphogenesis,	 Wnt	 orchestrates	 the	 mesenchyme-to-epithelial	
transition	necessary	for	nephrogenesis147.	The	involvement	of	aberrantly	activated	canonical	
Wnt	 pathway	 with	 renal	 fibrosis	 has	 been	 extensively	 shown	 in	 different	 injury	 animal	
model,	as	reviewed	elsewhere148.
3.4.2.2 PKD
In	 the	 context	 of	 ADPKD,	 transgenic	 mice	 with	 increased	 β-catenin	 activation	 present	
with	 renal	 cyst	development149-151.	Moreover,	 PC1	 interacts	with	β-catenin	 at	 the	plasma	
membrane,	 at	 cell-cell	 contacts	 and	 in	 the	 nucleus,	 suggesting	 that	 PC1	 may	 have	 an	
important	regulatory	role	on	Wnt	signalling8,26,152.	Once	this	regulation	is	lost,	for	example	
due to Pkd1	mutation,	the	resulting	aberrant	Wnt	pathway	activation	might	contribute	to	
cyst	formation.	Indeed,	one	of	the	major	downstream	targets	of	the	Wnt	signalling,	c-MYC,	is	
upregulated	in	ADPKD,	especially	in	the	cystic	tubular	epithelium153.	Specific	overexpression	
of	 c-Myc	 in	 renal	 epithelial	 cells	mimicked	 human	 ADPKD,	 and	 both	 direct	 and	 indirect	
inhibition	 of	 c-Myc	 in vivo	 resulted	 in	 amelioration	of	 the	 cystic	 phenotype,	 placing	 this	
protein	 in	 a	 central	 position	 in	 PKD	 progression153.	 Interestingly,	 renal	 injury	 caused	 by	
ischemia-reperfusion	(IRI)	was	associated	with	activation	of	Wnt	signalling	and	increase	in	
c-Myc	expression	both	in	transgenic	Pkd1	mice	and	non-transgenic	control	mice,	in	line	with	
the	idea	that	injury	activates	pathways	involved	in	PKD	progression22.
Also	noncanonical	Wnt	signalling	has	been	implicated	in	cyst	formation,	 in	particular,	the	
PCP	route.	PCP	orchestrate	cell	polarity	within	the	plane	of	epithelial	cells	and	is	essential	
to	 establish	 proper	 cell	 function	 and	 organ	 architecture154.	 Alteration	 of	 oriented	 cell	
division	(OCD)	has	been	associated	with	cyst	formation18,155.	However,	a	recent	publication	
demonstrated	that,	although	altered	OCD	is	a	feature	of	expanding	cysts,	it	is	not	sufficient	
nor	necessary	for	cyst	initiation	after	Pkd1/2	mutation,	thus	challenging	the	role	of	PCP	in	
cyst	formation156.	In	chapter	2,	we	investigate	the	role	of	Four-jointed	box-1,	a	component	
of	the	PCP	route.
3.4.3 Hh signalling pathway
3.4.3.1 Renal injury
The	 Hh	 signalling	 pathway	 controls	 embryonic	 development	 and	 tissue	 homeostasis.	
Deregulation	 of	 this	 pathway	 during	 kidney	 morphogenesis	 is	 associated	 with	 severe	
malformations,	 indicating	 that	 Hh	 signalling	 plays	 a	 critical	 role	 in	 this	 process157.	 In	
mammals,	there	are	three	Hh	homologous.	One	of	them,	sonic	hedgehog	(Shh)	is	induced	
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early	after	renal	injury	in	tubular	epithelial	cells	and	has	been	implicated	in	the	pathogenesis	
of	fibrosis	and	CKD	by	acting	on	interstitial	fibroblasts	leading	to	their	activation	and	ECM	
deposition.	Moreover,	 Hh	 signalling	 pathway	 can	 interact	 and	 cooperate	with	 other	 key	
pathways	known	to	be	drivers	of	fibrosis,	such	as	TGF-β,	canonical	Wnt	and	Notch136,158.	
3.4.3.2 PKD
The	connection	between	Hh	signalling	and	ADPKD	is	complex	and	mainly	via	cilia-dependent	
signalling.	 Mutations	 in	 ciliary	 genes	 lead	 to	 cystic	 renal	 disease,	 but	 also	 aberrant	 Hh	
signalling159-161.	Also,	the	loss	of	a	functional	component	of	the	Hh	pathway,	Glis2,	resulted	
in	 the	 development	 of	 nephronophthisis	 in	 human	 and	 mice162.	 In	 the	 context	 of	 PKD,	
downregulation	of	Hh	signalling	is	accompanied	by	reduced	proliferation	and	cyst	formation	
in Pkd1	mutant	mice	and	human	primary	ADPKD	cell	cultures163,164.	However,	a	recent	study	
using	 a	 conditional	 mouse	 model	 lacking	 Pkd1	 in	 combination	 with	 three	 Hh	 signalling	
members	 (Smo, Gli2 and Gli3)	 demonstrated	 that	 Hh	 pathway	 is	 not	 required	 for	 cyst	
formation	in	mouse	models	of	developmental	or	adult-onset	of	ADPKD165.	Thus,	 it	seems	
that	 the	Hh	pathway	does	not	have	a	causative	 role	 for	 the	disease	 in vivo,	but	 it	might	
contribute	to	disease	progression	due	to	its	effect	on	renal	fibrosis.
3.4.4 Hippo signalling pathway
3.4.4.1 Renal injury
The	 Hippo	 pathway	 regulates	 tissue	 growth	 and	 development.	 Unlike	 the	 pathways	
mentioned	 above,	 which	 are	 activated	 by	 the	 binding	 of	 specific	 ligands,	 a	 diversity	 of	
upstream	 Hippo	 pathway	 regulators	 have	 been	 identified.	 Identified	 upstream	 signals	
include	cell	polarity,	cell	junctions,	cytoskeleton,	mechanical	forces,	GPCR	ligands	and	stress	
signals166.	The	core	components	of	the	Hippo	pathway	are	a	group	of	kinases	(mammalian	
Ste20	 like	kinases	1/2	or	MST1/2	and	 large	tumour	suppressor	1/2	or	LTS1/2),	which	are	
responsible	 for	 the	 phosphorylation	 of	 the	 final	 effectors	 Yes-associated	 protein	 (YAP)	
and	transcriptional	coactivator	with	PDZ-binding	motif	(TAZ).	When	the	Hippo	pathway	is	
activated,	YAP	and	TAZ	are	phosphorylated	and	 restrained	 into	 the	cytoplasm;	when	 the	
Hippo	pathway	is	 inactive,	YAP	and	TAZ	are	unphosphorylated	and	can	translocate	to	the	
nucleus	where	they	can	bind	with	a	series	of	 transcription	factors,	such	as	TEAD	1-4	but	
also	SMADs	and	β-catenin,	and	regulate	the	transcription	of	a	wide	range	of	genes	involved	
in	cell	proliferation,	apoptosis	and	migration167,168.	In	renal	development,	mutations	of	the	
core	kinases	or	the	final	effector	YAP,	lead	to	disruption	of	nephrogenesis169,170.	Interestingly,	
deletion	of	the	orthologous	protein	TAZ	in	a	developmental	mouse	model	does	not	impair	
nephrogenesis	but	results	 in	renal	cyst	 formation.	This	 indicates	that	these	two	proteins,	
although	 having	 largely	 redundant	 functions,	 also	 have	 distinct	 roles171.	 In	 kidney	 injury,	
nuclear	accumulation	of	YAP	and	TAZ	is	observed	in	both	in	epithelial	and	interstitial	cells	in	
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several	models	of	injury.	In	particular,	Yap	expression	is	observed	in	dedifferentiated	tubular	
cells	in	AKI-to-CKD	transition,	confirming	that	the	Hippo	pathway	has	a	role	in	injury-repair	
mechanism137.	Moreover,	after	injury,	ECM	production	causes	the	tissue	stiffness	to	increase,	
providing	the	driving	cue	for	fibroblast	TGF-β	activation.	The	mechanosensitive	response	to	
TGF-β-induced	activation	of	renal	fibroblasts	 is	mediated	by	YAP/TAZ,	which	interact	with	
SMAD2/3,	translocate	to	the	nucleus	and	drive	transcription	of	profibrotic	genes172.
3.4.4.2 PKD
Increased	nuclear	localisation	of	YAP	and	TAZ	has	been	described	in	several	diseases,	among	
which	ADPKD	and	nephronophthisis129,173.	Moreover,	zebrafish	mutant	for	Pkd2 and Scrib, 
a	member	 of	 the	 SCRIB	 complex	 involved	 in	 the	 establishment	 and	maintenance	 of	 cell	
polarity,	 showed	 increased	 nuclear	 YAP.	 Interestingly,	 expression	 of	 cytoplasmic	 but	 not	
nuclear	 YAP	 could	 rescue	 the	 phenotype,	 suggesting	 that	 cytoplasmic	 YAP	 has	 a	 role	 in	
the	suppression	of	cyst	formation174.	Knock-out	of	Yap in a Pkd1	mutant	mouse	model	was	
able	to	reduce	PKD	progression	mildly,	and	the	effect	was	even	increased	by	concomitant	
knock-out	of	Taz.	In	particular,	YAP	target,	c-MYC,	was	found	to	critically	contribute	to	kidney	
cystogenesis,	 implicating	 the	Hippo	pathway	 in	 the	pathogenesis	of	 PKD175.	 Interestingly,	
expression	 of	 Ctgf,	 a	 known	 YAP/TAZ	 target176,	 which	 is	 also	 induced	 by	 TGF-β127,	 was	
increased in Pkd1	mutant	mice	but	only	in	those	presenting	clear	signs	of	fibrosis,	suggesting	
that	a	certain	 level	of	signal	crosstalk	between	TGF-β	and	Hippo	pathways	is	occurring	in	
the	PKD	context	as	well129.	For	its	role	in	modulating	cell	proliferation	and	cell	migration	and	
fibrosis,	Hippo	pathway	regulation	has	been	proposed	as	a	possible	strategy	to	ameliorate	
ADPKD	progression	by	acting	on	two	major	aspects	of	the	disease.	However,	administration	
of	YAP-specific	antisense	oligonucleotides	 (ASOs)	 in	adult	Pkd1 mutant mouse model did 
not	result	in	a	reduction	of	cyst	growth	(data	presented	in	chapter	3).	Such	results,	together	
with	the	cystic	effect	of	TAZ	deletion	 in	a	developmental	mouse	model,	suggest	 that	 the	
role	of	these	proteins	and	the	effect	of	targeting	them	in	PKD	is	complex	and	need	further	
characterisation171.
3.5 Transcription factors (TFs) and epigenetics in renal injury and PKD
Injury-repair	 is	 a	 complex	 mechanism	 that	 involves	 several	 cell	 types	 and	 requires	 the	
modulation	of	a	plethora	of	signalling	pathways.	Thus,	a	perfect	time-	and	space-regulated	
transcription	program	 is	paramount	 for	 the	good	outcome	of	 the	tissue	 injury	 response.	
For	 this	 reason,	 a	 series	 of	 transcription	 factors	 (TFs)	 and	 epigenetic	 changes	 intervene	
to	orchestrate	all	 the	different	steps	we	discussed	above,	which	ultimately	 lead	to	organ	
repair177.	Altered	TFs	expression	or	epigenetic	regulation	can	interfere	with	injury-repair	and	
lead	to	CKD178	and	orchestrate	and	modulate	signalling	in	PKD.
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Gene	 expression	 analysis	 in	 ADPKD	 revealed	 dysregulation	 of	 TFs,	 many	 of	 which	 are	
involved	in	key	processes	of	kidney	development.	Interestingly,	from	a	meta-analysis	study	
that	identified	a	set	of	1515	genes	dysregulated	in	PKD	emerged	that	92	of	them	are	TFs,	and	
that	about	35%	of	the	identified	TFs	are	known	to	be	involved	in	injury-repair	mechanisms	
(further	shown	in	chapter	5).	Mutations	in	Pkd1	are	also	associated	with	other	epigenetic	
changes,	 such	 as	 increased	 expression	 of	 DNA	 methyltransferases	 (DNMTs),	 histone	
deacetylases	(HDACs)	and	bromodomain	proteins179.	For	example,	SET	and	MYND	domain	2	
(SMYD2)	protein	is	a	lysine	methyltransferase	upregulated	in	PKD.	Inhibition	of	SMYD2	was	
able	to	delay	cysts	growth	via	interfering	with	SMYD2-dependent	activation	of	STAT3	and	the	
p65	subunit	of	NF-κB180.	Treatment	with	HDACs	inhibitors	has	also	been	proven	effective	in	
delaying	cyst	growth	and	preserving	renal	function	in	several	Pkd1/2 mutant mouse models, 
pointing	 to	 epigenetic	modifiers	 drugs	 as	 promising	 candidates	 for	 PKD	 treatment181-186.	
Moreover,	epigenetic	changes	such	as	hypomethylation	of	the	Pkd1	gene-body	have	been	
described	in	cystic	tissues	from	ADPKD	patients187,188.	These	modifications	can	interfere	with	
the	normal	expression	of	Pkd1 and might	be	responsible	for	disease	progression.
4. Conclusions
Altogether,	the	current	knowledge	suggests	that	injury-repair	mechanisms	are	part	of	ADPKD	
progression.	The	two	events	are	so	intertwined	that	it	is	difficult	to	dissect	them.	Indeed,	
injury	can	cause	or	accelerate	cyst	formation,	but	at	the	same	time,	cyst	enlargement	is	a	
source	of	local	injury,	establishing	an	injury-like	cyst	milieu	that	exacerbates	renal	function	
decline.	 Further	 investigations	 are	 required	 to	 be	 able	 to	 separate	 a	 direct	 effect	 of	 the	
polycystins	on	the	cyst	initiating	dysfunctional	molecular	mechanisms,	from	the	secondary	
effects	of	disease	progression	and	cyst	expansion.
5. Aim and outline of the thesis
There	is	a	consistent	body	of	literature	that	describes	the	strong	connections	between	the	
injury-repair	mechanisms	and	ADPKD	progression.	The	scope	of	this	thesis	is	to	identify	and	
investigate	molecular	pathways	involved	in	injury-repair	and	ADPKD	progression	to	better	
characterise	the	steps	in	disease	progression,	and	provide	new	cues	for	future	studies	and	
therapeutic	approaches.
In chapter 2,	we	investigate	the	role	of	Four-jointed	box	protein	1	(FJX1)	in	injury	and	ADPKD	
progression.	FJX1	is	a	Golgi	kinase	implicated	in	the	regulation	of	two	important	dysregulated	
pathways	 in	 ADPKD:	 planar	 cell	 polarity	 (PCP)	 and	 Hippo	 signalling.	 In	 a	 previous	 study	
performed	in	our	group,	FJX1	was	found	aberrantly	expressed	during	both	the	injury-repair	
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phase	and	PKD	progression	in	mice,	suggesting	a	possible	role	for	FJX1	in	cyst	formation	and	
progression.	Specifically,	we	investigated	if	genetic	deletion	of	FJX1	might	influence	PCP	or	
Hippo	pathway	regulation,	and	result	in	a	modification	of	the	normal	PKD	progression.	We	
did	not	find	any	evidence	for	differential	regulation	of	PCP	or	Hippo	pathway.	However,	we	
observed	an	effect	of	FJX1	on	fibrosis	and	cellular	infiltrates.
In chapter 3,	 we	 investigate	 further	 the	 role	 of	 the	 Hippo	 pathway	 in	 PKD	 progression.	
Hippo	pathway	is	a	highly	conserved	signalling	pathway	that	regulates	organ	size.	Several	
of	the	molecular	mechanism	modulated	by	Hippo	pathways	are	also	central	to	cyst	growth.	
Indeed,	in	a	previous	study,	we	observed	increased	expression	of	one	of	the	downstream	
effectors	of	the	Hippo	pathway,	YAP,	in	the	nucleus	of	the	cystic	epithelium.	Therefore,	in	
chapter	3	we	hypothesise	 that	 reducing	YAP	 level	 in	Pkd1	KO	mice	might	ameliorate	 the	
cystic	 phenotype.	We	decided	 to	 take	 an	 approach	 based	 on	 antisense	 oligonucleotides	
(ASO)	that	target	specifically	YAP	transcripts	leading	to	a	significant	reduction	of	expression	
in	the	kidneys.	We	found	no	effect	on	cyst	progression.	We	also	investigated	the	effect	of	
Yap or Taz	knock-out	on	cyst	formation	in vitro	using	a	3D	cyst	assay.
In chapter 4,	we	use	a	combined	approach	based	on	RNAseq	analysis	of	in	house	generated	
Pkd1-mutant	mouse	model	and	a	meta-analysis	of	publicly	available	PKD	expression	profile	
to	identify	a	list	of	genes	normally	dysregulated	in	PKD.	Moreover,	we	investigated	the	link	
between	 PKD	 progression	 and	 injury-repair	mechanisms.	 Finally,	 we	 employed	 different	
Pkd1-mutant	mice,	with	or	without	toxic	renal	injury,	to	validate	the	findings.
In chapter 5,	we	elaborate	on	the	work	presented	in	chapter	4	using	computational	analysis.	
We	primarily	focus	on	the	transcription	factors	(TFs)	altered	during	both	PKD	progression	
and	 injury-repair.	 We	 validated	 our	 computational	 analysis	 with	 wet-lab	 experiments,	
including	qPCR,	immunohistochemistry,	and	chromatin	immunoprecipitation.
Lastly,	a	general	overview	of	the	results	described	in	the	previous	chapters	and	suggestions	
for	future	research	are	discussed	in	chapter 6.
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Abstract
Autosomal	Dominant	Polycystic	Kidney	Disease	(ADPKD)	is	characterized	by	the	development	
of	fluid-filled	cysts	in	the	kidneys	which	lead	to	end-stage	renal	disease	(ESRD).	In	the	majority	
of	 cases,	 the	disease	 is	 caused	by	 a	mutation	 in	 the	Pkd1	 gene.	 In	 a	previous	 study,	we	
demonstrated	that	renal	injury	can	accelerate	cyst	formation	in	Pkd1	knock-out	(KO)	mice.	
In	that	study,	we	found	that	Four-jointed	(FJX1),	an	upstream	regulator	of	planar	cell	polarity	
and	the	Hippo	pathway,	was	aberrantly	expressed	in	Pkd1	KO	mice	compared	to	wild-type	
after	injury.	Therefore	we	hypothesized	a	role	for	FJX1	in	injury/repair	and	cyst	formation.	
We	generated	single	and	double	deletion	mice	for	Pkd1 and Fjx1,	and	we	induced	toxic	renal	
injury	using	 the	nephrotoxic	 compound	1,2-dichlorovinyl-cysteine	 (DCVC).	We	 confirmed	
that	 nephrotoxic	 injury	 can	 accelerate	 cyst	 formation	 in	Pkd1	mutant	mice.	 This	 caused	
Pkd1	 KO	mice	 to	 reach	 ESRD	 significantly	 faster;	 unexpectedly,	 double	 KO	mice	 survived	
significantly	longer.	Indeed,	cyst	formation	was	comparable	in	both	models,	but	we	found	
significantly	 lower	fibrosis	and	macrophage	infiltrates	 in	double	KO	mice.	Taken	together,	
these data suggest that Fjx1	disruption	protects	the	cystic	kidneys	against	kidney	failure	by	
reducing	inflammation	and	fibrosis.	Moreover,	we	describe,	for	the	first	time,	an	interesting	
(yet	unidentified)	mechanism	that	partially	discriminates	cyst	growth	from	fibrogenesis.
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Introduction
Autosomal	Dominant	Polycystic	Disease	(ADPKD)	is	a	genetic	disease	caused	in	the	majority	
of	the	cases	by	a	mutation	in	the	Pkd1	gene,	which	encodes	Polycystin	1,	and	in	the	remaining	
cases	by	a	mutation	in	the	Pkd2	gene,	encoding	Polycystin	21.	The	hallmark	of	this	disease	
is	 the	 formation	of	 fluid-filled	 cysts	 in	 the	 kidneys,	which	 slowly	 grow	and	progressively	
disrupt	the	renal	parenchyma,	ultimately	leading	to	kidney	failure1,2.	The	exact	mechanisms	
behind	cyst	formation	are	still	elusive,	and	effective	therapies	are	still	missing,	although	the	
Vasopressin	V2R	antagonist	Tolvaptan	has	become	recently	available	for	selected	patients3-5.
Recently,	 our	 group	 showed	 that	 a	 substantial	 proportion	of	 genes	 typically	 deregulated	
in	ADPKD	also	plays	a	role	 in	 injury-repair	mechanisms6.	 Indeed,	 less	 than	a	decade	ago,	
injury	has	emerged	as	an	important	player	in	cyst	formation	and	progression,	and	now	it	
is	 considered	a	 “modifier”	of	ADPKD7.	 Several	 other	 groups	and	we	described	 that	both	
nephrotoxic8	and	ischemic	injury,	as	well	as	unilateral	nephrectomy9-12,	were	able	to	speed	
up	 cyst	 formation	and	progression,	 reinforcing	 the	 link	between	ADPKD	progression	and	
injury.	 In	 particular,	 we	 identified	 one	 gene,	 Four-jointed box1	 (Fjx1),	 as	 an	 interesting	
player	in	these	processes.	 In	our	study,	Fjx1	showed	aberrant	expression	during	both	the	
injury-repair	phase	and	cyst	progression	in	Pkd1	KO	mice	compared	with	wild-type	mice8.	
Moreover, Fjx1	 is	 implicated	with	 two	 important	 pathways	normally	 aberrant	 in	ADPKD:	
planar	cell	polarity	(PCP)	and	the	Hippo	pathway.
FJX1	is	the	mammalian	homolog	of	the	Drosophila	protein	Fj,	discovered	for	its	pivotal	role	
in	the	correct	development	of	leg	joints,	wings	and	eyes9,10.	Fj	regulates	the	interaction	of	
Fat	(Ft)	with	Dachsous	(Ds),	which	controls	PCP	signalling,	most	 likely	 in	parallel	with	the	
Frizzled	signals10-12.	Fj mutant Drosophila	models	have	a	clear	alteration	of	PCP,	while	Fjx1 
KO	mice	do	not	show	any	evident	morphological	defects	in	the	kidneys	or	other	organs13,14.	
However,	deleting	 the	 target	of	FJX1,	Fat4,	 leads	 to	 loss	of	PCP	 in	 the	 inner	ear,	 cochlea	
and	the	neural	tube,	and	mild	cyst	formation	in	mouse	kidney.	Loss	of	both,	Fat4 and Fjx1, 
slightly	aggravates	the	phenotype	suggesting	that	FJX1	may	also	act	via	Fat4-independent	
pathways.	Yet,	the	effect	of	Fjx1 in a Pkd1	mutant	context	is	to	date	unknown14.	
In Drosophila,	Fj	is	also	an	upstream	regulator	of	the	Hippo	pathway,	through	its	downstream	
target	 Ft.	 The	Hippo	pathway	 regulates	 proliferation	 and	tissue	 size	 through	 the	 activity	
of	the	final	effector	and	transcriptional	co-activator	Yorki	(Yki)15-16.	 In	mammals,	there	are	
two	 Yki orthologs: Yes-associated protein 1	 (Yap1)	 and	 transcriptional coactivator with 
PDZ-binding motif	 (Wwtr1 or Taz).	When	 the	Hippo	pathway	 is	active,	YAP1	and	TAZ	are	
phosphorylated	and	retained	in	the	cytoplasm,	preventing	their	nuclear	translocation	and	
transcriptional	 activity.	 In	 ADPKD,	 YAP	 and	 TAZ	 activity	 is	 upregulated	 in	 the	 cyst-lining	
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epithelium	as	indicated	by	their	nuclear	localization,	suggesting	a	role	for	this	pathway	in	
cyst	progression17.	In	mammals,	regulation	of	the	Hippo	pathway	by	FAT4	has	recently	been	
shown	in	the	prenatal	heart18;	however,	whether	this	regulatory	mechanism	also	takes	place	
in	the	kidneys	is	not	clear14,19.
This	study	aims	to	investigate	the	role	of	FJX1	during	ADPKD	progression,	particularly	after	
kidney	injury	and	the	involvement	of	the	PCP	and	Hippo	pathways.	We	show	that	mice	that	
are	double	mutant	 for	Fjx1 and Pkd1	display	cyst	 formation	comparable	to	that	of	single	
Pkd1	KO	mice	but	survive	longer.	This	effect	was	probably	not	due	to	differences	in	PCP	and	
the	Hippo	pathway,	which	were	not	affected	by	Fjx1	deletion,	but	rather	due	to	reduced	
fibrosis	and	macrophage	 infiltration	 in	the	double	KO	mice.	We	also	show	a	reduction	of	
fibrosis	which	is	independent	of	cyst	formation.	Indeed,	in	our	study,	reduced	fibrogenesis	
is	directly	caused	by	Fjx1	deletion	and	not	an	indirect	consequence	of	the	improved	cystic	
phenotype.
FOUR-JOINTED KNOCK-OUT DELAYS RENAL FAILURE IN AN ADPKD MODEL WITH KIDNEY INJURY 
45
2
Materials and Methods
Animal Models
All	the	animal	experiments	were	evaluated	and	approved	by	the	local	animal	experimental	
committee	of	the	Leiden	University	Medical	Centre	and	the	Commission	Biotechnology	in	
Animals	of	the	Dutch	Ministry	of	Agriculture.	The	kidney	specific	tamoxifen-inducible	Pkd1-
deletion	mouse	model	(Pkd1-cKO)	and	the	Fjx1-/-	(Fjx1	KO)	has	been	described	previously13,20.	
By	 cross-breeding	 Pkd1-cKO	 with	 the	 Fjx1	 KO	 mice,	 we	 generated	 the	 Fjx1-/-/Pkd1-cKO	
double	KO	mouse	model	(double	KO).	Inactivation	of	the	Pkd1	gene	was	achieved	by	oral	
administration	of	tamoxifen	in	adult	mice	(13	to	14	weeks	old).	Renal	injury	was	induced	a	
week	after	gene	disruption	by	a	single	 intraperitoneal	 injection	of	S-(1,2-dichlorovinyl)-L-
cysteine	(DCVC)	or	vehicle.	 Injury	was	evaluated	by	measurement	of	blood	urea	nitrogen	
(BUN)	level	after	40	hours,	as	described	before8.	More	detailed	protocols	in	Supplementary	
materials.
Immunohistochemistry
Formalin-fixed	paraffin-embedded	kidneys	were	sectioned	at	4	μm	thickness.	Sections	were	
stained	with	Periodic	acid-Schiff	(PAS)	to	determine	the	cystic	index	(CI)	and	with	Picro	Sirius	
Red	(PSR)	to	determine	fibrotic	index.	Kidney	slides	were	also	stained	for	αSMA,	F4/80,	YAP,	
pSTAT3,	GM130.	More	detailed	protocols	in	Supplementary	materials.
qPCR
Snap-frozen	kidneys	were	homogenized	using	Magnalyser	 technology	 (Roche).	Total	RNA	
was	 isolated	using	Tri-Reagent	 (Sigma-Aldrich).	 cDNA	 synthesis	was	performed	using	 the	
Transcriptor	First	Strand	cDNA	Synthesis	Kit	(Roche),	and	qPCR	was	done	using	2×	FastStart	
SYBR-Green	Master	 (Roche)	according	 to	 the	manufacturer’s	protocol.	Primer	 sequences	
are	provided	in	Supplementary	Table	1.	Gene	expression	was	normalized	to	Hprt	and	fold-
change	was	used	for	representation	in	the	graphs.	
Statistical Analysis
Data	were	analysed	using	ANOVA	 in	GraphPad	Prism	8.00	 for	Windows	and	 linear-mixed	
effects	models	in	IBM	SPSS	Statistics	for	Windows,	version	23.
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Results
Mice double KO for Pkd1 and Fjx1 survive longer after toxic tubular damage compared 
with mice single KO for Pkd1. 
Inactivation	of	 the	Pkd1	 gene	was	 achieved	by	oral	 administration	of	 tamoxifen	 in	 adult	
mice.	This	type	of	mouse	model	is	characterized	by	a	relatively	slow	cyst	growth	that	allows	
having	reasonable	time	windows	for	the	study	of	the	different	steps	of	disease	progression.
We	 showed	previously	 that	 upon	nephrotoxic	 injury	 cyst	 initiation	 is	 faster	 in	mice	with	
Pkd1	 deletion	 compared	with	 the	 non-injured	 group8.	 Using	 the	 same	 injury	model,	we	
administered	 the	 nephrotoxic	 compound	DCVC	 to	Wt,	Pkd1	 KO,	 Fjx1	 KO	 and	 double	 KO	
mice	(Figure	1A).	We	used	PBS	 injection	as	a	control	 (vehicle	group).	At	40	h	upon	DCVC	
injections,	renal	injury	was	confirmed	by	a	substantial	rise	in	the	BUN	level	in	all	mice,	which	
returned	to	baseline	after	1	week,	suggesting	a	full	recovery	of	the	kidney	function	with	no	
differences	among	the	genotypes	(Figure	1B).	
Figure 1. Blood Urea Nitrogen (BUN) level after DCVC 
injection and during disease progression 
(A)	 Graphical	 representation	 of	 the	 mouse	 experiment	
pipeline.	Adult	mice	(13-14	weeks	old)	were	fed	with	5	mg/
day	of	Tamoxifen	for	three	days	(week	-1).	A	week	later	they	
were	injected	intraperitoneally	with	15	mg/kg	of	DCVC	or	PBS	
as	a	control	(week	0).	Mice	were	sacrificed	1,	2,	5	and	10	weeks	
after	DCVC	or	PBS	injection	and	at	kidney	failure,	indicated	by	
a	rise	in	BUN	over	25	mmol/l.	(B)	BUN	level	in	the	first	weeks	
after	DCVC	 injection.	 All	 the	 genotypes	 are	 back	 to	 normal	
level	after	a	week	post	injury	induction.	(C) BUN level in Pkd1 
KO	mice	 and	 (D)	 in	 double	 KO	mice	 with	 (black	 solid	 line)	
and	without	(grey	dashed	line)	injury.	Each	line	represents	a	
mouse.	Kidney	failure	was	accelerated	by	DCVC	treatment	in	
Pkd1	 KO	mice	 (median	DCVC	group:	14	weeks;	median	PBS	
group:	19	weeks;	Mann-Whitney	test	P	value	<0.05)	but	not	in	
double	KO	mice	(median	DCVC	group:	20	weeks;	median	PBS	
group:	21	weeks),	which	reached	kidney	 failure	significantly	
later than Pkd1	 KO	 +	 DCVC	 (Two-way	 ANOVA	 with	 Tukey’s	
multiple	comparisons	test,	P	value	<0.05).	(E)	Representative	
whole-mount	 kidneys	 at	 renal	 failure	 (Pkd1	 KO	 and	 double	
KO)	or	24	weeks	after	DCVC	(Wt	and	Fjx1	KO).	Pkd1	KO	and	
double	 KO	 kidneys	 show	 enlarged	 cystic	 kidneys,	 opposite	
to	Wt	 and	 Fjx1	 KO	 kidneys	 which	 do	 not	 show	 any	 visible	
alteration.	Analysis	of	the	renal	structure	was	performed	on	
paraffin-fixed	kidney	section	of	all	genotypes	confirming	the	
absence	of	tubule	dilation	and	cysts	formation	in	Wt	and	Fjx1 
KO	mice	at	all	time	points	(data	not	shown).
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Pkd1	KO	mice	injected	with	DCVC	reached	end-stage	renal	disease	(ESRD)	around	14	weeks	
after	 injury.	 This	 was	 significantly	 earlier	 than	 in	 the	 vehicle	 group,	 which	 survived	 for	
about	19	weeks,	 in	accordance	with	previously	generated	data	 (Figure	1C)8.	 Surprisingly,	
we	observed	that	the	double	KO	mice	did	not	show	a	difference	between	DCVC	and	vehicle	
treatment	 with	 a	 median	 survival	 of	 20	 and	 21	 weeks,	 respectively	 (Figure	 1D).	 When	
compared	with	Pkd1	 KO	mice,	 double	 KO	mice	 survived	 significantly	 longer	 after	 injury,	
indicating	that	the	lack	of	Fjx1	improved	survival	of	double	KO	mice	upon	renal	damage.
Both	Wt	and	Fjx1	KO	mice	subjected	to	renal	injury	did	not	develop	cysts	still	24	weeks	after	
DCVC,	the	time	point	when	mice	were	sacrificed	(Figure	1E	and	data	not	shown).
Knocking-out Fjx1 in Pkd1 mutant mice does not affect cyst formation
Since	renal	injury	accelerates	cyst	formation	in	Pkd1	KO	mice8,21-24,	we	wondered	whether	
prolonged	survival	observed	 in	 the	double	KO	group	 treated	with	DCVC	could	be	due	 to	
delayed	cyst	initiation.	We	measured	the	cystic	index	in	kidneys	from	Pkd1	KO	and	double	
KO	mice	at	10	weeks	after	DCVC	injection	when	mice	start	to	show	a	mild	cystic	phenotype.	
We	compared	Pkd1	KO	and	double	KO	mice	with	and	without	DCVC,	and	did	not	find	any	
difference	 in	 the	 cystic	 index,	 and	 two	 kidneys	weight	 to	 body	weight	 (2KW/BW)	 ratio’s	
between	the	genotypes	at	this	time	point	(Figure	2A-C).	Thus,	the	initiation	of	cyst	formation	
is	not	different	in	the	two	models,	suggesting	a	role	in	cyst	growth.	
Figure 2. Cysts formation at 10 weeks after DCVC 
(A)	Representative	Periodic	Acid	Schiff	 (PAS)	 staining	of	Pkd1	KO	and	double	KO	mice	at	10	weeks	after	DCVC,	
showing	comparable	cyst	formation	in	the	two	genotypes.	Scale	bars,	1	mm.	(B)	Evaluation	of	kidney	size	at	10	
weeks	time-point	in	Pkd1	KO	and	double	KO	mice	with	and	without	injury	using	two	kidney	weight/body	weight	
ratio.	(C)	Cystic	index	at	10	weeks	time-point	in	Pkd1	KO	and	double	KO	mice	with	and	without	injury.	Each	symbol	
shows	data	from	one	mouse.	Mean	±	SD.	Two-way	ANOVA	with	Tukey’s	multiple	comparisons	test.
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Figure 3. Cysts size at kidney failure 
(A)	Representative	PAS	staining	of	Pkd1	KO	and	double	KO	mice	at	kidney	failure.	Scale	bars,	1	mm.	(B)	Quantification	
of	cysts	size	frequency	in	Pkd1	KO	and	double	KO	mice	with	and	without	injury.	Data	represent	the	mean	of	4	mice	
±	SD.	Three-way	ANOVA	(P	value	<0.0001)	with	Tukey’s	multiple	comparisons	test.	*	P	value	<0.05.
This	is	also	evident	when	ESRD	kidneys	are	compared.	Indeed,	Pkd1	KO	mice	injected	with	
DCVC,	which	reach	ESRD	faster,	had	a	shorter	phase	of	cyst	growth	and	displayed	mainly	
small	cysts	at	kidney	failure.	Conversely,	double	KO	mice,	which	have	a	slower	progression	
to	ESRD	and	therefore	a	longer	phase	of	cyst	growth,	show	frequently	larger	cysts	(Figure	
3A,	B).	Thus,	our	data	suggest	that	FJX1	is	not	directly	involved	in	cyst	formation	and	that	
prolonged	survival	of	the	double	KO	mice	cannot	be	explained	by	delayed	cyst	formation.	
Chronic injury caused by cyst formation leads to differences in injury markers expression, 
fibrosis and inflammatory responses in double KO compared with Pkd1 KO mice
Cyst	 formation	 is	 accompanied	 by	 inflammation	 and	 fibrosis	 which	 ultimately	 leads	 to	
complete	 loss	of	 renal	 function.	As	 changes	 in	 these	processes	might	 affect	 survival,	we	
analysed	 whether	 Fjx1	 deletion	 altered	 the	 expression	 of	 injury	 markers,	 fibrosis	 and	
inflammation.	
The	expression	of	the	well-established	kidney	injury	molecule	Kim1	(Havcr1)25	was	analysed	
using	qPCR.	We	observed	increased	Kim1	expression	already	at	10	weeks	after	DCVC	injection	
in Pkd1	KO	and	in	double	KO	mice,	a	time-point	when	dilation	of	tubules	and	small	cysts	
were	evident.	In	contrast,	Wt	and	Fjx1	KO	mice,	which	do	not	develop	a	renal	phenotype	
after	DCVC	injection,	did	not	show	increased	Kim1	expression,	reinforcing	the	idea	of	cyst-
induced	 chronic	 injury	 (Figure	 4A).	 Interestingly,	 at	 kidney	 failure,	 Kim1 expression	 was	
significantly	higher	in	Pkd1	KO	mice	compared	to	double	KO	(Figure	4B).
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Figure 4. Expression of genes involved in injury-repair in Pkd1 KO and double KO mice 
(A)	 Gene	 expression	of	Kim1	 (Havcr1)	 at	 10	weeks	 after	DCVC	 injection.	 Both	Pkd1	 KO	 and	double	 KO	have	 a	
significant	increase	of	Kim1	expression	compared	to	the	PBS	groups	and	the	Wt	and	Fjx1	KO	with	and	without	injury	
(significance	not	shown	on	graph),	but	not	compared	to	each	other.	(B)	Gene	expression	of	Kim1	at	kidney	failure	
after	DCVC	 injection	 (significance	to	Wt	and	Fjx1	KO	not	shown	on	graph).	 (C)	Gene	expression	of	Col1a1, Vim 
and Fn1	at	10	weeks	after	DCVC	injection.	(D)	Gene	expression	of	Col1a1, Vim and Fn1	at	kidney	failure.	(E) Gene	
expression	of	Acta2, Tgfb1 and Adgre1	 (F4/80)	at	10	weeks	after	DCVC	injection. (F) Gene	expression	of	Acta2, 
Tgfb1 and Adgre1	at	kidney	failure.	Each	symbol	shows	data	from	one	mouse.	Mean	±	SD.	Two-way	ANOVA	with	
Tukey’s	multiple	comparisons	test.	*	P	value	<0.05;	**	P	value	<0.01;	***	P	value	<0.001.	
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When	we	analysed	fibrogenesis	at	10	weeks	after	DCVC	and	kidney	failure,	expression	of	
alpha-1	type	I	collagen	(Col1a1)	and	Vimentin	(Vim)	was	significantly	reduced	in	the	double	
KO	compared	 to	Pkd1	KO	at	10	weeks	after	DCVC,	both	at	 the	mRNA	 (Figure	4C,	D)	and	
protein	levels	(Figure	5A,	B);	expression	of	Fibronectin	(Fn1)	showed	a	similar	trend	(Figure	
4C,	D).	Interestingly,	while	in	Pkd1	KO	mice	the	expression	of	these	genes	was	significantly	
correlated	with	kidney	size,	this	was	not	observed	in	the	double	KO	mice,	suggesting	that	in	
these	mice	cyst	progression	and	fibrosis	are	two	independent	events	(Supplementary	Figure	
1).	Likewise,	the	expression	of	transforming	growth	factor	beta-1	(Tgfb1),	was	significantly	
less	in	double	KO	compared	to	Pkd1	KO	mice	at	10	weeks	and at	kidney	failure.	Also,	double	
KO	mice	at	10	weeks	had	tendentially	lower	alpha-smooth	muscle	actin	(Acta2)	transcript	
and	significantly	less	αSMA	positive	area	(Figure	4E,	F;	Figure	5C,	D).	
To	characterize	the	inflammatory	response,	we	looked	at	the	expression	of	the	macrophage	
marker	Adgre1	(F4/80)	and	found	it	to	be	significantly	less	expressed	in	double	KO	compared	
to Pkd1	KO	mice	at	kidney	failure	(Figure	4E,	F).	At	10	weeks	after	DCVC	Adgre1	showed	a	
trend	but	at	the	protein	level	F4/80	expression	was	significantly	reduced	in	double	KO	mice	
(Figure	5E,	F).	We	also	checked	the	expression	of	Jak2 and Stat1,	involved	in	the	transduction	
of	a	series	of	signals,	 like	growth	factors	and	cytokines in	response	to	 injury26.	We	found	
significantly	lower	expression	in	double	KO	compared	to	Pkd1	KO	mice	(Figure	5G,	H).	On	
the	other	hand,	Stat3	activation,	known	to	be	involved	in	cyst	growth27,	was	not	significantly	
different	between	the	two	genotypes,	supporting	the	idea	that	FJX1	role	is	related	to	the	
inflammatory/fibrotic	response	and	not	to	cyst	formation	(Supplementary	Figure	2).	These	
results	 indicate	 that	 the	 lack	 of	 Fjx1	 leads	 to	 a	 reduced	 inflammatory/fibrotic	 response	
which	translates	into	a	longer	survival	after	DCVC	administration.
Investigation of pathways involved in renal fibrosis
We	also	studied	the	expression	of	key	genes	of	several	pathways	known	to	be	involved	in	
renal	fibrosis,	such	as	Notch28,29,	Hedgehog30,31,	Wnt32,33,	hypoxia34-38	and	Egf39-41.	However,	we	
could	not	find	any	differences	between	the	double	KO	and	Pkd1	KO	mice,	except	for	Pdgfb	
(Supplementary	Figure	3)	and	Wnt	target	genes.	Indeed,	Axin2, Cd44, Ccnd1	(Figure	6A,	B)	
and	to	certain	extent	Myc	(Supplementary	Figure	4),	showed	significantly	lower	expression	
in	double	KO	compared	with	Pkd1	 KO	mice,	both	at	10	weeks	after	DCVC	and	at	 kidney	
failure,	suggesting	a	reduced	activation	of	the	canonical	Wnt	signalling	 in	the	absence	of	
Fjx1.
Mice double KO for Pkd1 and Fjx1 show less sensitivity to DCVC induced injury than mice 
single KO for Pkd1
To	 further	 investigate	 the	 role	 of	 FJX1	 in	 injury,	 we	 performed	 a	 pilot	 experiment	 in	
which	mice	 treated	with	DCVC	were	 sacrificed	after	24	h,	48	h	and	72	h,	 i.e.	during	 the	
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Figure 5. Fibrosis, fibroblast activation and macrophage infiltrates in Pkd1 KO and double KO mice 
(A) Representative	Picro	Sirius	Red	(PSR)	staining	of	Pkd1	KO	and	double	KO	mice	at	10	weeks	after	DCVC.	Scale	
bars,	50	μm.	(B) Quantification	of	PSR	staining	in	the	cortico-medullary	region.	(C)	Representative	αSMA	staining	of	
Pkd1	KO	and	double	KO	mice	at	10	weeks	after	DCVC.	Scale	bars,	50	μm.	(D)	Quantification	of	αSMA	staining	in	the	
cortico-medullary	region.	(E)	Representative	F4/80	staining	of	Pkd1	KO	and	double	KO	mice	at	10	weeks	after	DCVC.	
Scale	bars,	50	μm.	(F)	Quantification	of	F4/80	staining	 in	the	cortico-medullary	region.	Each	symbol	 is	a	mouse	
and	data	represent	the	mean	±	SD.	Two-way	ANOVA	with	Tukey’s	multiple	comparisons	test.	*	P	value	<0.05;	**	
P	value	<0.01.	(G)	Gene	expression	of	Stat1 and Jak2	at	10	weeks	after	DCVC	in	Pkd1	KO	and	double	KO	mice.	(H) 
Gene	expression	of	Stat1 and Jak2	at	kidney	failure	in	Pkd1	KO	and	double	KO	mice	treated	with	DCVC.	Each	symbol	
shows	data	from	one	mouse.	Mean	±	SD.	Unpaired	t-test.	*	P	value	<0.05;	**	P	value	<0.01.
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nephrotoxin-induced	 acute	 injury	 phase.	At	 all	 time-points,	we	 found	 a	 trend	 consistent	
with	that	observed	in	the	cyst-induced	chronic	injury,	showing	that	the	Kim1	expression	was	
less	in	double	KO	mice	than	in	Pkd1	KO.	At	1	week	after	DCVC	Kim1	expression	is	strongly	
reduced	in	both	genotypes	suggesting	that	the	DCVC-induced	acute	injury	is	largely	repaired	
in	the	first	week	(Supplementary	Figure	5).	In	line	with	the	findings	from	the	chronic	injury	
experiments,	the	expression	of	genes	involved	in	fibrogenesis,	such	as	Cola1a, Vim and Fn1, 
was	lower	in	double	KO	compared	with	Pkd1	KO	mice	(Supplementary	Figure	5).	
Together	with	the	results	observed	during	the	cyst-induced	chronic	injury,	these	data	suggest	
that	the	lack	of	Fjx1 leads	to	a	reduced	sensitivity	to	DCVC-induced	injury.
PCP is altered in Pkd1 mutant mice after injury but is not significantly affected by the lack 
of Fjx1
Tissue	 injury	causes	 inversion	or	 loss	of	PCP	 in	epithelial	cells,	which	recovers	during	the	
repair	phase42.	Fj	has	been	described	as	an	important	PCP	gene	in	Drosophila as is Fjx1 in 
mammals,	in	particular	in	the	regulation	of	the	brain	architecture13	and	inner	ear	polarity14.	
Therefore	we	decided	to	characterize	renal	PCP	at	1	week	after	injury	in	Pkd1	KO	and	double	
KO	mice.
The	levels	of	expression	of	Fat4 and its ligand Dchs143	were	unchanged	by	Fjx1	KO	(Figure	6C)	
suggesting	that,	at	the	expression	level,	the	Fat/Ds	PCP	pathway	was	unaltered	in	kidneys	of	
mutant	mice.	We	also	used	the	Golgi	position	to	assess	the	degree	of	polarity	perturbation	
in	 tubular	 cells	 (Figure	6D).	Although	Golgi	 position	 is	 not	 a	direct	 read-out	of	 PCP	 core	
proteins,	it	is	found	to	be	aberrant	when	PCP	genes	are	knocked-out44, and is also associated 
with	loss	of	directed	secretion,	cell	polarity	and	wound	healing	capacity45.	
We	 confirmed	 that	 altered	 polarity	 was	 associated	 with	 loss	 of	 Pkd1	 and	 kidney	 injury	
already	at	the	pre-cystic	stage,	with	a	significantly	higher	aberrant	Golgi	position	 in	Pkd1 
KO	and	double	KO	mice	compared	with	Wt	and	Fjx1	KO.	However,	we	could	not	 identify	
any	difference	between	double	KO	and	Pkd1	KO	or	between	Wt	and	Fjx1	KO	(Figure	6E),	
indicating	that	Fjx1	did	not	contribute	to	an	altered	PCP.	
The effect of Fjx1 on injury response is not mediated by the Hippo pathway 
FJX1	is	thought	to	be	an	upstream	regulator	of	the	Hippo	pathway	through	the	activity	of	
FAT446.	The	Hippo	pathway	is	pivotal	in	the	regulation	of	organ	growth,	tissue	renewal	and	
regeneration47	but	is	also	deregulated	in	ADPKD17.	Therefore,	we	investigated	this	pathway	
in Pkd1	KO	and	double	KO	mice	after	DCVC	treatment.
The	Yap	staining	of	kidney	sections	confirmed	the	pattern	described	before	in	our	lab	with	
increased	 nuclear	 localization	 of	 Yap	 in	 the	 cystic	 epithelium17.	 However,	 we	 could	 not	
detect	 any	 significant	 difference	 between	 double	 KO	 and	 Pkd1	 KO.	 Also,	 neither	mRNA	
levels	of	Yap1	 and	 its	paralog	Taz,	nor	 their	 transcriptional	 targets,	Amotl2, Cyr61, Wtip, 
Ctgf, Ajuba	(Supplementary	Figure	6),	showed	any	significant	difference	among	genotypes.	
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Figure 6. Expression of Wnt pathway target genes and expression level of Fjx1 targets and Golgi position in 
tubular cells 
(A) Axin2, Cd44 and Ccnd1	mRNA	levels	at	10	weeks	after	DCVC	injection.	(B) Gene	expression	of	Axin2, Cd44 and 
Ccnd1	at	kidney	failure.	(C)	Gene	expression	of	Fat4 and Dchs1	at	1	week	after	DCVC	injection.	Each	symbol	shows	
data	from	one	mouse.	Mean	±	SD.	Two-way	ANOVA	with	Tukey’s	multiple	comparisons	test.	*	P	value	<0.05;	**	P	
value	<0.01;	***	P	value	<0.001.	(D)	Representative	GM130	(green)	staining	on	kidney	tissue.	Nuclei	are	stained	
in	blue.	 In	the	normal	situation	the	Golgi	 is	positioned	 in	a	peri-centrosomal	position	at	the	top	of	the	nucleus	
towards	the	lumen	of	the	tubules,	but	after	injury	we	often	observed	altered	Golgi	position.	Scale	bars,	10	μm.	(E) 
Golgi	position	has	been	scored	from	1	(normal	position)	to	3	(really	abnormal	position)	in	the	round	shaped	tubules	
in	the	cortico-medullary	region.	Results	are	represented	as	the	percentage	of	aberrant	Golgi	position	(score	≥2.5)	
per	tubules.	Each	symbol	is	the	mean	±	SD	of	about	90	tubules	scored	in	a	mouse.	Two-way	ANOVA	with	Fisher’s	
LSD.	**	P	value	<0.01.
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This	suggests	that	despite	the	clear	nuclear	localization	of	Yap	in	the	cystic	epithelium	this	
pathway	is	not	responsible	for	the	difference	in	survival	between	Pkd1	KO	and	double	KO	
mice.
Taken	 together,	 these	 data	 indicate	 that	 knocking-out	 Fjx1	 does	 not	 affect	 PCP	 and	 the	
Hippo	pathway	in	the	kidneys.	Therefore,	the	differences	observed	in	response	to	injury	in	
double	KO	mice	cannot	be	explained	by	the	effect	of	Fjx1	on	one	of	its	canonical	targets	but	
suggests	the	existence	of	other,	yet	unknown,	FJX1	targets.
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Discussion
In	this	study	we	showed	that	nephrotoxic	injury	can	accelerate	disease	progression	in	Pkd1 
KO	mice	but	that	this	effect	is	abolished	in	the	absence	of	Fjx1	expression,	allowing	the	Pkd1/
Fjx1	double	KO	mice	to	survive	on	average	5	weeks	longer	than	the	single	Pkd1	KO	mice.	
Interestingly,	the	initiation	of	cyst	formation	and	cyst	growth	were	not	different	among	the	
two	models,	as	shown	by	2KW/BW	ratios	and	the	cystic	index.	At	10	weeks	after	DCVC	and	
kidney	failure,	however,	we	observed	a	reduction	in	injury	marker	expression	together	with	
reduced	fibrosis	and	macrophage	 infiltration	 in	Pkd1	KO	mice	compared	with	double	KO.	
Therefore,	these	data	suggest	that	FJX1	does	not	play	a	critical	role	in	cyst	formation	and	
expansion	but	seems	to	be	involved	in	the	fibrotic	and	inflammatory	response	to	injury.	As	
a	result,	the	mice	lacking	both,	Fjx1 and Pkd1,	have	less	fibrosis,	which	 leads	to	a	slower	
progression	to	ESRD	and	longer	survival.	
Fj	is,	together	with	the	Ft-Ds	cassette,	part	of	a	signalling	complex,	which	is	involved	in	the	
regulation	of	PCP	in	Drosophila48-51.	Nevertheless,	the	absence	of	Fjx1 did not alter PCP in 
the	kidneys	when	compared	with	Wt	mice,	or	 in	double	KO	compared	 to	Pkd1	KO	mice.	
Although	we	observed	significant	deregulation	of	PCP	in	pre-cystic	kidneys	after	 injury	 in	
both	single	Pkd1	mutant	mice	and	double	KO,	the	additional	deletion	of	Fjx1	did	not	further	
change	the	PCP	phenotype	in	the Pkd1	KO.	These	results	are	consistent	with	the	published	
work	of	Probst	et al.13	showing	that	Fjx1	KO	mice	do	not	have	aberrant	PCP	in	the	kidneys	
but	show	only	defects	 in	neuronal	branching.	An	effect	on	renal	PCP	was	only	seen	after	
knocking-out	 Fat4,	 a	 target	 of	 FJX1,	 suggesting	 a	more	 indirect	 effect	 of	 FJX1	 on	 PCP	 in	
mammals14,19.	We	already	showed	in	a	previous	study	that	PCP	is	impaired	in	Pkd1	KO	mice	
but	not	 in	Wt	mice	after	 injury,	and	 that	Pkd1	KO	mice	 injected	with	DCVC	also	develop	
cysts	earlier	when	compared	with	the	PBS	group8.	Whether	pre-cystic	alterations	of	PCP	are	
critical	for	cyst	formation	is	still	controversial.	Several	studies	are	suggesting	that	PCP	and	
cilium-associated	control	of	oriented	cell	division	(OCD)	as	well	as	convergent	extension	(CE)	
are	necessary	during	renal	tubular	morphogenesis	and	also	during	proliferation	phases	in	
adult	kidneys.	Alterations	of	both	OCD	and	CE	are	involved	in	PKD23,52-54.	However,	there	are	
also	studies	showing	that	alterations	in	OCD	and	CE	occur	only	after	cyst	formation,	or	that	
mutations	of	PCP-core	proteins	do	not	result	in	cyst	formation55,56.	This	means	that	simple	
alteration	of	PCP	is	not	sufficient	to	start	cyst	formation	but	disrupted	PCP	together	with	
other	events,	such	as	injury,	presumably	increases	the	likelihood	of	cyst	initiation.
Another	pathway	altered	 in	ADPKD	is	the	Hippo	pathway,	which	 is	also	regulated	via	the	
FJX1	target	FAT4.	In	particular,	the	pathway’s	effectors	Yap1	and	Taz	have	been	associated	
with	 cyst	 formation.	We	 showed	 in	 the	 past	 that	 Yap1	 accumulates	 in	 the	 nuclei	 of	 the	
cyst-lining	 epithelium8,17,	 and	 other	 groups	 showed	 how	 deregulations	 of	 YAP1	 activity	
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could	 induce	cyst	 formation	 in	Zebrafish	models57,58.	Moreover,	 knocking-out	Taz in mice 
leads	to	glomerular	and	proximal	tubular	cyst	formation59-61.	Nevertheless,	we	did	not	see	
an	 effect	of	 FJX1	on	 the	Hippo	pathway	when	 comparing	Pkd1	 KO	and	double	 KO	mice.	
Yap1 and Taz	levels,	as	well	as	the	levels	of	several	of	their	target	genes,	were	comparable	
in	 the	 two	genotypes	 throughout	disease	progression.	Also,	Fat4	 levels	were	unchanged	
by	Fjx1 deletion	(data	not	shown).	Currently,	clear	proof	that	the	FJX1-FAT4-DCHS	cassette	
interaction	controls	PCP	and	Hippo	pathway	in	kidneys	is	still	missing14,19,62.		
Once	cysts	start	to	form	and	expand,	they	compress	the	surrounding	tissue,	compromise	
the	 normal	 tubular	 structure	 and	 also	 interfere	 with	 the	 extracellular	 compartment.	
This	 is	 accompanied	 by	 the	 expression	 of	 injury	markers	 and	 activation	 of	 transcription	
factors	 like	Stat3,	Creb	and	ERK,	known	to	be	 involved	 in	ADPKD	pathogenesis,	and	with	
an	increased	likelihood	of	more	cyst	formation22,27,63,64.	All	these	cues	are	perceived	by	the	
organ	like	a	constant	injury	insult	and	accompanied	by	a	fibrotic	and	inflammatory	response.	
Concomitantly,	a	severe	cystic	phenotype	is	associated	with	renal	function	decline	due	to	
the	accumulation	of	fibrosis	and	inflammatory	infiltrates,	which	interfere	with	normal	organ	
function65,66.	Nonetheless,	 it	 is	unclear	whether	inflammation	and	fibrosis	are	responsible	
for	or	just	a	consequence	of	cyst	formation.	In	our	study,	we	observed	separation	between	
cyst	formation	and	fibrotic	response	when	Fjx1	is	inactivated.	Indeed	double	KO	mice	had	
significantly	reduced	fibrosis	and	leukocytes	infiltrates	compared	with	Pkd1	KO	mice	even	
though	cyst	formation	was	comparable.	We	could	exclude	the	involvement	of	some	fibrosis-
related	pathways,	 such	as	Notch,	Hedgehog,	hypoxia	and	Egfr	 signalling,	while	we	 found	
a	 significant	 reduction	 of	 expression	 of	Pdgfb, Tgfb1, Jak2 and Stat1,	 and	Wnt	 pathway	
target	genes	in	double	KO	compared	to	Pkd1	KO	mice.	Considering	the	well	described	role	
of	Tgfb	and	Wnt	pathways	 in	renal	fibrosis32,33,67,68,	 it	 is	plausible	 to	think	that	 they	might	
be	 responsible	 for	 the	 reduced	 fibrosis	 observed	 in	 double	 KO	 mice.	 Indeed,	 Tgfb	 can	
regulate	the	expression	of	Pdgfb69, Fn1	and	type	I	collagen70,71	all	found	downregulated	in	
double	KO	mice.	Similarly,	Wnt	targets	Axin272, Cd4473, Ccnd174,75 and Myc76	were	lower	in	
double	KO	mice.	Further	studies	are	required	to	link	FJX1	with	the	Tgfb	and	Wnt	pathways	
mechanistically.	An	interesting	connection	between	FJX1	and	Jak/Stat	pathways	has	been	
described	 in	 the	 literature,	with	 Fj	 as	 the	effector	of	 the	pleiotropic	pathway	 Jak/Stat	 in	
Drosophila10.	Although	it	is	tempting	to	speculate	that	this	might	be	the	route	through	which	
FJX1	modulates	the	injury	response,	it	is	more	likely	that	reduced	Jak2/Stat1 levels in the 
double	KO	mice	mirror	a	reduced	inflammatory	response.	Overall,	these	data	suggest	that	
FJX1	is	involved	in	the	fibrotic/inflammatory	response	after	injury.	We	also	showed	that	a	
different	response	to	injury	in	the	double	KO	mice	could	also	play	a	role	during	the	acute	
injury	phase	between	24	and	72	h	after	DCVC	injection.	This	is	not	surprising,	considering	
that Fjx1	is	mainly	expressed	in	the	developing	kidneys	while	its	expression	is	almost	absent	
in	adult	kidneys77.	Indeed,	as	for	many	other	developmental	genes,	injury	causes	an	increase	
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in	expression	of	Fjx18.	Yet,	the	mechanism	through	which	FJX1	is	influencing	these	processes	
is	still	unclear.
As	 the	 function	 of	 FJX1	 is	 still	 obscure,	 we	 cannot	 exclude	 that,	 besides	 the	 canonical	
targets	Fat	and	Dachsous,	additional	direct	targets	of	FJX1	exist.	This	 is	because	FJX1	 is	a	
Golgi	secretory	pathway	kinase	and	therefore	likely	involved	in	many	biological	processes,	
as	 already	 shown	 for	 its	 closely	 related	 homolog	 Fam20C78,79.	 Additionally,	 FJX1	 protein	
undergoes	partial	proteolytic	cleavage	at	the	N-terminus,	with	the	secretion	of	the	resultant	
fragment	 that	can	 function	as	signalling	 ligand,	 influencing	surrounding	cells.	FJX1	 fusion	
protein	 experiments	 have	 shown	 several	 FJX1	 binding	 sites	 present	 in	 different	 organs,	
including	kidneys77.	Therefore,	a	better	understanding	of	FJX1	functions	in	mammals	might	
help	to	explain	the	effect	we	unveiled	on	fibrogenesis.	
In	conclusion,	we	show	that	cyst	progression	and	fibrosis	in	Pkd1/Fjx1	double	KO	mice	are	
partially	uncoupled	and	demonstrate	a	new,	yet	undefined,	role	of	FJX1	in	fibrosis,	ultimately	
resulting	in	longer	survival.	Unveiling	the	underlying	molecular	mechanism	might	open	the	
path	for	future	therapies	that	can	specifically	target	injury-induced	fibrosis,	and	could	not	
only	help	to	slow	down	ADPKD,	but	also	the	progression	of	other	chronic	kidney	diseases.
Acknowledgements
This	work	was	supported	by	grants	from	the	People	Program	(Marie	Curie	Actions)	of	the	
European	Union’s	Seventh	Framework	Program	FP7/2077-2013	under	Research	Executive	
Agency	 Grant	 Agreement	 317246,	 and	 by	 the	 Dutch	 Kidney	 Foundation	 consortium	
grant	 (CP10.12	 -DIPAK).	 The	DIPAK	Consortium	 is	 an	 inter-university	 collaboration	 in	The	
Netherlands	 that	 is	 established	 to	 study	 Autosomal	 Dominant	 Polycystic	 Kidney	 Disease	
and	to	develop	rational	treatment	strategies	for	this	disease.	Principal	investigators	are	(in	
alphabetical	order):	J.P.H.	Drenth	(Dept.	Gastroenterology	and	Hepatology,	Radboud	UMC	
Nijmegen),	J.W.	de	Fijter	(Dept.	Nephrology,	Leiden	UMC),	R.T.	Gansevoort	(Dept.	Nephrology,	
UMC	Groningen),	 D.J.M.	 Peters	 (Dept.	 Human	 Genetics,	 Leiden	 UMC),	 J.	Wetzels	 (Dept.	
Nephrology,	Radboud	UMC	Nijmegen)	and	R.	Zietse	(Dept.	Internal	Medicine,	Erasmus	MC	
Rotterdam).
Author contributions
C.F.	 (concept	 design,	 data	 acquisition,	 data	 interpretation,	 writing	 paper),	 H.	 H.	
(concept	 design),	 D.J.M.P.	 (concept	 design,	 data	 interpretation,	 writing	 paper),	 K.A.M.V.	
(histopathology),	 M.S.	 (data	 interpretation	 and	 manuscript	 reviewing),	 A.V.	 and	 H.M.N.	
(mice,	data	discussion,	manuscript	reviewing).
CHAPTER 2
58
References
1	 Igarashi,	P.	Genetics	and	Pathogenesis	of	Polycystic	Kidney	Disease.	Journal	of	the	American	Society	of	
Nephrology	13,	2384-2398,	doi:10.1097/01.asn.0000028643.17901.42	(2002).
2	 Takiar,	 V.	 &	 Caplan,	M.	 J.	 Polycystic	 kidney	 disease:	 pathogenesis	 and	 potential	 therapies.	 Biochim	
Biophys	Acta	1812,	1337-1343,	doi:10.1016/j.bbadis.2010.11.014	(2011).
3	 Torres,	V.	E.	et	al.	Tolvaptan	in	patients	with	autosomal	dominant	polycystic	kidney	disease.	N	Engl	J	Med	
367,	2407-2418,	doi:10.1056/NEJMoa1205511	(2012).
4	 Ong,	A.	C.	M.	Polycystic	kidney	disease:	Tolvaptan	slows	disease	progression	in	late-stage	ADPKD.	Nat	
Rev	Nephrol,	doi:10.1038/nrneph.2017.180	(2018).
5	 Gansevoort,	R.	T.	et	al.	Recommendations	for	the	use	of	tolvaptan	in	autosomal	dominant	polycystic	
kidney	disease:	a	position	statement	on	behalf	of	the	ERA-EDTA	Working	Groups	on	Inherited	Kidney	
Disorders	and	European	Renal	Best	Practice.	Nephrol	Dial	Transpl	31,	337-348,	doi:10.1093/ndt/gfv456	
(2016).
6	 Malas,	 T.	 B.	 et	 al.	 Meta-analysis	 of	 polycystic	 kidney	 disease	 expression	 profiles	 defines	 strong	
involvement	 of	 injury	 repair	 processes.	 American	 Journal	 of	 Physiology	 -	 Renal	 Physiology	 312,	
F806-F817	(2017).
7	 Leonhard,	W.	N.,	Happe,	H.	&	Peters,	D.	J.	Variable	Cyst	Development	in	Autosomal	Dominant	Polycystic	
Kidney	Disease:	The	Biologic	Context.	J	Am	Soc	Nephrol	27,	3530-3538,	doi:10.1681/ASN.2016040425	
(2016).
8	 Happé,	 H.	 et	 al.	 Toxic	 tubular	 injury	 in	 kidneys	 from	 Pkd1-deletion	 mice	 accelerates	 cystogenesis	
accompanied	 by	 dysregulated	 planar	 cell	 polarity	 and	 canonical	 Wnt	 signaling	 pathways.	 Human	
Molecular	Genetics	18,	2532-2542,	doi:10.1093/hmg/ddp190	(2009).
9	 Tokunaga,	 C.	 &	 Gerhart,	 J.	 C.	 The	 effect	 of	 growth	 and	 joint	 formation	 on	 bristle	 pattern	 in	 D.	
melanogaster.	J	Exp	Zool	198,	79-95,	doi:10.1002/jez.1401980110	(1976).
10	 Zeidler,	M.	P.,	Perrimon,	N.	&	Strutt,	D.	 I.	The	four-jointed	gene	is	required	in	the	Drosophila	eye	for	
ommatidial	 polarity	 specification.	 Curr	 Biol	 9,	 1363-1372,	 doi:Doi	 10.1016/S0960-9822(00)80081-0	
(1999).
11	 Rawls,	A.	S.,	Guinto,	J.	B.	&	Wolff,	T.	The	cadherins	fat	and	dachsous	regulate	dorsal/ventral	signaling	in	
the	Drosophila	eye.	Curr	Biol	12,	1021-1026	(2002).
12	 Casal,	J.,	Lawrence,	P.	A.	&	Struhl,	G.	Two	separate	molecular	systems,	Dachsous/Fat	and	Starry	night/
Frizzled,	act	independently	to	confer	planar	cell	polarity.	Development	133,	4561-4572,	doi:10.1242/
dev.02641	(2006).
13	 Probst,	B.,	Rock,	R.,	Gessler,	M.,	Vortkamp,	A.	&	Puschel,	A.	W.	The	rodent	Four-jointed	ortholog	Fjx1	
regulates	dendrite	extension.	Dev	Biol	312,	461-470,	doi:10.1016/j.ydbio.2007.09.054	(2007).
14	 Saburi,	S.	et	al.	Loss	of	Fat4	disrupts	PCP	signaling	and	oriented	cell	division	and	leads	to	cystic	kidney	
disease.	Nat	Genet	40,	1010-1015,	doi:10.1038/ng.179	(2008).
15	 Staley,	B.	K.	&	Irvine,	K.	D.	Hippo	signaling	in	Drosophila:	recent	advances	and	insights.	Dev	Dyn	241,	
3-15,	doi:10.1002/dvdy.22723	(2012).
16	 Reddy,	B.	V.	V.	G.	&	Irvine,	K.	D.	The	Fat	and	Warts	signaling	pathways:	new	insights	into	their	regulation,	
mechanism	and	conservation.	Development	135,	2827-2838,	doi:10.1242/dev.020974	(2008).
FOUR-JOINTED KNOCK-OUT DELAYS RENAL FAILURE IN AN ADPKD MODEL WITH KIDNEY INJURY 
59
2
17	 Happe,	H.	et	al.	Altered	Hippo	signalling	in	polycystic	kidney	disease.	J	Pathol	224,	133-142,	doi:10.1002/
path.2856	(2011).
18	 Ragni,	C.	V.	et	al.	Amotl1	mediates	sequestration	of	 the	Hippo	effector	Yap1	downstream	of	Fat4	 to	
restrict	heart	growth.	Nat	Commun	8,	14582,	doi:10.1038/ncomms14582	(2017).
19	 Mao,	Y.	et	al.	Characterization	of	a	Dchs1	mutant	mouse	reveals	requirements	for	Dchs1-Fat4	signaling	
during	mammalian	development.	Development	138,	947-957,	doi:10.1242/dev.057166	(2011).
20	 Lantinga-van	 Leeuwen,	 I.	 S.	 et	 al.	 Kidney-specific	 inactivation	 of	 the	 Pkd1	 gene	 induces	 rapid	 cyst	
formation	in	developing	kidneys	and	a	slow	onset	of	disease	in	adult	mice.	Hum	Mol	Genet	16,	3188-
3196,	doi:10.1093/hmg/ddm299	(2007).
21	 Takakura,	A.	et	al.	Renal	 injury	 is	a	third	hit	promoting	rapid	development	of	adult	polycystic	kidney	
disease.	Hum	Mol	Genet	18,	2523-2531,	doi:10.1093/hmg/ddp147	(2009).
22	 Leonhard,	 W.	 N.	 et	 al.	 Scattered	 Deletion	 of	 PKD1	 in	 Kidneys	 Causes	 a	 Cystic	 Snowball	 Effect	 and	
Recapitulates	Polycystic	Kidney	Disease.	J	Am	Soc	Nephrol	26,	1322-1333,	doi:10.1681/ASN.2013080864	
(2015).
23	 Patel,	V.	et	al.	Acute	kidney	injury	and	aberrant	planar	cell	polarity	induce	cyst	formation	in	mice	lacking	
renal	cilia.	Hum	Mol	Genet	17,	1578-1590,	doi:10.1093/hmg/ddn045	(2008).
24	 Bell,	P.	D.	et	al.	Loss	of	primary	cilia	upregulates	renal	hypertrophic	signaling	and	promotes	cystogenesis.	
J	Am	Soc	Nephrol	22,	839-848,	doi:10.1681/ASN.2010050526	(2011).
25	 Han,	W.	K.,	Bailly,	V.,	Abichandani,	R.,	Thadhani,	R.	&	Bonventre,	J.	V.	Kidney	Injury	Molecule-1	(KIM-1):	
a	novel	biomarker	for	human	renal	proximal	tubule	injury.	Kidney	Int	62,	237-244,	doi:10.1046/j.1523-
1755.2002.00433.x	(2002).
26	 Yang,	N.	S.	et	al.	Blockage	of	JAK/STAT	signalling	attenuates	renal	ischaemia-reperfusion	injury	in	rat.	
Nephrol	Dial	Transpl	23,	91-100,	doi:10.1093/ndt/gfm509	(2008).
27	 Weimbs,	T.	&	Talbot,	J.	J.	STAT3	Signaling	in	Polycystic	Kidney	Disease.	Drug	Discov	Today	Dis	Mech	10,	
e113-e118,	doi:10.1016/j.ddmec.2013.03.001	(2013).
28	 Dees,	C.	et	al.	 Inhibition	of	Notch	signaling	prevents	experimental	fibrosis	and	 induces	regression	of	
established	fibrosis.	Arthritis	Rheum	63,	1396-1404,	doi:10.1002/art.30254	(2011).
29	 Hu,	B.	&	Phan,	S.	H.	Notch	in	fibrosis	and	as	a	target	of	anti-fibrotic	therapy.	Pharmacol	Res	108,	57-64,	
doi:10.1016/j.phrs.2016.04.010	(2016).
30	 Hu,	L.,	Lin,	X.,	Lu,	H.,	Chen,	B.	&	Bai,	Y.	An	overview	of	hedgehog	signaling	in	fibrosis.	Mol	Pharmacol	87,	
174-182,	doi:10.1124/mol.114.095141	(2015).
31	 Kramann,	 R.	 Hedgehog	 Gli	 signalling	 in	 kidney	 fibrosis.	 Nephrol	 Dial	 Transplant	 31,	 1989-1995,	
doi:10.1093/ndt/gfw102	(2016).
32	 Piersma,	B.,	Bank,	R.	A.	&	Boersema,	M.	Signaling	in	Fibrosis:	TGF-beta,	WNT,	and	YAP/TAZ	Converge.	
Front	Med	(Lausanne)	2,	59,	doi:10.3389/fmed.2015.00059	(2015).
33	 Tan,	R.	J.,	Zhou,	D.,	Zhou,	L.	&	Liu,	Y.	Wnt/beta-catenin	signaling	and	kidney	fibrosis.	Kidney	Int	Suppl	
(2011)	4,	84-90,	doi:10.1038/kisup.2014.16	(2014).
34	 Parrish,	A.	R.	The	cytoskeleton	as	a	novel	target	for	treatment	of	renal	fibrosis.	Pharmacol	Therapeut	
166,	1-8,	doi:10.1016/j.pharmthera.2016.06.006	(2016).
CHAPTER 2
60
35	 Kawakami,	T.,	Mimura,	 I.,	 Shoji,	K.,	 Tanaka,	T.	&	Nangaku,	M.	Hypoxia	and	fibrosis	 in	 chronic	 kidney	
disease:	crossing	at	pericytes.	Kidney	Int	Suppl	4,	107-112,	doi:10.1038/kisup.2014.20	(2014).
36	 Edeling,	M.,	 Ragi,	 G.,	 Huang,	 S.,	 Pavenstadt,	 H.	&	 Susztak,	 K.	 Developmental	 signalling	 pathways	 in	
renal	 fibrosis:	 the	 roles	 of	 Notch,	Wnt	 and	 Hedgehog.	 Nat	 Rev	 Nephrol	 12,	 426-439,	 doi:10.1038/
nrneph.2016.54	(2016).
37	 Ruthenborg,	R.	J.,	Ban,	J.	J.,	Wazir,	A.,	Takeda,	N.	&	Kim,	J.	W.	Regulation	of	wound	healing	and	fibrosis	
by	 hypoxia	 and	 hypoxia-inducible	 factor-1.	Mol	 Cells	 37,	 637-643,	 doi:10.14348/molcells.2014.0150	
(2014).
38	 Darby,	 I.	 A.	 &	 Hewitson,	 T.	 D.	 Hypoxia	 in	 tissue	 repair	 and	 fibrosis.	 Cell	 Tissue	 Res	 365,	 553-562,	
doi:10.1007/s00441-016-2461-3	(2016).
39	 Zhuang,	 S.	 G.	 &	 Liu,	 N.	 EGFR	 signaling	 in	 renal	 fibrosis.	 Kidney	 Int	 Suppl	 4,	 70-74,	 doi:10.1038/
kisup.2014.13	(2014).
40	 Chen,	J.	et	al.	EGFR	signaling	promotes	TGFbeta-dependent	renal	fibrosis.	J	Am	Soc	Nephrol	23,	215-
224,	doi:10.1681/ASN.2011070645	(2012).
41	 Terzi,	F.	et	al.	Targeted	expression	of	a	dominant-negative	EGF-R	in	the	kidney	reduces	tubulo-interstitial	
lesions	after	renal	injury.	J	Clin	Invest	106,	225-234,	doi:10.1172/JCI8315	(2000).
42	 Siegel,	N.	J.,	Devarajan,	P.	&	Van	Why,	S.	Renal	cell	injury:	metabolic	and	structural	alterations.	Pediatr	
Res	36,	129-136,	doi:10.1203/00006450-199408000-00001	(1994).
43	 Mao,	Y.	P.,	Francis-West,	P.	&	Irvine,	K.	D.	Fat4/Dchs1	signaling	between	stromal	and	cap	mesenchyme	
cells	influences	nephrogenesis	and	ureteric	bud	branching.	Development	142,	2574-U2569,	doi:10.1242/
dev.122630	(2015).
44	 Caddy,	 J.	 et	 al.	 Epidermal	 wound	 repair	 is	 regulated	 by	 the	 planar	 cell	 polarity	 signaling	 pathway.	
Developmental	cell	19,	138-147,	doi:10.1016/j.devcel.2010.06.008	(2010).
45	 Yadav,	S.,	Puri,	S.	&	Linstedt,	A.	D.	A	primary	role	for	Golgi	positioning	in	directed	secretion,	cell	polarity,	
and	wound	healing.	Mol	Biol	Cell	20,	1728-1736,	doi:10.1091/mbc.E08-10-1077	(2009).
46	 Das,	A.	et	al.	Stromal–epithelial	crosstalk	regulates	kidney	progenitor	cell	differentiation.	Nature	Cell	
Biology	15,	1035,	doi:10.1038/ncb2828	(2013).
47	 Piccolo,	S.,	Dupont,	S.	&	Cordenonsi,	M.	The	biology	of	YAP/TAZ:	hippo	signaling	and	beyond.	Physiol	Rev	
94,	1287-1312,	doi:10.1152/physrev.00005.2014	(2014).
48	 Casal,	J.,	Struhl,	G.	&	Lawrence,	P.	A.	Developmental	compartments	and	planar	polarity	in	Drosophila.	
Curr	Biol	12,	1189-1198	(2002).
49	 Yang,	 C.	 H.,	 Axelrod,	 J.	 D.	&	 Simon,	M.	 A.	 Regulation	 of	 Frizzled	 by	 fat-like	 cadherins	 during	 planar	
polarity	signaling	in	the	Drosophila	compound	eye.	Cell	108,	675-688	(2002).
50	 Matakatsu,	H.	&	Blair,	S.	S.	 Interactions	between	Fat	and	Dachsous	and	the	regulation	of	planar	cell	
polarity	in	the	Drosophila	wing.	Development	131,	3785-3794,	doi:10.1242/dev.01254	(2004).
51	 Cho,	E.	&	Irvine,	K.	D.	Action	of	fat,	four-jointed,	dachsous	and	dachs	in	distal-to-proximal	wing	signaling.	
Development	131,	4489-4500,	doi:10.1242/dev.01315	(2004).
52	 Fischer,	 E.	 et	 al.	 Defective	 planar	 cell	 polarity	 in	 polycystic	 kidney	 disease.	 Nat	 Genet	 38,	 21-23,	
doi:10.1038/ng1701	(2006).
FOUR-JOINTED KNOCK-OUT DELAYS RENAL FAILURE IN AN ADPKD MODEL WITH KIDNEY INJURY 
61
2
53	 Luyten,	A.	et	al.	Aberrant	regulation	of	planar	cell	polarity	in	polycystic	kidney	disease.	J	Am	Soc	Nephrol	
21,	1521-1532,	doi:10.1681/ASN.2010010127	(2010).
54	 Castelli,	M.	et	al.	Polycystin-1	binds	Par3/aPKC	and	controls	convergent	extension	during	renal	tubular	
morphogenesis.	Nat	Commun	4,	2658,	doi:10.1038/ncomms3658	(2013).
55	 Nishio,	S.	et	al.	Loss	of	oriented	cell	division	does	not	initiate	cyst	formation.	J	Am	Soc	Nephrol	21,	295-
302,	doi:10.1681/ASN.2009060603	(2010).
56	 Kunimoto,	K.	et	al.	Disruption	of	Core	Planar	Cell	Polarity	Signaling	Regulates	Renal	Tubule	Morphogenesis	
but	Is	Not	Cystogenic.	Curr	Biol	27,	3120-3131	e3124,	doi:10.1016/j.cub.2017.09.011	(2017).
57	 Skouloudaki,	 K.	 et	 al.	 Scribble	 participates	 in	 Hippo	 signaling	 and	 is	 required	 for	 normal	 zebrafish	
pronephros	development.	P	Natl	Acad	Sci	USA	106,	8579-8584,	doi:10.1073/pnas.0811691106	(2009).
58	 He,	 L.	 L.	 et	 al.	 Yes-Associated	Protein	 (Yap)	 Is	Necessary	 for	 Ciliogenesis	 and	Morphogenesis	 during	
Pronephros	Development	in	Zebrafish	(Danio	Rerio).	Int	J	Biol	Sci	11,	935-947,	doi:10.7150/ijbs.11346	
(2015).
59	 Hossain,	Z.	et	al.	Glomerulocystic	kidney	disease	in	mice	with	a	targeted	inactivation	of	Wwtr1.	Proc	
Natl	Acad	Sci	U	S	A	104,	1631-1636,	doi:10.1073/pnas.0605266104	(2007).
60	 Makita,	R.	et	al.	Multiple	renal	cysts,	urinary	concentration	defects,	and	pulmonary	emphysematous	
changes	in	mice	lacking	TAZ.	Am	J	Physiol	Renal	Physiol	294,	F542-553,	doi:10.1152/ajprenal.00201.2007	
(2008).
61	 Reginensi,	A.	et	al.	Yap-	and	Cdc42-dependent	nephrogenesis	and	morphogenesis	during	mouse	kidney	
development.	PLoS	Genet	9,	e1003380,	doi:10.1371/journal.pgen.1003380	(2013).
62	 Bagherie-Lachidan,	M.	et	al.	Stromal	Fat4	acts	non-autonomously	with	Dchs1/2	to	restrict	the	nephron	
progenitor	pool.	Development	142,	2564-2573,	doi:10.1242/dev.122648	(2015).
63	 Aguiari,	 G.	 et	 al.	 Polycystin-1	 regulates	 amphiregulin	 expression	 through	 CREB	 and	 AP1	 signalling:	
implications	 in	 ADPKD	 cell	 proliferation.	 J	Mol	Med	 90,	 1267-1282,	 doi:10.1007/s00109-012-0902-3	
(2012).
64	 Yamaguchi,	T.	et	al.	Cyclic	AMP	activates	B-Raf	and	ERK	in	cyst	epithelial	cells	from	autosomal-dominant	
polycystic	kidneys.	Kidney	Int	63,	1983-1994,	doi:10.1046/j.1523-1755.2003.00023.x	(2003).
65	 Norman,	J.	Fibrosis	and	progression	of	autosomal	dominant	polycystic	kidney	disease	(ADPKD).	Biochim	
Biophys	Acta	1812,	1327-1336,	doi:10.1016/j.bbadis.2011.06.012	(2011).
66	 Song,	C.	J.,	Zimmerman,	K.	A.,	Henke,	S.	J.	&	Yoder,	B.	K.	Inflammation	and	Fibrosis	in	Polycystic	Kidney	
Disease.	Results	Probl	Cell	Differ	60,	323-344,	doi:10.1007/978-3-319-51436-9_12	(2017).
67	 Akhmetshina,	A.	et	al.	Activation	of	canonical	Wnt	signalling	is	required	for	TGF-beta-mediated	fibrosis.	
Nat	Commun	3,	735,	doi:10.1038/ncomms1734	(2012).
68	 Meng,	X.	M.,	Tang,	P.	M.,	Li,	J.	&	Lan,	H.	Y.	TGF-beta/Smad	signaling	in	renal	fibrosis.	Front	Physiol	6,	82,	
doi:10.3389/fphys.2015.00082	(2015).
69	 Geng,	H.	et	al.	Lysophosphatidic	acid	increases	proximal	tubule	cell	secretion	of	profibrotic	cytokines	
PDGF-B	 and	 CTGF	 through	 LPA2-	 and	 Galphaq-mediated	 Rho	 and	 alphavbeta6	 integrin-dependent	
activation	of	TGF-beta.	Am	J	Pathol	181,	1236-1249,	doi:10.1016/j.ajpath.2012.06.035	(2012).
70	 Ono,	K.,	Ohtomo,	T.,	Ninomiya-Tsuji,	J.	&	Tsuchiya,	M.	A	dominant	negative	TAK1	inhibits	cellular	fibrotic	
responses	induced	by	TGF-beta.	Biochem	Biophys	Res	Commun	307,	332-337	(2003).
CHAPTER 2
62
71	 Kim,	S.	I.	et	al.	TGF-beta-activated	kinase	1	and	TAK1-binding	protein	1	cooperate	to	mediate	TGF-beta1-
induced	MKK3-p38	MAPK	activation	and	stimulation	of	type	I	collagen.	Am	J	Physiol	Renal	Physiol	292,	
F1471-1478,	doi:10.1152/ajprenal.00485.2006	(2007).
72	 Jho,	E.-h.	et	al.	Wnt/beta-catenin/Tcf	signaling	induces	the	transcription	of	Axin2,	a	negative	regulator	
of	the	signaling	pathway.	Molecular	and	cellular	biology	22,	1172-1183,	doi:10.1128/MCB.22.4.1172-
1183.2002	(2002).
73	 Wielenga,	V.	 J.	et	al.	Expression	of	CD44	 in	Apc	and	Tcf	mutant	mice	 implies	 regulation	by	the	WNT	
pathway.	Am	J	Pathol	154,	515-523,	doi:10.1016/s0002-9440(10)65297-2	(1999).
74	 Tetsu,	 O.	 &	McCormick,	 F.	 Beta-catenin	 regulates	 expression	 of	 cyclin	 D1	 in	 colon	 carcinoma	 cells.	
Nature	398,	422-426,	doi:10.1038/18884	(1999).
75	 Shtutman,	M.	et	al.	The	cyclin	D1	gene	is	a	target	of	the	beta-catenin/LEF-1	pathway.	Proc	Natl	Acad	Sci	
U	S	A	96,	5522-5527	(1999).
76	 He,	T.	C.	et	al.	Identification	of	c-MYC	as	a	target	of	the	APC	pathway.	Science	281,	1509-1512	(1998).
77	 Rock,	 R.,	Heinrich,	 A.	 C.,	 Schumacher,	N.	&	Gessler,	M.	 Fjx1:	 a	 notch-inducible	 secreted	 ligand	with	
specific	binding	sites	in	developing	mouse	embryos	and	adult	brain.	Dev	Dyn	234,	602-612,	doi:10.1002/
dvdy.20553	(2005).
78	 Tagliabracci,	 V.	 S.	 et	 al.	 Secreted	 Kinase	 Phosphorylates	 Extracellular	 Proteins	 That	 Regulate	
Biomineralization.	Science	336,	1150-1153,	doi:10.1126/science.1217817	(2012).
79	 Sreelatha,	A.,	Kinch,	 L.	N.	&	Tagliabracci,	V.	S.	The	secretory	pathway	kinases.	Biochim	Biophys	Acta	
1854,	1687-1693,	doi:10.1016/j.bbapap.2015.03.015	(2015).
FOUR-JOINTED KNOCK-OUT DELAYS RENAL FAILURE IN AN ADPKD MODEL WITH KIDNEY INJURY 
63
2
Supplementary Figures
Supplementary Figure 1. Correlation of fibrosis and kidney size in Pkd1 KO and Pkd1/Fjx1 double KO mice 
Linear	regression	of	2KW/BW	ratio	and	gene	expression	normalized	on	Hprt	of	Col1a1, Vim and Fn1	at	10	weeks	
time	point.	**	P	value	<0.01
Supplementary Figure 2. Expression of pSTAT3 in Pkd1 KO and double KO mice 
(A)	Representative	immunostaining	for	pSTAT3	at	10	weeks	after	injection	of	the	nephrotoxic	compound	S-(1,2-
dichlorovinyl)-L-cysteine	 (DCVC)	 in	Pkd1	 KO	and	Pkd1/Fjx1 double	KO	mice	kidneys,	 indicated	as	±	 injury.	 Scale	
bars,	50	μm.	(B)	Quantification	of	pSTAT3	staining.	Each	symbol	shows	data	from	one	mouse.	Mean	±	SD.	Two-way	
ANOVA	with	Tukey’s	multiple	comparisons	test.	*	P	value	<0.05.
CHAPTER 2
64
Supplementary Figure 3. Investigation of pathways involved in renal fibrosis at 10 weeks after injection of the 
nephrotoxic compound S-(1,2-dichlorovinyl)-L-cysteine (DCVC) 
Gene	expression	in	Pkd1	KO	mice	and	Pkd1/Fjx1	double	KO	mice	with	or	without	renal	injury	induced	via	injection	
of	DCVC,	of	Notch	target	genes	(Notch1, Notch2, Notch3);	Hedgehog	target	genes	(Hes1, Hey1, Gli2);	Egf	pathway	
(Hb-egf, Egfr);	hypoxia	pathway	(Hif1a, Vegfa, Pdgfb).	Each	symbol	shows	data	from	one	mouse.	Mean	±	SD.	Two-
way	ANOVA	with	Tukey’s	multiple	comparisons	test.	*	P	value	<0.05;	**	P	value	<0.01.
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Supplementary Figure 4. Wnt pathway target Myc 
(A)	Gene	expression	of	Myc	10	weeks	after	injection	of	the	nephrotoxic	compound	S-(1,2-dichlorovinyl)-L-cysteine	
(DCVC)	or	PBS	in	Pkd1	KO	mice	and	Pkd1/Fjx1	double	KO	mice.	(B)	Gene	expression	of	Myc	at	kidney	failure	in	Pkd1 
KO	mice	and	Pkd1/Fjx1	double	KO	mice.	Each	symbol	shows	data	from	one	mouse.	Mean	±	SD.	Two-way	ANOVA	
with	Tukey’s	multiple	comparisons	test.	**	P	value	<0.01.
Supplementary Figure 5. Injury and fibrotic genes expression at early time points after injury 
Gene	expression	of	Kim1, Col1a1, Vim and Fn1	at	24	h,	48	h,	72	h,	1	and	2	weeks	after	S-(1,2-dichlorovinyl)-L-
cysteine	(DCVC)	injection.	Each	point	is	the	mean	of	two	mice	(24	h,	48	h,	72	h)	or	six	mice	(1	and	2	weeks)	±	SD.	
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Supplementary Figure 6. Hippo Pathway activation in Pkd1 KO and Pkd1/Fjx1 double KO mice 
(A)	Representative	immunostaining	for	Yap1	on	kidney	tissue	in	Pkd1	KO	mice	after	injection	of	the	nephrotoxic	
compound	 S-(1,2-dichlorovinyl)-L-cysteine	 (DCVC)	 and	 (B)	 double	 KO	mice	 after	DCVC.	 In	 both	 genotypes,	 it	 is	
possible	 to	observe	 some	dilated	 tubules	which	 intensely	 stain	 for	 Yap1	and	diffuse	nuclear	 localization.	 Scale	
bars,	100	μm.	Arrows	indicate	tubules	showing	nuclear	Yap1;	asterisks	indicate	dilated	tubules.	(C) Yap1 and Taz 
expression	during	disease	progression.	(D)	Gene	expression	of	representative	Yap1/Taz	targets.	Each	point	is	the	
mean	expression	of	six	mice	±	SD.
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Supplementary Methods
Animal Models
The	kidney	specific	tamoxifen-inducible	Pkd1-deletion	mouse	model	(Pkd1-cKO)	has	been	
described	previously1.	The	Fjx1-/-	 (Fjx1	KO)	were	generated	via	 insertion	of	the	LacZ gene 
followed	 by	 a	 PGK-neo	 resistance	 cassette	 in	 the	 single	 exon	 of	Fjx1	 gene,	 as	 described	
previously2.	This	results	in	a	germline	disruption	of	Fjx1.	By	cross-breeding	the	kidney	specific	
tamoxifen-inducible	Pkd1-deletion	mice	(Pkd1	KO)	with	the	Fjx1	KO	mice,	we	generated	the	
Fjx1-/-/Pkd1-cKO	double	KO	mouse	model	(double	KO).	Control	mice	(Wt)	carry	the	LoxP site 
that	flanks	Pkd1	exons	2-11	but	miss	the	tamoxifen-inducible	Cre	recombinase	(Pkd1lox,lox).	
Inactivation	 of	 the	Pkd1	 gene	was	 achieved	 by	 oral	 administration	 of	 tamoxifen	 (5	mg/
day,	3	consecutive	days)	 in	adult	mice	that	were	between	13	to	14	weeks	old.	Only	male	
mice	were	used	for	all	the	experimental	groups.	The	Fjx1	KO	and	the	Wt	mice	also	received	
tamoxifen.	Renal	injury	was	induced	a	week	after	gene	disruption	by	a	single	intraperitoneal	
(i.p.)	 injection	of	S-(1,2-dichlorovinyl)-L-cysteine	(DCVC)	(15	mg/kg)	or	vehicle.	 Injury	was	
evaluated	by	measurement	of	blood	urea	level	after	40	hours,	as	described	before3.
Mice	were	sacrificed	at	24,	48	and	72	hours	after	DCVC	injection	to	study	acute	injury;	at	1,	
2,	5	and	10	weeks	after	DCVC	injection	to	study	injury/repair	and	disease	progression	and	
when	reaching	renal	failure	indicated	by	urea	levels	in	the	blood	equal	or	over	25	mmol/l.	
Blood	urea	nitrogen	 (BUN)	 level	assessment	has	been	described	previously3.	At	 sacrifice,	
mice	were	weighed;	then	kidneys	were	collected	and	weighed	to	calculate	the	2	kidneys	
weight	to	body	weight	ratios	(2KW/BW).
IHC, Golgi position, Cystic and Fibrotic indices
Formalin-fixed	 paraffin-embedded	 kidneys	 were	 sectioned	 at	 4µm	 thickness.	 Section	
stained	with	Periodic	acid-Schiff	(PAS)	staining	were	used	to	determine	cystic	index	(CI).	CI	is	
measured	as	the	ratio	of	cystic	area	over	the	total	parenchyma	area	using	Image	J	software	
(open	 source	 software;	National	 Institutes	of	Health,	Bethesda,	MD)	 and	expressed	as	 a	
percentage.	Sections	stained	with	Picro	Sirius	Red	(PSR)	staining	were	used	to	determine	
fibrotic	index	(FI).	FI	was	calculated	using	a	designed	color	palettes	and	Photoshop	software	
(Adobe	Systems,	Inc.,	San	Jose,	CA).	First	a	palette	was	used	to	remove	the	pixels	of	the	renal	
outline	area	and	of	the	cystic	and	tubular	areas.	Then	a	second	palette	was	used	to	remove	
the	pixels	of	the	kidney	parenchyma	except	those	colored	by	the	PSR	staining.	Big	arteries	
were	manually	excluded.	The	ratio	of	PSR	positive	pixels	over	the	total	parenchyma	pixels	
was	expressed	as	a	percentage	and	indicated	as	FI.	The	same	analysis	was	used	to	calculate	
the	area	positive	for	alpha	Smooth	Muscle	Actin	(αSMA)	and	for	the	area	positive	for	F4/80.	
These	antibodies	were	used	for	the	IHC:	rabbit	anti	αSMA-AP	(1:50;	Sigma-Aldrich	#A5691);	
rat	anti-F4/80	(1:250;	Serotec);	rabbit	anti-Yap	(1:800;	Cell	Signaling	Technology	#14074),	
rabbit	 anti-pStat3	 (1:75;	Cell	 Signaling	#9145);	mouse	anti-GM130	 (1:500;	BD	Bioscience	
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#610822).	Anti-rabbit	envision	HRP	(Dako)	or	anti-rat	Immpress	HRP	(Vector	Laboratories)	
or	Alexa	488	goat	anti-mouse	IgG1	(1:200;	Invitrogen)	were	used	as	secondary	antibodies.
The	frequency	of	cyst	size	was	calculated	using	Image	J	software.	Pictures	of	whole	kidneys	
stained	with	PAS	staining	were	used.	The	area	of	the	renal	outline	was	removed	and	then	
the	area	of	the	tubules	lumen	was	measured	in	pixels	and	divided	in	four	groups:	Normal	
tubule	or	mildly	dilated	tubules	up	to	1000	pixels;	small	cysts	between	1000	and	2000	pixels;	
medium	cysts	between	2000	and	10000	pixels;	big	cysts	more	than	10000	pixels.
For	 the	evaluation	of	 the	Golgi	position	as	a	read-out	of	 the	PCP	we	used	a	mouse	anti-
GM130	 followed	 by	 a	 secondary	 Alexa	 488	 Goat	 Anti-mouse	 IgG1	 and	 mounted	 with	
Vectashield	with	Dapi	 (Vector	 Laboratories)	 to	 visualize	 the	 nuclei.	 From	each	 individual	
kidney	we	selected	at	least	90	tubules	with	a	circularity	≥	0.995,	which	was	evaluated	by	
Image	J	software.	We	scored	the	Golgi	position	in	relation	to	the	nucleus	from	1	to	3,	with	1	
being	the	normal	peri-centrosomal	position	at	the	top	of	the	nucleus	towards	the	lumen,	and	
3	being	very	aberrant	at	the	bottom	of	the	nucleus;	a	score	≥	2,5	was	considered	aberrant	
and	the	total	count	was	normalized	on	the	number	of	cells	per	tubule	and	expressed	as	a	
percentage.
References
1	 Lantinga-van	 Leeuwen,	 I.	 S. et al.	 Kidney-specific	 inactivation	 of	 the	 Pkd1	 gene	 induces	 rapid	 cyst	
formation	in	developing	kidneys	and	a	slow	onset	of	disease	in	adult	mice.	Hum Mol Genet 16,	3188-
3196,	doi:10.1093/hmg/ddm299	(2007).
2	 Probst,	B.,	Rock,	R.,	Gessler,	M.,	Vortkamp,	A.	&	Puschel,	A.	W.	The	rodent	Four-jointed	ortholog	Fjx1	
regulates	dendrite	extension.	Dev Biol 312,	461-470,	doi:10.1016/j.ydbio.2007.09.054	(2007).
3	 Happé,	 H. et al.	 Toxic	 tubular	 injury	 in	 kidneys	 from	 Pkd1-deletion	 mice	 accelerates	 cystogenesis	
accompanied	 by	 dysregulated	 planar	 cell	 polarity	 and	 canonical	 Wnt	 signaling	 pathways.	 Human 
Molecular Genetics 18,	2532-2542,	doi:10.1093/hmg/ddp190	(2009).
FOUR-JOINTED KNOCK-OUT DELAYS RENAL FAILURE IN AN ADPKD MODEL WITH KIDNEY INJURY 
69
2
Forward Reverse
Kim1 TCTCTAAGCGTGGTTGCCTT TGTCTTCAGCTCGGGAATGC
Col1a1 TGACTGGAAGAGCGGAGAGT AGACGGCTGAGTAGGGAACA
Vim CCAACCTTTTCTTCCCTGAA TGAGTGGGTGTCAACCAGAG
Fn1 AATCCAGTCCACAGCCATTCC CCTGTCTTCTCTTTCGGGTTCA
Acta2 CATCATGCGTCTGGACTTG ATCTCACGCTCGGCAGTAG
Tgfb ACTATTGCTTCAGCTCCACAGA AAGTTGGCATGGTAGCCCTT
Adgre1 GGCAGGGATCTTGGTTATGCT GCTGCACTCTGTAAGGACACT
Fat4 ACCGATGCAGATGATGGTGTC ACTCCGTGCTTATCCACTGC
Dchs1 GACAATCGTCCCACCATCCC AGCCCAACAGTGCATCTTCT
Yap1 TTCCGATCCCTTTCTTAACAGT GAGGGATGCTGTAGCTGCTC
Taz (Wwtr1) ATGGACGAGATGGATACAGGTGA AGACTCCAAAGTCCCGAGGT
Amotl2 ACCAGGAGATGGAGAGCAGATT GAAGGACCTTGATCACCGCA
Cyr61 CACTGAAGAGGCTTCCTGTCT CCAAGACGTGGTCTGAACGA
Wtip TTCATCTGTGACTCCTGTGGGA TGGCAGTACACTTTCTCACCC
Notch1 GGTGCTCTGATGGACGACAA TACTGGCTCCTCAAACCGGA
Notch2 AGGCTAACCTGATTGGTTCTGG AAGCCTCATCCTCAGCCTTG
Notch3 CTGGGAGTCAGTGTCAGAACC GGTGGACAAATGCAGTAAGCC
Hes1 GGCCTCTGAGCACAGAAAGT TTGGAATGCCGGGAGCTATC
Heyl AAGAAGCGCAGAGGGATCATAG GGGACCAATCGTCGCAATTC
Gli1 CAGCATGGGAACAGAAGGACT ACCCTGGGACCCTGACATAA
Hb-egf GAGGAGGACCTGAGCTATAGGAA AACGTGTAACGAACCACTGTCT
Egfr GAAGTACAGCTTTGGTGCCACCTG CTTGCGGATGCCATCTTCTTCCAC
HIF1a AGTCAGCAACGTGGAAGGTG GCACGTCATGGGTGGTTTCT
Vegfa CTCCACCATGCCAAGTGGTC GTCCACCAGGGTCTCAATCG
Pdgfb CAAGAGTGTGGGCAGGGTTAT CCGAATCAGGCATCGAGACA
Axin2 GACAGCGAGTTATCCAGCGA AGGAGGGACTCCATCTACGC
Jak2 ACCTTTGCTGTTGAGCGAGA CTTAGTCCCGCTGAGGTTGT
Stat1 TTCCGACACCTGCAACTGAAG TCTTCGGTGACAATGAGAGGC
Supplementary Tables
 Supplementary Table 1. List of primer sequences used for qPCR
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Abstract
The	Hippo	pathway	is	a	highly	conserved	signalling	route	involved	in	organ	size	regulation.	
The	 final	 effectors	 of	 this	 pathway	 are	 two	 transcriptional	 co-activators,	 Yes-associated	
protein	 (YAP)	 and	 Transcriptional	 co-activator	 with	 PDZ-binding	 motif	 (WWTR1	 or	 TAZ).	
Previously,	we	showed	aberrant	activation	of	the	Hippo	pathway	in	Autosomal	Dominant	
Polycystic	 Kidney	Disease	 (ADPKD),	 suggesting	 that	 YAP/TAZ	might	 play	 a	 role	 in	 disease	
progression.	 Using	 Antisense	Oligonucleotides	 (ASOs)	 in	 a	mouse	model	 for	 ADPKD,	we	
efficiently	downregulated	Yap	levels	in	the	kidneys.	However,	we	did	not	see	any	effect	on	
cyst	formation	or	growth.	Moreover,	the	expression	of	YAP/TAZ	downstream	targets	was	not	
changed,	while WNT	and	TGF-β	pathways	downstream	targets Myc, Acta2 and Vim,	were	
more	expressed	after	Yap	knock-down.	Differences	 in	YAP/TAZ	expression	pattern	 in vivo, 
as	well	as	 in vitro	experiments	using	Yap or Taz	mutant	 renal	cells,	 suggest	 that	YAP/TAZ	
might	play	cell-type-specific	roles	in	kidneys.	In vitro	experiments	revealed	that	knock-out	
of	Yap	is	associated	with	cytoskeleton	changes	and	aberrant	expression	of	Itga1 and Itgav.	
Although	highly	impaired,	cyst	formation	and	swelling	were	not	prevented	by	Yap nor Taz 
knock-out	in vitro	indicating	that	YAP	levels	reduction	is	not	a	viable	strategy	to	modulate	
PKD	progression.
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Introduction
The	Hippo	pathway	is	a	highly	conserved	signalling	route	involved	in	the	regulation	of	key	
cellular	processes	like	proliferation,	apoptosis	and	differentiation,	which	ultimately	results	
in	the	regulation	of	organ	size.	The	pathway	is	named	after	the	core	pathway	component,	
the	 kinase	 Hippo,	 which	 has	 two	 homologues	 in	 mammals:	 mammalian	 sterile	 20-like	
protein	kinases	1	and	2	(MST1/2).	MST1/2	together	with	large	tumour	suppressors	1	and	
2	(LATS1/2)	can	phosphorylate	the	pathway	effectors	Yes-associated	protein	(YAP)	and	its	
paralogue	Transcriptional	 co-activator	with	PDZ-binding	motif	 (WWTR1	or	TAZ),	 resulting	
in	their	retention	into	the	cytoplasm.	When	the	Hippo	pathway	is	inactive,	YAP	and	TAZ	are	
unphosphorylated	and	can	shuttle	to	the	nucleus	where	they	can	work	as	transcriptional	
co-activators	driving	 the	 transcription	of	 genes	 involved	 in	proliferation	and	apoptosis1,2.	
Indeed,	 elevated	 YAP/TAZ	 protein	 levels	 and	 nuclear	 localisation	 have	 been	 observed	 in	
multiple	human	cancers1,3-6.	
In	a	previous	study,	we	showed	altered	Hippo	signalling	in	Autosomal	Dominant	Polycystic	
Kidney	Disease	 (ADPKD)7.	 ADPKD	 is	 characterised	 by	 progressive	 deterioration	of	 kidney	
function	 as	 a	 consequence	 of	 the	 formation	 of	 thousands	 of	 epithelium-derived	 cysts,	
leading	to	renal	failure	beyond	mid-life.	In	the	majority	of	the	cases,	ADPKD	is	caused	by	a	
mutation	in	either	the	PKD1 or PKD2	gene,	which	encode	for	Polycystin	1	(PC1)	and	Polycystin	
2	(PC2)	respectively8,9.	We	observed	strong	nuclear	accumulation	of	YAP	in	dilated	tubules	
and	cysts	of	several	orthologous	mouse	models,	which	was	accompanied	by	up-regulation	
of	 the	YAP	 transcriptional	 targets	Birc-3, Ctgf, Inhba and Fjx1.	 This	was	 further	observed	
also	 in	 human	 ADPKD	 cystic	 kidneys	 and	 cystic	 liver	 tissues7.	 Interestingly,	 YAP	 and	 TAZ	
have	been	described	to	interact	with	and	regulate	the	activity	of	many	other	transcription	
factors	implicated	in	APDKD,	such	as	TEAD,	GLIS3,	SMAD,	ERBB4,	TP73	and	RUNX210-17.	 In	
addition,	canonical	WNT	signalling,	as	well	as,	the	stability	of	the	PC1	and	PC2	proteins	can	
be	modulated	by	Hippo	signalling,	placing	YAP	and	TAZ	in	a	central	position	in	the	regulation	
of	PKD	associated	molecular	pathways18-21.	Therefore,	we	hypothesise	that	reducing	nuclear	
localisation	of	YAP	may	slow	down	the	renal	cystic	disease.	
In	this	study,	we	used	Antisense	Oligonucleotides	(ASOs)	to	specifically	downregulate	YAP	
level	in	iKspPkd1del	mice	to	modulate	renal	cyst	growth.	However,	we	did	not	see	any	effect	
of	YAP	downregulation	on	cyst	formation	or	growth.	This	suggests	that	knockdown	of	Yap is 
not	sufficient	to	slow	disease	progression	in	a	mouse	model	for	ADPKD.
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Materials and Methods
Cell culture
Wild-type	 (Wt)	 mouse	 inner	 medulla	 collecting	 duct	 cells	 from	 ATCC	 (mIMCD3,	 CRL-
2123™	ATCC®,	 City	 of	Manassas,	 VA,	USA)	 and	Madin-Darby	 canine	 kidney	 (MDCK)	 cells	
(CCL-34™;	ATCC)	were	commercially	available.	Briefly,	cells	were	maintained	at	37°C,	and	
5%	 CO2	 in	 DMEM/F-12	with	 GlutaMAX	 (#31331-093;	 Gibco,	 Life	 Technologies,	 Carlsbad,	
CA,	 USA)	 supplemented	with	 100	U/mL	 Penicillin-Streptomycin	 (#15140-122;	 Gibco,	 Life	
Technologies),	10%	Fetal	bovine	serum	(#S1860;	Biowest,	Nuaillé,	France).	Cell	cultures	were	
monthly	tested	for	mycoplasma	contamination	using	MycoAlert	Mycoplasma	Detection	Kit.
For	3D	cyst	assay,	cells	were	grown	in	Matrigel	as	described	previously22.	Briefly,	cells	were	
mixed	with	Matrigel	(#354230;	Corning,	NY,	USA)	supplemented	with	10%	rat	tail	collagen	I	
(kindly	provided	by	OcellO	B.V.,	Leiden,	ZH,	The	Netherlands)	and	seeded	in	96-wells.	Cells	
were	 cultured	 in	 normal	 condition	 for	 72	 h	 and	 subsequently	 stimulated	 with	 forskolin	
(#344270,	Calbiochem,	Millipore	B.V.,	Amsterdam,	NH,	The	Netherlands)	or	DMSO	for	72	h.	
Cells	were	collected	for	immunohistochemistry	(IHC)	or	RNA	extraction.
Generation of knock-out cell lines
Generation	 of	 the	 Pkd1	 knock-out	 cell	 line	 mIMRFNPKD5E4	 was	 described	 before23	 by	
making	use	of	 the	FokI	nucleases	 (RFN)	method,	described	by	Tsai et al.24	 in	mIMCD3.	A	
comparable	method	was	used	to	generate	the	Yap1	knock-out	cell	 lines,	using	RFN	guide	
RNAs	for	Yap1	exon	2.	Sequencing	of	the	selected	clones		mIMRFNYap9	and	mIMRFNYap14,	
revealed	an	8bp	out	of	frame	deletion	in	one	allele	and	a	22bp	out	of	frame	deletion	in	the	
other	allele	for	clone	mIMRFNYap9	and	revealed	13bp	and	26bp	out	of	frame	deletions	for	
clone	mIMRFNYap14.	
Using	 a	 similar	 method	 we	 set	 out	 to	 make	 knock-out	 cell	 lines	 for	 Wwtr1	 (202:	
ENSMUST00000120977.1),	by	targeting	exon	2	or	exon	4.	However,	after	screening	200	single	
clones,	we	noticed	that	mIMCD3	has	three	Wwtr1	alleles,	and	we	were	unable	to	identify	
any	clone	with	an	out	of	frame	deletion	in	all	three	alleles.	Therefore,	we	switched	strategy:	
using	two	guide	RNAs	to	delete	exon	3	to	be	sure	that	every	Cas9	induced	deletion	leads	
to a Wwtr1	mRNA	with	an	out	of	frame	deletion.	CRISPR/Cas9	RNA-guides	were	designed	
targeting	introns	2	and	3	with	the	online	tool	of	the	Zhang	lab	(https://zlab.bio/guide-design-
resources)	to	obtain	a	genomic	exon	3	deletion.	In	the	end,	single	clones	were	isolated	using	
G418	selection.	In	none	of	the	250	clones	analysed	exon	3	deletion	was	observed	in	three	
alleles.	We	applied	the	same	exon	deletion	strategy	to	MDCK	cells.	We	designed	guide	RNAs	
to	delete	exon	4	of	the	canine	Wwtr1	gene	(201:	ENSCAFT00000013268.4).	In	4	out	of	40	
clones,	deletion	of	exon	4	was	found	in	both	alleles,	leading	to	a	frameshift	in	the	Wwtr1 
mRNA.
To generate Yap1/Pkd1	double	knock-outs,	mIMCD3	cells	guide	RNAs	were	designed	and	
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cloned	 into	a	vector	containing	a	hygromycin	selection	gene,	 to	 facilitate	 the	deletion	of	
exon	3	Yap1 gene in the Pkd1	knock-out	cell	line	mIMRFNPKD5E4.	After	co-transfection	with	
eSpCasCsy	and	hygromycin	 selection	 (0.1	mg/ml),	approximately	75	 single	 colonies	were	
analysed:	2	clones	had	deletions	on	both	Yap1	alleles	and	were	verified	using	RT-PCR	and	
sequencing.	For	detailed	protocols,	see	Supplementary	Methods.
Experimental animals and study design
All	the	animal	experiments	performed	have	been	approved	by	the	local	animal	experimental	
committee	of	the	Leiden	University	Medical	Center	and	the	Commission	Biotechnology	in	
Animals	of	the	Dutch	Ministry	of	Agriculture.
Inducible	 kidney-specific	 Pkd1	 deletion	 mice	 (iKspPkd1del)	 and	 tamoxifen	 administration	
have	been	described	before25.	Pkd1	gene	has	been	knocked-out	at	post-natal	day	18	(PN18).	
32	male	mice	have	been	divided	 into	 two	experimental	 groups	of	 16	 animals	 each:	 one	
received	scrambled	antisense	oligonucleotide	(ASO),	the	other	received	Yap-specific	ASO.	
Both	groups	received	an	injection	of	100	mg/kg	of	ASO	via	i.p.	injection,	starting	two	weeks	
after	Pkd1	 inactivation	 (PN18	+	2	weeks),	once	a	week,	until	 sacrifice	 (PN18	+	8	weeks).	
ASOs	 were	 provided	 by	 IONIS	 Pharmaceuticals	 (Carlsbad,	 CA,	 USA).	 Both	 ASOs	 were	
16mer	S-constrained	ethyl	gapmers	with	a	3-10-3	chimeric	design	and	a	phosphorothioate	
backbone.	Yap	ASO	sequence	was:	5’-AACCAACTATTACTTC-3’;	scrambled	ASO	sequence	was:	
5’-	GGCCAATACGCCGTCA-3’.	The	Yap	ASO	was	 selected	 from	 leads	 identified	 following	 in 
vitro	screens	which	were	then	evaluated	in vivo	for	renal	activity	and	tolerability.	Scrambled	
ASO	did	not	bind	to	any	known	target	and	was	included	as	a	control	for	non-specific	effects.
At	sacrifice,	both	kidneys	were	collected	and	used	for	IHC	or	snap-frozen	for	RNA	and	protein	
extraction.	Blood	urea	nitrogen	level	(BUN)	was	measured	using	the	Reflotron	Plus	(Roche	
Basel,	Switzerland).	Three	age-matched	Wt	mice	were	also	included	for	IHC	purposes.
Immunofluorescence, Immunohistochemistry and Western blotting
Cells	 were	 grown	 on	 coverslips	 and	 fixed	 in	 4%	 paraformaldehyde	 for	 15	min,	 at	 room	
temperature.	 Then,	 cells	 were	 permeabilised	 in	 0.2%	 Triton-X100	 in	 PBS	 for	 10	min,	 at	
room	temperature.	Cells	were	blocked	in	5%	non-fat	dried	milk	in	PBS	for	1	hour	and	then	
incubated	with	Phalloidin	Atto	594	(1:1500)	in	2%	BSA	in	PBS.	Immunofluorescence	slides	
were	 mounted	 with	 Vectashield	 containing	 DAPI	 and	 pictures	 were	 taken	 on	 the	 Leica	
DM5500	B	microscope.
For	 IHC,	 formalin-fixed	paraffin-embedded	kidneys	or	cysts	 in	Matrigel	were	sectioned	at	
4µm	thickness.	Sections	were	stained	with	Haematoxylin-Eosin	(H&E),	Periodic	acid-Schiff	
(PAS)	or	with	these	antibodies:	rabbit	anti-YAP	(1:800	for	kidneys	and	1:1000	for	3D	cysts;	
#14074;	Cell	Signaling	Technology,	Danvers,	MA,	USA);	rabbit	anti-TAZ	(1:500	for	kidneys	and	
1:1000	for	3D	cysts;	#4883;	Cell	Signaling	Technology);	rabbit	anti-Ki-67	(1:3000,	Novocastra,	
Leica	Biosystems,	Wetzlar,	Germany).
CHAPTER 3
76
For	Western	blot,	snap-frozen	kidneys	were	homogenised	using	the	Magnalyser	technology	
(Roche)	 in	 Ripa	 buffer	 supplemented	 with	 protease	 inhibitors	 cocktails	 (#05892970001;	
Roche).	Antibodies	used:	rabbit	anti-YAP	(1:1000;	#14074;	Cell	Signaling	Technology),	rabbit	
anti-TAZ	(1:1000;	#4883;	Cell	Signaling	Technology),	mouse	anti-GAPDH	(1:5000;	#97166;	
Cell	Signaling	Technology).	Secondary	antibodies:	goat-anti-rabbit	IRDye	800CW	(1:10000;	
#926-32211;	 LI-COR	 Biosciences;	 Lincoln,	 NE,	 USA)	 and	 goat-anti-mouse	 IRDye	 680RD	
(1:10000;	#926-32220;	LI-COR	Biosciences).	
Quantification of Ki-67 positive cells
Formalin-fixed	paraffin-embedded	kidneys	were	sectioned	at	4	µm	thickness	and	stained	
overnight	 at	 room	 temperature	with	 rabbit	 anti-Ki-67	 antibody	 and	 counterstained	with	
haematoxylin.	Sections	were	acquired	using	Philips	Ultra	Fast	Scanner	at	20x	magnification	
factor	 and	 pictures	 of	 15	 random	 areas	 of	 the	 kidney	 were	 taken.	 ImageJ	 software	
(public	domain	software,	NIH,	USA)	was	used	to	measure	the	Ki-67	positive	area	and	the	
haematoxylin	positive	area.	The	relative	Ki-67	area	was	calculated	as	a	percentage	of	the	
ratio	of	Ki-67	positive	area	over	haematoxylin	positive	area.
Gene expression analysis
Total	RNA	was	isolated	from	cultured	cells	or	snap-frozen	kidneys	using	TRI	Reagent	(#T9424;	
Sigma-Aldrich;	St.	Louis,	MO,	USA)	according	to	manufacturer’s	protocol,	and	gene	expression	
analysis	was	performed	by	quantitative	PCR	(qPCR)	as	described	previously26.	Briefly,	cDNA	
synthesis	was	done	using	Transcriptor	First	Strand	cDNA	Synthesis	Kit	(#04897030001;	Roche)	
according	to	the	manufacturer’s	protocol.	qPCR	was	done	in	triplicate	on	the	LightCycler	480	
II	(Roche)	using	2x	FastStart	SYBR-Green	Master	(#04913914001;	Roche)	according	to	the	
manufacturer’s	 protocol.	 Data	were	 analysed	with	 LightCycler	 480	 Software,	 Version	 1.5	
(Roche).	Gene	expression	was	normalised	to	the	housekeeping	gene	Hprt or GAPDH.	For	
primer	sequences	see	Supplementary	Table	1.
Quantification of cysts swelling
Cells	were	seeded	in	Matrigel	in	triplicate	and	cultured	for	four	days.	Subsequently,	cells	were	
stimulated	with	forskolin	or	DMSO	as	a	control,	for	three	days.	At	the	end	of	the	stimulation,	
the	plates	were	imaged	using	a	transmitted	light	microscope	(Leica	AXIO	Observer.A1)	at	a	
magnification	factor	of	5x.	One	picture	per	well	was	taken,	and	the	experiment	was	repeated	
four	times.	Using	ImageJ,	the	circumference	of	the	cysts	was	manually	assessed.	Around	90	
cysts	per	well	in	triplicate	have	been	evaluated,	and	the	average	cyst	size	was	calculated	for	
the	four	independent	experiments.	The	average	cyst	size	of	the	forskolin-treated	cells	was	
divided	by	the	average	cyst	size	of	the	DMSO	treated	cells	(i.e.	Wt	cells	+	FSK	/	Wt	cells	-	FSK)	
and	compared	between	genotypes.
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Statistical Analysis
Data	were	analysed	using	GraphPad	Prism	7.00	for	Windows	(GraphPad	Software,	La	Jolla	
California	USA,	www.graphpad.com)
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Results
Effect of YAP knock-out on cyst formation in vitro
To	study	the	effect	of	YAP	on	cyst	growth,	we	generated	mIMCD3	Yap	knock-out	(KO)	cells	and	
cultured	them	in	Matrigel.	Epithelial	cells	grown	in	this	condition,	spontaneously	develop	
cystic	structures	with	a	visible	lumen.	After	stimulation	with	forskolin,	the	cysts	start	to	swell	
(Figure	1a).	Interestingly,	Yap	KO	cells	(two	different	clones)	showed	impaired	cyst	formation,	
with	only	sporadic	lumen	formation.	Most	structures	were	very	disorganised,	resembling	a	
tumour-like	mass.	Stimulation	with	 forskolin	did	not	 result	 in	 swelling	of	 the	 tumour-like	
agglomerates.	Only	the	sporadic	cysts	that	already	had	developed	a	lumen	before	forskolin	
treatment,	 increased	 in	size.	These	data	 indicate	 that	cyst	growth	per	se	 is	not	 impaired	
(Figure	1a),	suggesting	that	Yap	KO	impairs	cyst	formation,	but	not	growth,	in vitro.
mIMCD3 cells double knock-out for Yap and Pkd1 do not form cysts in vitro
We	are	 interested	 in	 the	 role	 of	 YAP	 in	 the	 context	 of	 ADPKD.	 Therefore,	we	 generated	
mIMCD3	 cells	 knock-out	 for	Pkd1	 as	well	 as	 cells	 double	 KO	 for	Yap and Pkd1.	Pkd1	 KO	
cells,	when	grown	in	Matrigel,	form	cysts	that	respond	to	forskolin	stimulation	(Figure	1a)23.	
However,	Yap/Pkd1	double	KO	cells	showed	impaired	cyst	formation,	as	observed	before	for	
single Yap	KO	cells.	Again,	we	saw	sporadic	forskolin-responsive	cysts	while	the	majority	of	
cells	grew	in	tumour-like	agglomerates,	suggesting	that	Yap	KO,	alone	or	together	with	Pkd1 
KO,	causes	impaired	cyst	formation	in	cell	culture	(Figure	1a).
Effect of TAZ knock-out on cyst formation in vitro
YAP	has	a	paralogue	protein,	TAZ	(or	WWTR1).	To	study	the	role	of	TAZ	in	cyst	formation	in 
vitro,	we	tried	to	generate	mIMCD3	cells	knock-out	for	Taz.	To	our	surprise,	we	could	not	
obtain	any	viable	knock-out	clone	for	Taz.	We	screened	hundreds	of	clones	and,	although	
we	found	evidence	for	CRISPR/Cas	guide	RNA	activity,	we	were	not	able	to	produce	Taz	KO	
clones	suggesting	that	full	deletion	of	Taz,	but	not	Yap,	in	mIMCD3	cells	is	lethal.	Thus,	YAP	
and	TAZ	might	play	specific	roles	in	the	different	cells	of	the	kidney.	Indeed,	differences	in	
the	expression	of	YAP	and	TAZ	 in	 the	different	 renal	 segments	are	also	observed	 in vivo.	
Staining	of	sequential	sections	of	Wt	kidneys	showed	a	complementary	pattern	of	expression	
for	YAP	and	TAZ,	with	tubule	segments	strongly	positive	for	one	protein	but	not	the	other	
(Supplementary	Figure	1).
Next,	we	tried	to	generate	TAZ KO	MDCK	cells.	MDCK	cells,	when	grown	in	Matrigel,	can	
form	cystic	structures	that	respond	to	forskolin	stimulation,	as	observed	in	mIMCD3	cells	
(Figure	1b).	We	could	successfully	achieve	homozygous	deletion	of	TAZ,	and	when	cultured	
in	Matrigel,	MDCK	TAZ	KO	cells	were	able	to	form	cysts.	Interestingly,	although	cysts	were	
formed,	the	size	of	cysts	was	reduced	in	TAZ	KO	compared	to	MDCK	Wt	cells	(Figure	1b).	
Nevertheless,	 the	 relative	 increase	 in	 the	 size	of	TAZ	 KO	cysts	upon	 forskolin	 stimulation	
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was	comparable	 to	 that	observed	 in	Wt	 (Figure	1c).	Thus,	TAZ KO	does	not	prevent	 cyst	
formation	and	growth	in vitro,	and	we	found	a	cell-type	difference	in	TAZ dependency.
Figure 1. 3D cyst assay using Wt and mutant cells 
(a)	 Light	microscopy	 of	mIMCD3	Wt	 and	mutant	 cells	 before	 and	 after	 forskolin	 stimulation	 (respectively	 -FSK	
and	+FSK).	H&E	staining	of	formalin-fixed,	paraffin-embedded	cysts	grown	in	Matrigel	after	forskolin	stimulation	
(bottom	 row).	 (b)	 Light	microscopy	 of	MDCK	Wt	 and	mutant	 cells	 before	 and	 after	 forskolin	 stimulation.	H&E	
staining	of	 formalin-fixed,	paraffin-embedded	cysts	grown	 in	Matrigel	 after	 forskolin	 stimulation	 (bottom	 row).	
White	scale	bar	200	µm;	black	scalebar	50	µm.	(c)	Bar	graph	representing	the	cyst	swelling	ratio	calculated	in	MDCK	
Wt	cells	versus	two	different	TAZ	KO	clones.	Every	symbol	represents	one	independent	experiment.	Mean	with	±SD.	
Mann-Whitney	test.	n.s.	not	significant.
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The localisation of YAP and TAZ in 3D cysts assay
Since	nuclear	YAP	accumulation	was	previously	seen	in	cyst-lining	epithelia7,	we	investigated	
whether	knocking	out	Yap or Taz	has	an	influence	on	each	other’s	subcellular	localisation	
during	cyst	growth.	Staining	of	Wt	and	mutant	cells	that	were	grown	in	Matrigel	revealed	
that	both	YAP	and	TAZ	are	expressed	in	the	cytoplasm	and	the	nuclei	of	Wt	cysts	(mIMCD3	
and	MDCK).	Particularly,	mIMCD3	cells	 formed	small	cysts	with	a	relatively	thick	wall	but	
also	larger	stretched	cysts.	These	cysts	had	a	thin	epithelial	layer	and	showed	more	often	
nuclear	YAP	and	TAZ	 staining	 (Figure	2a).	 In	Yap	 KO	cells,	 and	Yap/Pkd1	 double	KO	cells,	
nuclear	TAZ	staining	was	observed,	and	it	was	not	limited	to	stretched	cysts	but	also	visible	
in	the	tumour-like	agglomerates.	This	was	especially	clear	in	the	tumour-like	agglomerates	
before	forskolin	treatment	(Supplementary	Figure	2),	suggesting	that	lack	of	YAP	increases	
TAZ	shuttling	(Figure	2a).	In	MDCK	cells,	3D	cysts	assay	lead	to	the	formation	of	cysts	with	
an	 overall	 flatter	wall,	 and	 both	 nuclear	 and	 cytoplasmic	 YAP	 and	 TAZ	 localisation	were	
visible	within	the	same	cyst.	In	TAZ	KO	cells,	YAP	expression	does	not	clearly	differ	from	the	
localisation	observed	in	Wt	cells	(Figure	2b).	Thus,	Yap	KO	seems	to	affect	TAZ	localisation	in 
vitro,	but	not	vice	versa.
Figure 2. Immunostaining of Wt and mutant cells in 
forskolin-treated 3D cysts 
(a)	 Representative	 IHC	 of	 formalin-fixed,	 paraffin-
embedded	cysts	of	forskolin-treated	Wt	and	mutant	
mIMCD3 cells and (b) forskolin-treated	 Wt	 and	
mutant	 MDCK	 cells,	 stained	 for	 YAP	 and	 TAZ.	 For	
mIMCD3 Yap/Pkd1	KO	and	MDCK	TAZ KO	cells,	cysts	
from	multiple	fields	of	view	are	shown	separated	by	
a	white	line.	White	arrowheads	indicate	cytoplasmic	
localisation	 of	 the	 proteins;	 black	 arrowheads	
indicate	 nuclear	 localisation	 of	 the	 proteins.	 Scale	
bar	50	µm.
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YAP knock-down using ASOs does not improve cystic phenotype in vivo
We	showed	in	the	past	that	cyst-lining	epithelia	have	intense	nuclear	YAP	localisation,	both	
in Pkd1-mutant	mouse	models	and	 in	ADPKD	patients7.	Therefore,	we	hypothesised	 that	
YAP	 could	 actively	 contribute	 to	 cyst	 formation	 or	 cyst	 growth,	 through	 upregulation	 of	
target	genes	involved	in	cell	proliferation	and	apoptosis.
To	check	the	effect	of	YAP	on	the	cystic	phenotype	in vivo,	we	knocked-down	Yap	using	ASOs	
in	young	adult	iKspPkd1del	mice.	The	Pkd1	gene	was	inactivated	in	18	day	old	mice	(PN18),	
and	2	weeks	after	gene	inactivation	they	were	injected	i.p.,	with	Yap	specific	ASO	(n=16)	or	
scrambled	ASO	(n=16),	every	week	until	sacrifice.	Mice	were	sacrificed	8	weeks	after	gene	
inactivation	(PN18	+	8	weeks)	(Figure	3a).
The Yap	 ASO	 treatment	 resulted	 in	 about	 70%	 reduction	 of	 Yap	 gene	 expression	 levels	
without	 affecting	 Taz	 expression,	 confirming	 its	 efficacy	 and	 specificity	 in vivo	 (Figure	
3b).	YAP	reduction	was	confirmed	at	 the	protein	 level,	while	TAZ	protein	expression	was	
unchanged	by	the	ASO	treatment	(Figure	3c-e).
Analysis	of	kidney	size,	by	measuring	two	kidney	weight/body	weight	ratios,	and	of	renal	
function,	using	BUN	levels,	revealed	comparable	disease	progression	in	the	two	experimental	
groups	(Figure	4b,	c).	PAS	staining	revealed	tubule	dilation	and	cyst	formation	in	different	
segments	of	the	kidneys,	both	in	Yap	ASO	and	scrambled	ASO	treated	mice,	suggesting	that	
Yap	knock-down	did	not	affect	cyst	formation	in vivo	(Figure	4a).	
YAP and TAZ downstream targets expression are not changed by Yap knock-down in vivo
YAP	and	TAZ	are	transcriptional	co-activators	and	can	translocate	 into	the	nucleus	where	
they	can	drive	gene	expression.	To	study	the	effect	of	Yap	knock-down	on	the	expression	of	
its	target	genes,	we	quantified	the	expression	of	known	YAP/TAZ	targets,	Wtip, Ajuba,	Cyr61 
and Amotl227.	Despite	the	consistent	Yap	 reduction	at	the	mRNA	level,	 the	expression	of	
target genes is not changed in Yap	ASO	treated	compared	to	scrambled	ASO	treated	mice	
(Figure	4d).	Additionally,	we	evaluated	the	expression	of	Ki-67,	a	marker	for	cell	proliferation,	
as	YAP	and	TAZ	can	regulate	transcriptional	programs	that	control	cell	proliferation27.	The	
Ki-67	positive	 areas	 in	Yap	 ASO	 treated	mice	were	not	 significantly	 different	 from	 those	
observed	in	scrambled	ASO	treated	mice	(Figure	4e,	f).	In	conclusion,	the	knockdown	of	Yap 
does	not	affect	the	expression	of	the	downstream	targets	we	tested.
WNT and TGF-β pathways seem to be more active in Yap ASO mice 
It	 is	well	 known	 that	both	YAP	and	TAZ	 can	 interact	with	 the	final	 effectors	of	 the	WNT	
and	TGF-β	pathways28.	For	this	reason,	we	checked	the	expression	levels	of	several	target	
genes	regulated	by	β-catenin	 (Axin2 and Myc)	and	Smads	 (Acta2, Col1a1, Vim, Fn1, Pai1 
and Mmp2).	We	observed	 increased	Myc expression	 in	Yap	ASO	 treated	mice	compared	
to	 scrambled	ASO,	 but	 only	 a	 trend	 for	Axin2	 expression	 (Figure	 5a).	Moreover,	we	 saw	
significantly	increased	expression	of	alpha-smooth	muscle	actin	(Acta2)	and	vimentin	(Vim)	
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and	 a	 consistent	 trend	 for	 collagen	 1	 alpha-1	 (Col1a1),	 fibronectin	 (Fn1),	 plasminogen	
activator	 inhibitor-1	 (Pai1)	 and	 matrix	 metallopeptidase	 2	 (Mmp2)	 (Figure	 5b).	 Thus,	
although	 not	 conclusive,	 these	 results	 suggest	 that	WNT	 and	 TGF-β	 pathways	are more 
active	upon	Yap	knock-down.
Figure 3. In vivo downregulation of Yap with ASOs 
(a)	Schematic	representation	of	the	in vivo	experimental	pipeline.	Pkd1	gene	inactivation	was	achieved	with	three	
consecutive	administrations	of	 tamoxifen	at	post-natal	day	18	 (PN18).	Two	weeks	after	gene	 inactivation,	mice	
were	injected	weekly	intraperitoneally	with	Yap	specific	ASO	or	scrambled	ASO	as	control.	Mice	were	sacrificed	at	
8	weeks	after	gene	inactivation.	(b)	Gene	expression	(fold-change)	of	Yap and Taz	at	the	sacrifice	in	mice	treated	
with	Yap	ASO	and	scrambled	ASO.	Each	symbol	represents	a	mouse.	Mean	with	±	SD.	****	P	<	0.0001,	t-test.	(c) 
Representative	IHC	of	renal	tissue	from	mice	treated	with	scrambled	ASO	and	Yap	ASO,	showing	YAP	and	TAZ.	Scale	
bar	1	mm.	(d)	Total	kidney	protein	lysates	of	mice	treated	with	scrambled	ASO	and	Yap	ASO	blotted	for	endogenous	
YAP,	TAZ		and	GAPDH.	(e)	Quantification	of	YAP	and	TAZ	protein	level	in	total	kidney	normalised	on	GAPDH.	Each	
symbol	represents	a	mouse.	Mean	with	±	SD.	*	P	<	0.05,	n.s.	not	significant,	t-test.	
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Figure 4. Effect on PKD progression of in vivo downregulation of Yap with ASOs 
(a) Representative	Periodic	acid-Schiff	 (PAS)	staining	of	renal	tissue	from	mice	treated	with	scrambled	ASO	and	
Yap	ASO.	Scale	bar	200	µm.	(b)	Quantification	of	kidney	size	using	two	kidney	weight/body	weight	ratio.	n.s.	not	
significant (c)	Blood	urea	nitrogen	(BUN)	level	at	the	sacrifice.	n.s.	not	significant (d)	Gene	expression	(fold-change)	
of	YAP/TAZ	targets	at	the	sacrifice	 in	mice	treated	with	Yap	ASO	and	scrambled	ASO.	Each	symbol	represents	a	
mouse.	Mean	with	 ±	 SD.	 n.s.	 (not	 significant)	 refers	 to	 all	 the	 genes	 in	 the	 graph,	 t-test.	 (e)	Quantification	 of	
Ki-67	positive	area.	Each	symbol	represents	a	mouse.	Mean	with	±	SD.	n.s.	not	significant,	t-test.	(f)	Representative	
pictures	of	renal	tissue	stained	for	Ki-67.	Scale	bar	50	µm.
Yap KO affects cytoskeleton integrity and integrins expression in vitro
Following	 up	 on	 the	 aberrant	 phenotype	 observed	 in	 Yap	 KO	 cells	 grown	 in	 Matrigel,	
we	 decided	 to	 characterise	 these	 cells	 further.	We	 stained	 the	 actin	 cytoskeleton	 using	
fluorescent	 dye-conjugated	 phalloidin,	 a	 well-known	 marker	 for	 filamentous	 actin.	 Wt	
mIMCD3	 cells	 showed	 a	 normal	 cytoskeleton	 with	 clear	 cortical	 cytoskeletal	 and	 stress	
fibres	present	throughout	the	cell	body.	Also,	TAZ	KO	cells	showed	a	normal	cytoskeleton,	
similar	to	Wt	cells.	Conversely,	Yap	KO	cells	showed	aberrant	cytoskeleton	and	rarely	stress	
fibres,	 suggesting	 that	 the	 effect	 on	 the	 actin	 structure	was	 a	 consequence	of	Yap gene 
disruption	(Figure	5c).
Additionally,	gene	expression	of	integrin-alpha	1	(Itga1)	and	-alpha	v	(Itgav)	was	significantly	
reduced in Yap	KO	cells,	before	and	after	forskolin	stimulation,	compared	to	Wt	cells.	This	
was	not	observed	 in	TAZ	 KO	cells,	 in	which	 the	 level	of	 Itga1	was	 significantly	 increased	
compared	to	Wt	cells	(Figure	5d).	These	results	might	explain	the	loss	of	polarity	observed	in	
Yap	KO	cells	leading	to	impaired	cyst	formation	and	development	of	tumour-like	structures	
in	3D	cultures.
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Figure 5. WNT and TGF-β pathway targets in vivo, and characterisation of mutant cell lines 
(a)	Gene	expression	(fold-change)	of	WNT	pathway	targets	Axin2 and Myc	at	the	sacrifice	 in	mice	treated	with	
Yap	ASO	and	scrambled	ASO.	Each	symbol	represents	a	mouse.	Mean	with	±	SD.	**	P	<	0.01,	n.s.	not	significant,	
t-test.	(b)	Gene	expression	(fold-change)	of	TGF-β	pathway	targets,	Acta2, Col1a1, Vim, Fn1, Pai1 and Mmp2, at 
the	sacrifice	in	mice	treated	with	Yap	ASO	and	scrambled	ASO.	Each	symbol	represents	a	mouse.	Mean	with	±SD.	
*	P	<	0.05,	**	P	<	0.01, t-test.	If	no	significance	is	indicated,	the	comparison	is	not	significant.	(c)	Representative	
immunofluorescence	of	Wt	and	mutant	mIMCD3	cells	and	Wt	and	mutant	MDCK	cells.	In	red,	the	actin	cytoskeleton	
is	stained	using	phalloidin	Atto	594.	In	blue,	nuclei	are	stained	using	Vectashield	containing	DAPI.	Scale	bar	20µm.	
(d) Gene	expression	normalised	on	housekeeping	genes	(Hprt	 for	mIMCD3	cell	 lines	and	GAPDH	 for	MDCK	cell	
lines)	 of	 Integrins	 alpha-1	 and	 alpha-v.	 Cells	 are	 grown	 in	Matrigel	 and	 allowed	 to	 form	 cysts.	 Subsequently,	
forskolin	is	added	to	the	medium	(+FSK)	or	DMSO	as	control	(-FSK).	Cells	are	then	collected	for	RNA	extraction,	
and	gene	expression	of	 the	 integrins	mentioned	above	 is	evaluated.	For	mutant	cells,	 two	different	clones	are	
included.	Each	symbol	represents	an	 independent	experiment.	Mean	with	±	SD.	Asterisks	 indicates	significance	
of	the	comparison	of	mutant	cell	lines	versus	the	Wt	in	the	same	stimulation	group	(Wt-FSK	vs.	mutant-FSK	and	
Wt+FSK	vs.	mutant+FSK)	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001,	****	P	<	0.0001.	§	indicates	the	significance	of	the	
comparison	of	the	same	cell	line	in	the	two	stimulation	group	(Wt-FSK	vs.	Wt+FSK	or	mutant-FSK	vs.	mutant+FSK).	
ANOVA	significance	test	with	Tukey’s	multiple	comparisons	test.
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Discussion
ADPKD	is	the	fourth	most	common	renal	disease	that	requires	renal	replacement	therapy29.	
Indeed,	 the	 majority	 of	 patients	 with	 ADPKD	 will	 develop	 the	 end-stage	 renal	 disease	
(ESRD),	severely	impacting	patients’	lives	and	representing	a	substantial	economic	burden	
to the healthcare system30.	Thus,	finding	viable	intervention	strategies	aimed	to	slow	down	
the	disease	progression	is	of	paramount	importance.
In	a	previous	study,	we	showed	that	the	Hippo	pathway’s	effector	YAP	was	more	active	in	the	
cyst-lining	epithelia	both	in	murine	and	human	renal	tissues	with	PKD7.	When	in	the	nucleus,	
YAP	can	modulate	the	transcription	of	genes	involved	in	the	regulation	of	proliferation	and	
apoptosis3,4,6.	Therefore,	we	hypothesised	that	reducing	nuclear	 localisation	of	YAP	might	
slow	down	the	renal	cystic	disease.	In	this	study,	we	used	ASOs	to	selectively	knock-down	
the	expression	of	Yap	in	young	adult	iKspPkd1del	mice.	We	reached	about	70%	reduction	in	
gene	expression,	indicating	that	ASOs	can	be	a	viable	strategy	to	effectively	and	selectively	
downregulate	a	target	in	kidneys	in	models	for	PKD,	as	also	shown	for	a	few	other	targets31,32.	
Our	data	clearly	indicate	that	Yap	knock-down	using	ASOs	in	a	mouse	model	for	ADPKD	does	
not	improve	the	cystic	phenotype.	Indeed,	also	in vitro, Yap	KO	did	not	impair	the	growth	
of	the	sporadic	cysts	that	were	able	to	form,	suggesting	that	proliferation	is	not	affected.	
Considering	that	TAZ	(or	WWTR1)	levels	are	not	changed	by	Yap	ASO,	we	hypothesised	that	
TAZ	 could	 be	 compensating	 for	Yap	 knock-down.	 Indeed,	 expression	 levels	 of	 the	 target	
genes	are	not	changed	by	Yap	knock-down,	and	TAZ	shows	a	clear	nuclear	localisation	in	most	
of	the	renal	tubules,	both	cystic	and	dilated	ones.	This	suggests	that	TAZ	is	compensating	
for	the	loss	of	YAP	and	might	be	contributing	to	cyst	growth,	hence	targeting	TAZ	together	
with	YAP	might	be	a	viable	strategy	to	inhibit	cyst	progression.	However,	we	also	showed	
that TAZ	KO	did	not	result	 in	 impaired	cyst	 formation	nor	cyst	growth	 in	a	3D	cyst	assay,	
arguing	against	it.	This	is	further	supported	by	in vivo results,	since	mice	with	a	constitutive	
or	 conditional	 Taz	 KO,	 develop	 mild	 cysts	 even	 in	 the	 absence	 of	 a	 Pkd1	 mutation18,33.	
Moreover, Merrick et al.	 showed	 that	 TAZ	physically	 interacts	with	 the	C-terminal	 tail	 of	
PC1	(PC1-CTT)	in	HEK293	cells.	They	also	proved	in	zebrafish,	that	the	bone	phenotype	and	
curly	tail	observed	after	injection	of	Pkd1 morpholino	were	rescued	by	co-injection	of	PC1-
CTT	mRNA	but	not	if	also	Taz	was	knocked	out21.	Altogether,	these	results	suggest	that	PC1	
and	TAZ	participate	in	common	signalling	routes,	and	reducing	or	depleting	Taz levels might 
worsen	PKD	progression.	
In	contrast	to	our	work,	a	recent	paper	showed	that	Yap	KO,	especially	together	with	Taz	KO,	
was	able	to	reduce	PKD	progression	mildly	in	Pkd1	deficient	mice.	However,	the	mouse	model	
used	was	based	on	leaky	Cre	recombinase	activity,	suggesting	that	gene	inactivation	already	
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occurred	during	development,	rather	than	in	adult	mice34.	Indeed,	constitutive	Yap	KO	can	
lead	to	impaired	kidney	development,	which	might	affect	subsequent	cyst	development35.	
Another	 difference	with	 our	 study	 is	 that	we	did	 not	 use	 a	 genetic	 deletion	of	Yap,	 but	
we	decided	 to	use	 a	 strategy	based	on	antisense	oligonucleotides	 that	 could	potentially	
be	 translated	 to	 the	clinic.	The	use	of	ASOs	allows	 to	 reduce	YAP	 levels	consistently,	but	
not	 to	altogether	abolish	 the	expression.	Additionally,	by	 treating	young	adult	mice	 that	
develop	cysts	relatively	slowly	and	in	every	renal	segment,	we	mimic	the	disease	observed	
in	patients	even	more.	
Although	YAP	and	TAZ	have	some	overlapping	functions,	they	also	partly	interact	with	and	
are	regulated	by	different	partners,	indicating	that	YAP	and	TAZ	also	have	unique	functions36.	
Interestingly,	we	could	generate	Yap	KO	but	not	Taz	KO	mIMCD3	cells,	suggesting	that	TAZ	
plays	 a	 crucial	 role	 in	mIMCD3	 cells	 and	 potentially	 in	 specific	 segments	 of	 the	 kidney.	
Indeed,	we	observed	differential	expression	patterns	for	YAP	and	TAZ	in	the	various	renal	
segments	(Supplementary	Figure	1),	corroborating	the	idea	that	the	two	transcriptional	co-
activators	also	have	distinct	functions	in	the	kidneys.	However,	 if	and	how	modulation	of	
YAP	levels	affects	the	activity	of	TAZ	in	kidneys,	and	vice	versa,	is	not	clear	and	should	be	
further	investigated.
YAP	 and	 TAZ	 are	 transcriptional	 co-activators	 that	 can	 modulate	 a	 variety	 of	 biological	
processes.	 They	 have	 been	 associated	 with	 fibrogenesis	 and	 epithelial-to-mesenchymal	
transition	in vivo and in vitro	via	interaction	with	both	TGF-β	and	WNT	signalling	pathways.	
Particularly,	 when	 the	 Hippo	 pathway	 is	 active,	 YAP	 and	 TAZ	 are	 phosphorylated	 and	
restrained	in	the	cytoplasm	where	they	can	interact	with	SMADs	and	β-catenin,	preventing	
their	nuclear	translocation	and	transcriptional	activity28.	In	our	study,	we	observed	increased	
expression	of	 some	of	 the	downstream	 targets	of	WNT	and	TGF-β	pathways	 in	Yap	ASO	
treated	mice.	This	might	suggest	that	reduced	YAP	levels	cause	an	imbalance	in	the	regulation	
of	these	interacting	signalling	pathways,	either	because	YAP	cannot	physically	interact	with	
SMADs	and	β-catenin	anymore,	or	due	to	increased	activation	of	TAZ	overcompensating	for	
YAP	loss.	Indeed,	YAP	has	been	shown	to	inversely	regulate	TAZ	protein	levels	in	a	process	
conserved	from	mouse	to	human,	and	we	also	observed	increased	nuclear	TAZ	in	Yap	KO	
cells	grown	in	3D37.	Based	on	this,	Yap	knock-down	might	result	 in	overactivation	of	TAZ,	
in	turn	causing	increased	activation	of	WNT	or	TGF-β	pathways,	which	are	well	known	for	
promoting	cyst	formation	in	ADPKD38,39.	Such	a	process	might	explain	why	we	did	not	see	
any	amelioration	of	the	phenotype	with	Yap	knock-down	in vivo,	although	further	studies	
are	necessary	to	unveil	the	exact	molecular	mechanisms.
YAP/TAZ	were	initially	identified	as	downstream	effectors	of	the	Hippo	pathway.	Nevertheless,	
in	the	last	years	a	variety	of	upstream	regulators,	dependent	or	independent	of	the	Hippo	
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pathway,	have	been	identified	affecting	YAP/TAZ	sub-localization.	These	include	mechanical	
signals	 via	 cell-cell	 contacts,	 polarity	 proteins	 and	 cadherin-β-catenin	 complexes,	 focal	
adhesions,	extracellular	matrix	(ECM)	elasticity	and	cytoskeletal	tension40,	as	well	as	several	
mitogens	 like	 epidermal	 growth	 factor	 (EGF),	 lysophosphatidic	 acid	 (LPA),	 sphingosine-1	
phosphate,	insulin	and	the	protease	thrombin,	which	can	control	YAP/TAZ	localisation41-45.	
Indeed,	 we	 also	 showed	 that	 in	 Yap	 KO	mIMCD3	 cells,	 expression	 of	 Itga1 and Itgav is 
impaired	and	that	the	architecture	of	the	cytoskeleton	is	aberrant.	In	3D	cysts,	this	results	
in	non-polarized	growth	of	 the	cells	 that	 fail	 to	 form	a	 lumen	and	grow	as	a	 tumour-like	
mass.	In vivo,	mice	mutant	for	proteins	involved	in	the	formation	of	cell-cell	junctions,	focal	
adhesions	and	related	to	cytoskeletal	assembly,	develop	renal	cysts46.	Thus,	the	aberration	
of	any	of	the	processes	mentioned	above	can	lead	to	cyst	formation.	For	these	reasons,	the	
modulation	of	Hippo	pathway	effectors	YAP	and	TAZ	to	intervene	on	cyst	progression	might	
not	be	a	viable	option.
In	 conclusion,	 although	 we	 cannot	 exclude	 that	 the	 Hippo	 pathway	 is	 involved	 in	 cyst	
growth,	we	believe	that	the	strong	nuclear	YAP	localisation	observed	in	cyst-lining	epithelia	
is	more	a	consequence	of	cell	stretching	or	stiffer	ECM	or	mitogen-induced	signalling	rather	
than	a	driving	force	for	cell	proliferation.	Indeed,	downregulation	of	YAP	using	ASOs	did	not	
affect	cell	proliferation	nor	the	cystic	phenotype	in	our	Pkd1	KO	mouse	model.	Moreover,	
due	to	its	profound	interconnection	with	other	signalling	pathways,	such	as	WNT	and	TGF-β, 
a	 therapeutic	 intervention	 for	 PKD	based	on	 the	modulation	of	 YAP	 levels	might	 not	 be	
feasible,	at	least	with	the	current	knowledge.	
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Supplementary Figures
Supplementary Figure 1. YAP and TAZ expression in Wt kidneys
Representative	IHC	for	YAP	and	TAZ	on	sequential	slides	of	Wt	mice	kidneys	at	post-natal	day	100.	The	staining	
shows	a	complementary	expression	pattern	of	YAP	and	TAZ	in	the	various	segments	of	the	kidneys,	with	tubule	
segments	strongly	positive	for	one	protein	but	not	the	other.	Arrowheads	show	the	same	tubules	stained	for	the	
two	different	proteins.	Scale	bar	200	µm.
Supplementary Figure 2. YAP and TAZ staining of Wt and mutant mIMCD3 cells 
Cells	are	grown	in	Matrigel	and	allowed	to	form	cysts.	In	the	pictures,	Wt	and	mutant	mIMCD3	cells	are	shown,	
which	were	not	stimulated	with	forskolin.	Representative	IHC	of	formalin-fixed,	paraffin-embedded	cysts	stained	
for	YAP	and	TAZ	shows	intense	nuclear	TAZ	staining	in	Yap	single	and	double	KO	cells.	White	arrowheads	indicate	
cytoplasmic	localisation	of	the	proteins;	black	arrowheads	indicate	nuclear	localisation	of	the	proteins.	Scale	bar	
50	µm
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Supplementary methods
Generation of knock-out cell lines
Generation	of	the	Pkd1	knock-out	cell	line	mIMRFNPKD	5E4	was	described	before1	by	making	
use	of	the	FokI	nucleases	(RFN)	method,	described	by	Tsai et al.2	in	mouse	kidney,	medulla/
collecting	duct	cell	line	mIMCD3	(mIMCD3,	ATCC®	CRL-2123™).	A	comparable	method	was	
used to generate the Yap1	knock-out	cell	lines.	In	short,	the	RFN	guide	RNAs	for	Yap1	exon	
2	were	selected	using	ZiFiT	(http://zifit.partners.org/ZiFiT/Disclaimer.aspx)	and	cloned	into	
vector	pSQT1313neo.	This	is		a	modified	version	of	pSQT1313	(Addgene	#53370),	in	which		we	
replaced	the	ampicillin	gene	of	pSQT1313	by	the	kanamycin/neomycin	resistance	cassette	
of	pEGFP-N1	(Clontech).	This	was	done	to	facilitate	G418	selection	of	clones	that	have	taken	
up	pSQT1313neoRFN	and	enrich	for	clones	that	carry	a	Yap1	exon	2	deletion.	The	RFN-guide	
RNA	clone	was	co-transfected	with	pSQT1601	(Addgene	#53369)	a	plasmid	expressing	the	
Csy4	and	dCas9-FokI	fusion	proteins.	mIMCD3	cells	were	grown	to	80%	confluency	in	a	9	cm	
petri	dish	and	transfected	with	2µg	Yap1ex2RFN	and	8µg	pSQT1601	DNA	using	Lipofectamin	
2000	(Invitrogen).	G418	(0.5mg/ml)	selection	was	applied	after	48	hours.	After	7	days,	cells	
were	 re-plated	at	 a	density	of	 ~50	 cells	 per	 9	 cm	plate.	 In	 total	 60	 single	 colonies	were	
picked	and	analysed	using	PCR	with	primers	flanking	 the	RFN	 target	 sites.	 PCR	products	
were	digested	with	restriction-endonuclease	BpmI,	which	cuts	between	the	Yap1ex2	RFN	
target	sites.	From	7	clones	that	showed	undigested	PCR	products,	demonstrating	a	deletion	
of	 the	BpmI,	 restriction	site	on	both	alleles,	 the	PCR	products	were	subcloned	using	 the	
TOPO®	cloning	kit	(Invitrogen).	Fifteen	subclones	were	analysed	by	Sanger	sequencing.	The	
sequences	for	clone	mIMRFNYap9	revealed	an	8bp	out	of	frame	deletion	in	one	allele	and	a	
22bp	out	of	frame	deletion	in	the	other	allele	and	clone	mIMRFNYap14,	revealed	13bp	and	
26bp	out	of	frame	deletions.	
Using	 a	 similar	 method	 we	 set	 out	 to	 make	 knock-out	 cell	 lines	 for	 Wwtr1	 (202:	
ENSMUST00000120977.1),	 by	 targeting	 exon	 2	 or	 exon	 4.	 However,	 after	 screening	 200	
single	 clones,	we	noticed	 that	mIMCD3	has	 three	Wwtr1	 alleles	 and	we	were	unable	 to	
identify	any	clone	with	an	out	of	frame	deletion	in	all	three	alleles.	We	switched	strategy:	
using	two	guide	RNAs	to	delete	exon	3	to	be	sure	that	every	Cas9	induced	deletion	leads	
to a Wwtr1	mRNA	with	an	out	of	frame	deletion.	CRISPR/Cas9	RNA-guides	were	designed	
targeting	introns	2	and	3	with	the	online	tool	of	the	Zhang	lab	(https://zlab.bio/guide-design-
resources)	to	obtain	a	genomic	exon	3	deletion.	RNA	guides	were	cloned	into	pSQT1313neo,	
both	guide	RNAs		flanked	and	separated	from	each	other	by	Csy4	recognition	sites,	and	co-
transfected	with	eSpCasCsy,	a	modified	eSpCas9(1.1)	 (Addgene	#71814)	which	expresses	
both	the	high	specificity	SpCas9	protein	together	with	the	Csy4	RNAse.	Single	clones	were	
isolated	 using	 G418	 selection.	 In	 none	 of	 the	 250	 clones	 analysed	 exon	 3	 deletion	was	
observed	in	three	alleles.	Sequencing	of	many	clones	revealed,	deletion	of	exon	3	in	two	
alleles	 and	 indels	were	observed	at	 the	Cas9	 cutting	 sides	of	 the	guide	RNA	 recognition	
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sides	in	the	third	allele,	but	these	events	did	not	lead	to	a	deletion	of	exon	3.	From	these	
results	 we	 conclude	 that	 knocking-out	 three	 alleles	 in	mIMCD3	 leads	 to	 cell	 death.	We	
applied	 the	 same	 exon	 deletion	 strategy	 to	MDCK	 cells	 (ATCC®	 CCL-34™).	We	 designed	
guide	RNAs	to	delete	exon	4	of	the	canine	Wwtr1	gene	(201:	ENSCAFT00000013268.4),	and	
cloned	these	into	pSQT1313neo.	After	co-transfection	with	eSpCasCsy	and	G418	selection	
40	single	colonies	were	analysed	using	PCR.	In	4	clones	a	deletion	of	exon	4	in	both	alleles	
was	observed.	RT-PCR	and	sequencing	on	RNA	isolated	of	these	clones,	revealed	deletion	of	
exon	4	leading	to	a	frameshift	in	the	Wwtr1	mRNA	and	knocking-out	both	alleles.
Finally,	we	generated	a	Pkd1/Yap1	double	knock-out	in	mIMCD3.	Guide	RNAs	were	designed	
and	cloned	into	a	vector	containing	a	hygromycin	selection	gene,	to	facilitate	the	deletion	
of	exon	3	Yap1 gene in the Pkd1	knock-out	cell	line	mIMRFNPKD	5E4.	After	co-transfection	
with	 eSpCasCsy	 and	 hygromycin	 selection	 (0.1mg/ml),	 approximately	 75	 single	 colonies	
were	analysed:	2	clones	had	deletions	on	both	Yap1	alleles,	and	were	verified	using	RT-PCR	
and	sequencing.
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Mouse Forward Reverse
Acta2 CATCATGCGTCTGGACTTG ATCTCACGCTCGGCAGTAG
Ajuba CCAGAGAAGATTACTTTGGCACC ACAAAGCACTGGGTGTGGTA
AmotL2 ACCAGGAGATGGAGAGCAGATT GAAGGACCTTGATCACCGCA
Axin2 GACAGCGAGTTATCCAGCGA AGGAGGGACTCCATCTACGC
Col1a1 TGACTGGAAGAGCGGAGAGT AGACGGCTGAGTAGGGAACA
Cyr61 CACTGAAGAGGCTTCCTGTCT CCAAGACGTGGTCTGAACGA
Fn1 AATCCAGTCCACAGCCATTCC CCTGTCTTCTCTTTCGGGTTCA
Hprt GGCTATAAGTTCTTTGCTGACCTG AACTTTTATGTCCCCCGTTGA
Itga1 ACCAGTACGTCGCTGGTTC GCAGACGCCTAGGATAACGG
Itgav GGTCGCCTATCTTCGGGATG CGTTCTCTGGTCCAACCGAT
Mmp2 GACCGGTTTATTTGGCGGAC TCATTCCCTGCGAAGAACACA
Myc CCTTCTCTCCTTCCTCGGACT CCTCATCTTCTTGCTCTTCTTCAG
Pai1 GCCAACAAGAGCCAATCAC ACCCTTTCCCAGAGACCAG
Taz (Wwtr1) ATGGACGAGATGGATACAGGTGA AGACTCCAAAGTCCCGAGGT
Vim CCAACCTTTTCTTCCCTGAA TGAGTGGGTGTCAACCAGAG
Wtip TTCATCTGTGACTCCTGTGGGA TGGCAGTACACTTTCTCACCC
Yap1 TTCCGATCCCTTTCTTAACAGT GAGGGATGCTGTAGCTGCTC
Dog Forward Reverse
Gapdh GAGTCCACTGGGGTCTTCAC TCAGCAGAAGGAGCAGAGATG
Itga1 GTGCTGCCCTCTTCTGGTC TTTCCTTCCACACGGCAGTT
Itgav CAAAGGAGCACTTCCCACGA ACCTGGAGACCGGTTATGGA
Supplementary Tables
 Supplementary Table 1. List of primer sequences used for qPCR
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Abstract
Polycystic	 kidney	disease	 (PKD)	 is	 a	major	 cause	of	 end-stage	 renal	disease.	 The	disease	
mechanisms	are	not	well	understood	and	 the	pathogenesis	 toward	 renal	 failure	 remains	
elusive.	In	this	study,	we	present	the	first	RNASeq	analysis	of	a	Pkd1-mutant mouse model 
in	a	combined	meta-analysis	with	other	published	PKD	expression	profiles.	We	introduce	
the	PKD	Signature,	a	set	of	1,515	genes	that	are	commonly	dysregulated	 in	PKD	studies.	
We	show	that	the	signature	genes	include	many	known	and	novel	PKD-related	genes	and	
functions.	Moreover,	 genes	with	 a	 role	 in	 injury	 repair,	 as	 evidenced	by	 expression	data	
and/or	automated	literature	analysis,	were	significantly	enriched	in	the	PKD	Signature,	with	
35%	of	the	PKD	Signature	genes	being	directly	implicated	in	injury	repair.	NF-kB	signaling,	
epithelial-mesenchymal	transition,	inflammatory	response,	hypoxia,	and	metabolism	were	
among	the	most	prominent	injury	or	repair	related	biological	processes	with	a	role	in	the	
PKD	etiology.	Novel	PKD	genes	with	a	role	in	PKD	and	in	injury	were	confirmed	in	another	
Pkd1-mutant	mouse	model	 as	 well	 as	 in	 animals	 treated	with	 a	 nephrotoxic	 agent.	We	
propose	that	compounds	that	can	modulate	the	injury-repair	response	could	be	valuable	
drug	candidates	for	PKD	treatment.
META-ANALYSIS OF PKD EXPRESSION PROFILES DEFINES INVOLVEMENT OF INJURY REPAIR 
99
4
Introduction
Polycystic	 Kidney	 Disease	 (PKD)	 is	 a	 genetic	 disease	 of	 the	 kidney	 characterized	 by	 the	
gradual	replacement	of	normal	kidney	parenchyma	by	fluid-filled	cysts	and	fibrotic	tissue.	
Autosomal	 Dominant	 Polycystic	 Kidney	 Disease	 (ADPKD)	 is	 caused	 by	 mutations	 in	 the	
PKD1 or PKD2	gene	and	the	less	frequent	autosomal	recessive	form,	Autosomal	Recessive	
Polycystic	 Kidney	Disease	 (ARPKD),	 is	 caused	 by	mutations	 in	 the	PKHD1 gene4,40,67.	 It	 is	
not	entirely	clear	why	the	disruption	of	these	genes	lead	to	PKD	and	what	functions	their	
protein	products	might	have	in	normal	and	diseased	kidneys.	Furthermore,	it	 is	expected	
that	a	vasopressin	V2	receptor	antagonist,	recently	approved	in	Europe,	will	probably	not	be	
sufficient	for	life-long	treatment,	warranting	the	search	for	additional	therapies65.	Therefore,	
a	detailed	knowledge	of	the	molecular	pathology	and	signaling	pathways	at	different	phases	
of	the	disease	is	needed.	To	answer	these	questions,	several	PKD-related	expression	profiling	
studies	have	been	conducted	 in	the	 last	decade10,20,30,39,43-45,51,54,56.	These	studies,	however,	
varied	considerably	by	the	type	and	number	of	the	samples	used,	 i.e.,	cystic	and	normal	
cell	lines,	patient-derived	material,	kidneys	from	different	rat	or	mouse	models	at	different	
stages	of	 the	disease,	and	 the	analysis	platforms	and	methods,	as	 reviewed	by	Menezes	
and	Germino37.	As	a	result,	a	variety	of	different	pathways	and	processes	were	suggested	to	
contribute	to	the	disease,	but	with	no	strong	evidence	of	which	of	these	differences	in	the	
reported	results	are	a	consequence	of	experimental	biases	or	disease	complexity.	
Several	 studies	 indicated	a	tissue	 injury-repair	 component	 in	 the	pathology	of	PKD16,24,70.	
Indeed,	there	are	numerous	similarities	between	PKD	and	renal	injury,	since	both	phenotypes	
are	accompanied	by	a	combination	of	processes	including	proliferation,	secretion	of	growth	
factors,	 as	well	 as	 inflammation.	Weimbs70	 proposed	 a	model	where	 Polycystin	 1	 (PC1),	
the	 protein	 encoded	by	PKD1,	 and	 primary	 cilia	 have	 a	 critical	 function	 in	 sensing	 renal	
injury	 by	 detecting	 changes	 in	 luminal	 fluid	 flow	 and	 triggering	 proliferation.	 Besides	 a	
proposed	mechanistic	overlap,	several	studies	showed	that	renal	injury	could	stimulate	cyst	
progression.	For	example,	nephrotoxic	injury	in	an	ADPKD	adult	mouse	model	resulted	in	
accelerated	cyst	formation	and	a	more	progressive	phenotype16.	This	is	further	supported	
by	 findings	 that	 ischemic	 reperfusion	 injury	 and	 also	 tubular	 cell	 hypertrophy	 following	
unilateral	nephrectomy	accelerated	PKD6,16,33,47,62.	Although	the	link	between	PKD	and	renal	
injury	seems	rather	strong,	until	now	a	thorough	comparison	between	the	two	conditions	
at	 the	molecular	 level	 has	not	been	made,	 and	 little	 is	 known	about	 the	 key	 genes	 and	
pathways	shared	between	the	two.
In	 this	 work,	 we	 performed	 a	 meta-analysis	 of	 PKD	 expression	 profiles	 to	 come	 to	 a	
consistent	expression	signature	of	the	disease	that	minimizes	experimental	and	technology	
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biases.	We	also	performed	an	in-depth	comparison	between	PKD	and	injury-repair	models	
to	characterize	genes	and	functions	involved	in	injury-repair	processes	and	PKD	pathology.	
The	novelty	of	our	approach	lies	in	its	ability	to	overcome	single	study	biases	in	describing	
the	PKD	and	injury-repair	expression	signatures,	and	in	the	combined	use	of	experimental	
data	and	prior	knowledge,	retrieved	from	databases	and	mined	from	the	literature.	
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Materials and methods
Experimental animals and RNA Sequencing
Pkd1 Mutant and Wild-type mice
The	 inducible	 kidney-specific	 Pkd1-deletion	 mouse	 model	 (tam-KspCad-CreERT2;Pkd1lox2-
11;lox2-11,	referred	to	as	iKsp-Pkd1del)	and	tamoxifen	treatments	were	previously	described32,42.	
RNA	sequencing	was	done	on	five	wild-type	(Wt)	mice	and	kidneys	of	four	iKsp-Pkd1del mice 
with	gene	disruption	at	the	age	of	38-40	days	(mutant).	Mutant	mice,	euthanized	84	days	
later,	had	moderate	cystic	disease.	The	local	animal	experimental	committee	of	the	Leiden	
University	 Medical	 Center	 and	 the	 Commission	 Biotechnology	 in	 Animals	 of	 the	 Dutch	
Ministry	of	Agriculture	approved	the	experiments	performed.
DCVC Injury Model
Wt	mice	were	fed	with	tamoxifen	(5	mg/day,	3	consecutive	days)	at	adult	age,	i.e.	between	
13	 to	 14	 weeks	 of	 age42	 as	 a	 control	 for	 the	 tamoxifen	 treatment	 used	 in	 the	 iKsp-
Pkd1del mice.	Renal	injury	was	induced	one	week	after	tamoxifen	administration	by	a	single	
intraperitoneal	 injection	of	S-(1,2-dichlorovinyl)-L-cysteine	(DCVC)	 (15	mg/kg).	Mice	were	
euthanized	at	determined	time	points	(1,	2,	5,	10	and	24	weeks	after	DCVC	injection).	RNA	
sequencing	was	performed	on	the	DCVC-injected	Wt	mice	euthanized	at	1,	2	and	5	weeks	
after	DCVC	(4	mice	per	each	time	point).
RNA Sequencing Methodology.
RNA	sequencing	was	performed	on	the	Illumina®	Hi	Seq	2500.	mRNA-Seq	Sample	Prep	Kit	
was	used	to	process	the	samples	according	to	the	manufacturer’s	protocol.	Briefly,	mRNA	
was	isolated	from	total	RNA	using	the	oligo-dT	magnetic	beads.	After	fragmentation	of	the	
mRNA,	a	cDNA	synthesis	was	performed.	This	was	used	 for	 ligation	with	 the	sequencing	
adapters	and	PCR	amplification	of	the	resulting	product.	The	quality	and	yield	after	sample	
preparation	 were	measured	 with	 a	 DNA	 1000	 Lab-on-a-Chip.	 The	 expected	 broad	 peak	
between	300	and	500	bp	was	observed.	
Clustering	 and	DNA	 sequencing	 using	 the	 Illumina	 cBot	 and	HiSeq	 2500	was	 performed	
according	to	manufacturer’s	protocols.	A	concentration	of	15.0	pM	of	DNA	was	used.
HiSeq	control	software	HCS	v2.2.38	was	used.	Image	analysis,	base	calling,	and	quality	check	
was	performed	with	the	Illumina	data	analysis	pipeline	RTA	v1.18.64	and	Bcl2fastq	v1.8.4.	
All	samples	had	a	quality	score	Q30	for	more	than	93.6%	of	reads.	
Resulting	 reads	 were	 aligned	 to	 the	 mouse	 reference	 genome	 version	 GRCm3868 using 
Tophat225	 followed	 by	 bowtie231	 in	 the	 local	 highly	 sensitive	 mode	 (bowtie2-local-very-
sensitive-local).	After	alignment,	HTSeq-count3	 (Version	0.6.1)	was	used	to	estimate	gene	
expression	 by	 counting	 reads	 that	 were	 mapped	 to	 each	 gene	 using	 default	 options.	
CHAPTER 4
102
Differential	 gene	 expression	 analysis	 was	 performed	 using	 limma	 package	 with	 default	
parameters	 after	 applying	 Voom	 transformation52.	 Differentially	 expressed	 genes	 were	
selected	where	false	discovery	rate	(FDR)	is	<	0.05.	Data	were	deposited	in	ArrayExpress27 
and	given	the	following	identifier	E-MTAB-5319.
Experimental animals and Fluidigm Assay
Pkd1 Mutant, Wt and DCVC-induced mice
Wt	mice	and	iKsp-Pkd1del	mice	were	feed	with	tamoxifen	(5	mg/day,	3	consecutive	days)	in	
adult mice, i.e.	between	13	to	14	weeks	of	age42 to achieve Pkd1 gene inactivation in the 
mutant.	Renal	injury	was	induced	in	Wt	mice	by	a	single	intraperitoneal	Injection	of	DCVC	
(15	mg/kg).	All	Mice	were	euthanized	at	determined	time	points	(1,	2,	5,	10	and	24	weeks	
after	DCVC	injection	for	the	DCVC	induced	Wts	and	respective	time	points	for	the	non-DCVC	
treated	mice).
Fluidigm quantitative PCR and data processing
The	TaqMan	Gene	Expression	Assays	of	the	selected	genes	and	three	housekeeping	genes	
were	obtained	from	Applied	Biosystems.	Best	coverage	probes	were	used,	according	to	the	
sample	characteristics.	Real-Time	PCR	analysis	was	performed	at	GenomeScan	(GenomeScan	
B.V.,	 Leiden,	 The	 Netherlands)	 using	 the	 96.96	 BioMark™	 Dynamic	 Array	 for	 Real-Time	
PCR	 (Fluidigm	 Corporation,	 San	 Francisco,	 CA,	 U.S.A),	 according	 to	 the	 manufacturer’s	
instructions.	Before	use	on	 the	BioMark	array,	 the	cDNA	was	first	 subjected	 to	14	cycles	
of	Specific	Target	Amplification	using	a	0.2X	mixture	of	all	Taqman	Gene	Expression	assays	
in	 combination	with	 the	 TaqMan	PreAmp	Master	Mix	 (Applied	Biosystems),	 followed	by	
fivefold	 dilution.	 Thermal	 cycling	 and	 real-time	 imaging	 of	 the	 BioMark	 array	was	 done	
on	 the	 BioMark	 instrument,	 using	 the	 default	 Taqman	 PCR	 protocol	 with	 an	 annealing	
temperature	 of	 60˚C	 and	 a	 total	 of	 35	 cycles	 of	 PCR.	 Ct	 values	 (cycle	 threshold	 values)	
were	extracted	using	the	BioMark	Real-Time	PCR	analysis	software	(version	3.0.2)	and	the	
threshold	 default	 value	of	 0.65.	 The	quality	 of	 the	 amplification	 curves	was	 checked	 for	
each	reaction,	evaluating	the	curve	shape	and	signal	level.	For	each	gene,	Ct	values	were	
normalized	based	on	the	geometric	mean	of	the	housekeeping	genes	(Rplp0, Hnrnpa2b1, 
Ywhaz)	and	then	compared	across	the	samples	for	differential	expression	in	PKD	(PKD	vs	Wt)	
and	injury	(Wt	injury	induced	by	DCVC	vs	Wt)	by	using	(ANOVA).	A	P	<	0.01	cut-off	was	used	
to	determine	significantly	dysregulated	genes.	
Data Acquisition and Meta-Analysis
Meta-Analysis PKD Signature.
In	 addition	 to	 our	 iKsp-Pkd1del,	 public	 expression	 profiling	 experiments	 of	 PKD	 were	
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downloaded	from	ArrayExpress	using	ArrayExpress	R	Package23	available	on	Bioconductor15.	
Published	PKD	expression	profiling	studies	were	included	based	on	the	following	selection	
criteria:	1)	expansion	renal	cystic	tissues	were	obtained	from	animal	models	with	disruption	
of	a	gene	either	involved	in	ADPKD	or	in	ARPKD	(PCK	rat	used	as	a	model	for	PKD)	or	taken	
from	 ADPKD	 patients.	 For	 the	 large	 phenotypic	 and	 physiological	 differences	 between	
postnatal	and	embryonic	PKD	models,	embryonic	PKD	models	were	excluded.	Asymptotic	
models	were	 excluded	 as	well.	 2)	 The	 study	 included	 at	 least	 three	 biological	 replicates	
for	mutant	and	control	tissues	(Wts).	3)	Normalized	gene	expression	values	were	publicly	
available	for	all	samples.	Processed	data	were	used	for	each	dataset	and	log	transformed	
if	data	were	provided	on	a	linear	scale.	Then,	we	calculated	differentially	expressed	genes	
for	each	study	using	the	limma	package	with	default	parameters52.	Genes	were	considered	
significantly	dysregulated	if	they	had	FDR	<	0.05	and	<	0.0005	for	the	validation	study.	When	
a	 study	 had	 different	models	 or	 phenotypes	 of	 the	 disease,	 we	 processed	 the	 samples	
independently	 when	 calculating	 the	 differentially	 expressed	 genes,	 and	 only	 included	
in	 our	 analysis	 the	models/samples	 that	 are	useful	 to	 us	 (refer	 to	 the	 relevant	 table	 for	
sample	description).		When	including	more	than	one	model	from	a	single	study,	we	took	the	
resulting	lists	of	differentially	regulated	genes	of	each	model	and	combined	them	in	a	one	
gene-list	per	study.	Conversion	to	human	homologs	was	done	by	using	the	db2db	tool	part	
of	BioDBnet41.	
Public Injury Models and other Kidney Diseases.
In	addition	to	our	DCVC	treated	Wts,	we	included	six	published	studies	of	renal	ischemia.	
Study	inclusion	criteria	were	based	on	the	availability	of	treated	and	nontreated	Wts	and	
availability	 of	 data	 as	 described	 in	 the	 previous	 paragraph.	 Other	 kidney	 diseases	 were	
included	 as	 mentioned	 in	 Results.	 Differentially	 expressed	 genes	 for	 each	 study	 were	
calculated	as	described	in	the	previous	paragraph.
Literature-based Signatures
Literature-Based	 Signatures	 were	 obtained	 using	 Biosemantics	 Concept	 Profile	
technology17a,21,	 calculating	 the	 literature	 association	 scores	 between	 all	 Homo Sapiens 
genes	 with	 concept	 profiles	 and	 the	 literature	 concept	 profiles	 of	 renal	 injury	 repair	 in	
PubMed	 until	 July	 2012.	 The	 literature	 association	 (concept	 profile	 matching)	 score	 is	
based	on	the	strength	of	explicit	associations	(the	two	concepts	co-occurring	in	the	same	
PubMed	abstract)	and	implicit	associations	(the	two	concepts	not	co-occurring	in	the	same	
abstract	together,	but	each	in	abstracts	with	the	same	third	concept).	The	literature	mining	
technology	handles	and	disambiguates	gene	names	and	symbols.
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Functional enrichment analysis
Functional	 enrichment	 analysis	 was	 performed	 against	 Molecular	 Signature	 Database	
(MSigDB)	 collections58,59	 using	 standard	 hypergeometric	 distribution	 with	 correction	 for	
multiple	hypotheses	testing	using	the	FDR.	Annotation	with	DAVID	v6.827,28	was	performed	
with	default	parameters	for	confirmation	purposes	where	mentioned	in	the	text.	
The	significance	of	the	overlaps	between	gene	profiles	and	gene	sets,	were	evaluated	with	
a	χ2-test	(P	<	0.05)	and	the	representation	factor	(RF)	calculated	as	follows:	x	=	#	of	genes	in	
common	between	two	groups,	n	=	#	of	genes	in	group	1,	D	=	#	of	genes	in	group	2,	N	=	total	
genes	available,	the	RF	=	x	/	expected	#	of	genes,	expected	#	of	genes	=	(n	X	D)	/	N
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Results
Identification of PKD Signature 
To	 identify	a	 comprehensive	expression	 signature	of	PKD	during	disease	progression,	we	
generated	new	RNASeq-based	expression	profiles	of	 inducible,	kidney	epithelium-specific	
Pkd1-deletion	mice	 (iKsp-Pkd1del)	with	moderate	 cystic	 disease	 and	matched	 controls32,42 
(Figure	1A).	
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Figure 1. Overview of the approach used to identify the PKD Signature and comparison to renal injury and repair, 
macrophages and other kidney diseases
The	 approach	 consisted	 of	 five	 steps.	A:	 the	 PKD	 Signature	 was	 defined	 by	 combining	 publicly	 available	 PKD	
expression	 profiling	 studies	with	 our	 in-house	 RNAseq	of	 iKsp-Pkd1del	 in	mice.	B:	 the	 Injury	 Repair	 Profile	was	
defined	by	experimental	expression	profiles	of	kidneys	with	ischemia-reperfusion	injury	(IRI)	(b1),	in-house	RNAseq	
of	kidneys	from	DCVC-treated	animals	(b2)	and	literature-based	text-mining	of	genes	associated	with	injury	terms	
in	PubMed	abstracts	 (b3).	C:	 comparing	 significantly	dysregulated	genes	 from	PKD	Signature	and	 Injury	Repair	
Profile	we	identified	the	Injury	Repair	Component	of	PKD,	which	consists	of	~35%	of	the	genes	implicated	in	PKD.	
D:	we	used	 the	data	produced	by	Clements	et al.11	 in	 2016	of	 the	different	macrophage	populations	 triggered	
after	renal	injury	to	identify	macrophage-related	genes	in	PKD.	E:	we	acquired	expression	profiling	experiments	of	
different	renal	diseases	and	compared	them	to	the	PKD	Signature	to	identify	the	overlapping	genes	and	the	unique	
PKD	Signature	genes.	HLRCC,	hereditary	leiomyomatosis	and	renal	cell	cancer.
We	 identified	 2,376	 genes	 (FDR	 <	 0.05)	 that	 clearly	 distinguished	 iKsp-Pkd1del from	Wt	
mice	(Data	Set	1,	Figure	2A).	Next,	we	compared	our	expression	profile	to	other	publicly	
available	 PKD	 expression	 studies	 (Figure	 1A).	We	 used	 stringent	 study	 inclusion	 criteria	
(See	Methods)	 and	 identified	 three	 studies	 suitable	 for	meta-analysis39,43,56	 (Table	 1).	 By	
comparing	the	independent	PKD	expression	studies	(our	dataset	included),	we	assessed	the	
level	of	similarity/dissimilarity	between	each	study	and	defined	a	group	of	high	confidence	
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genes	that	are	consistently	dysregulated	in	PKD.	Every	significantly	dysregulated	gene	(PKD	
vs.	Wt)	obtained	from	the	studies,	was	classified	as	a	shared	gene	(if	dysregulated	in	at	least	
two	independent	studies)	or	a	unique	gene	(if	dysregulated	in	just	a	single	study).	Strikingly,	
only	~22%	(N=1515)	of	all	dysregulated	genes	from	all	PKD	studies	(N=6963),	were	shared,	
of	which	the	vast	majority	(~86%	of	the	1515	genes)	were	dysregulated	in	just	two	studies	
(Figure	2B).	Moreover,	none	of	the	PKD	studies	used	in	this	analysis	had	more	than	50%	of	
its	dysregulated	genes	shared	with	any	of	the	other	three	studies	(Figure	2C).	
To	arrive	to	a	robust	PKD	signature,	we	selected	PKD	genes	that	were	significantly	dysregulated	
in	at	least	two	independent	studies	(50%	of	the	studies).	Thus,	our	PKD	signature	consists	
of	1515	genes	(1641	mouse	homologs),	comprising	775	up-	and	740	downregulated	genes	
(Data	Set	2a	and	2b).	    
              
Authors Organism/Sex Accession Number Datasets Included No of DEGs after HC No. of DEGs in PKD Signature 
Menezes et al.39 Mouse/M and F GSE32586 
Pkd1cko.P12 vs WT.12 40 17 
Pkd1cko.P14 vs WT.14 1,200 594 
O'Meara et al.43 Rat/M GSE33056 PCK vs SD 1,586 561 
Song et al.56 Human/NM GSE7869 
Non-cystic vs normal 280 68 
Small cysts vs normal 4,554 025,1  
Medium cysts vs normal 4,650 033,1  
Malas et al. (this study) Mouse/M  E-MTAB-5319 Pkd1cko.P40 vs WT 2,376 924 
Table 1. Expression profiling studies used in the definition of the PKD Signature
PKD,	polycystic	kidney	disease;	DEGs,	differentially	expressed	genes;	HC,	homolog	conversion;	SD,	Sprague-Dawley;	
WT,	wild	type;	M,	males;	F,	females;	NM,	not	mentioned	in	the	Methods	of	the	paper.
Validation of the PKD Signature in an independent dataset
We	validated	the	PKD	Signature	in	an	independent	dataset	that	was	published	during	the	
writing	of	this	manuscript38.	This	dataset	includes	80	mouse	samples	with	induced	deletion	
of	Pkd1 at	P40	(14	control	 females,	21	mutant	 females,	19	control	males	and	26	mutant	
males).	We	evaluated	the	overlap	by	calculating	the	representation	factor	(RF),	defined	as	
the	number	of	overlapping	genes	divided	by	 the	expected	number	of	overlapping	genes	
drawn	from	two	independent	groups.	We	looked	for	the	enrichment	of	the	PKD	Signature	
genes	in	the	genes	differentially	expressed	(FDR	<	0.0005)	in	mild,	moderate	and	advanced	
stages	of	the	disease,	in	males	and	in	females	(Figure	2D).	We	repeated	the	enrichment	test	
with	equally	sized	gene	sets	from	the	genes	that	are	dysregulated	in	only	one	PKD	study	and	
from	randomly	sampled	genes.	The	results	revealed	that	the	PKD	Signature	is	at	least	three	
times	more	enriched	in	the	validation	dataset	in	contrast	to	the	random	genes	and	genes	
dysregulated	in	only	one	study.	This	significance	is	observed	in	all	stages	of	the	PKD	disease	
and	in	both	genders.	
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Functional annotation of the PKD Signature
We	annotated	the	up-	and	downregulated	gene	sets	using	the	Molecular	Signature	Database	
Hallmarks	 (MSigDB)34	 and	 The	 Database	 for	 Annotation,	 Visualization	 and	 Integrated	
Discovery	(DAVID)	v6.818,19	(Data	Set	3).	Both	resources	revealed	the	strong	downregulation	
of	mitochondrial	and	peroxisome	genes,	specifically	those	involved	in	fatty	acid	metabolism,	
lipogenesis,	and	oxidation-reduction	process.	 In	addition,	we	see	strong	dysregulation	of	
genes	involved	in	ion	transport	(i.e. CP, SLC4A1, SLC2A9, SLC12A1).
On	the	other	hand,	several	pathways	and	processes	are	upregulated	in	the	PKD	Signature	
listed	in	Data	Set	3.	We	further	grouped	the	genes	shared	between	three	or	more	studies	
into	 defined	 gene	 families	 (protein	 kinases,	 cytokines	 and	 growth	 factors,	 transcription	
factors	and	oncogenes)	to	facilitate	their	usage	in	translational	research	(Data	Set3c	and	3d).
To	 measure	 the	 relevance	 of	 the	 PKD	 Signature	 at	 the	 molecular-function	 level,	 we	
defined	four	categories	that	are	known	to	be	dysregulated	in	PKD:	cell	cycle46,	apoptosis13, 
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Figure 2. Identification of the PKD Signature
A:	Heat	map	showing	the	expression	values	of	all	differentially	expressed	genes	in	iKsp-Pkd1del	(M)	compared	to	
wild-type	mice	(WT).	Expression	values	were	normalized	using	the	Vroom	function	in	limma	R	Package.	Hierarchical	
clustering	was	applied	on	the	samples	and	values	were	scaled	by	row.	B:	analysis	of	the	number	of	overlapping	
genes	from	the	four	studies	included	in	the	meta-analysis.	C:	comparison	of	the	significantly	dysregulated	genes	in	
each	of	the	four	studies	revealed	that	none	of	the	studies	shared	more	than	50%	of	its	genes	with	other	studies.	
D:	bar	chart	plotting	the	enrichment	(representation	factor,	y-axis)	of	the	PKD	Signature	(blue	and	red	bars),	the	
genes	dysregulated	only	in	a	single	PKD	study	(yellow)	and	a	random	set	of	genes	(green)	in	an	independent	dataset	
from	Pkd1cko	mice	at	mild,	moderate	and	advanced	stages	of	 the	disease,	 in	males	and	 females.	E:	a	dot	plot	
showing	the	number	of	genes	from	the	PKD	Signature	(red)	and	from	10	equally	sized	gene-sets	randomly	sampled	
from	the	genes	dysregulated	in	only	one	study	(green)	with	functional	annotations	previously	attributed	to	PKD.	*P 
<	0.05	(binomial	test,	where	the	fraction	of	genes	in	the	PKD	Signature	was	compared	with	the	expected	fraction	of	
genes	in	a	functional	category	(averaged	gene	counts	from	the	10	random	sets).	Functional	categories	were	based	
on	three	annotation	databases	(GSEA_HALLMARKS,	KEGG	and	Gene	Ontology	–	Biological Processes).
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proliferation71	 and	 inflammatory	 response61.	 We	 found	 that	 the	 PKD	 Signature	 had	
significantly	 more	 functional	 annotations	 related	 to	 these	 categories	 than	 equally-sized	
random	sets	of	genes	pooled	from	the	genes	significant	 in	only	one	PKD	study	(binomial	
test, P	<	0.0005)	(Figure	2E).
Identification of Injury Repair genes in the PKD Signature
Experimental Injury Repair Profile 
We	acquired	datasets	from	renal	ischemia	reperfusion	(IRI)	experiments	in	murine	models	
and	identified	six	studies	(3	mouse	and	3	rat),	that	met	our	inclusion	criteria	(Table	2)	(Figure	
1B)9,12,28,35,57,73.	Differentially	expressed	genes	from	all	of	the	six	renal	 injury	repair	studies	
were	enriched	within	the	PKD	Signature	(RF	>	1	and	P	<	0.05)	(Figure	3B).	The	studies	varied	
in	 the	 reperfusion	 time,	 from	 immediately	 harvesting	 the	 samples	 after	 reperfusion	 to	
waiting	for	up	to	120	h.	Using	these	samples,	we	defined	a	1,193-gene	signature	of	early	
injury	repair	response,	by	combining	the	six	studies	and	looking	for	consistently	dysregulated	
genes	in	at	least	50%	of	the	studies	(Data	Set	4a).	
 
 
 
 
 
 
 
 
 
 
  
Authors Organism Accession Injury Model Time after reperfusion 
Chen et al.9 Mouse GSE34351 ARI 4 h 
Correa-Costa et al.12 Mouse GSE39548 ARI 6 h 
Liu et al.35 Mouse GSE52004 ARI 24 h 
Yuen et al.73 Rat GSE3219 ARI 2, 8 h 
Krishnamoorthy et al.28 Rat GSE27274 ARI 6, 24, 120 h 
Speir et al.57 Rat GSE58438 ARI Immediate 
 
Table 2. Published expression profiling studies used in the definition of the experimental injury repair profile
ARI,	acute	renal	injury
Several	renal	 IRI	studies	reported	that	the	maximum	peak	of	renal	damage	 is	reached	at	
the 3rd	day	of	injury	induction	and	gradually	drops	as	the	kidney	repairs	itself,	until	about	
day	7	when	the	tissue	looks	mostly	repaired.	Since	none	of	the	IRI	studies	we	could	include	
publicly	harvested	samples	within	the	late	injury	period	(after	7	days),	we	generated	novel	
data	by	 inducing	 renal	 injury	 in	Wt	mice	using	 the	nephrotoxic	DCVC.	The	samples	were	
harvested	at	1,	2	and	5	weeks	after	injury	induction.	Measurements	of	blood	urea	showed	
that	mice	have	normal	 functional	 kidneys	at	7	days	after	 injury,	 confirming	 that	most	of	
the	acute	 injury	 insult	 is	 repaired	at	that	time	point	 (Figure	3A).	Renal	histology	sections	
at	1	week	show	slightly	dilated	tubules	with	protein	casts,	 infiltrating	cells	and	fibrosis	at	
the	cortico-medullary	junction,	the	most	damage-sensitive	region	of	the	kidney.	At	2	weeks	
after	DCVC	treatment	the	tissue	morphology	is	improved	and	at	5	weeks,	the	kidneys	have	
almost	 completely	 been	 recovered	 from	 the	 injury	 (Figure	 3A).	 Comparing	 the	 different	
injury	repair	time	points	from	our	 injury-induced	model	against	each	other	we	 identified	
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1,137	differentially	expressed	genes	(Data	Set	4b).	Comparing	the	functional	annotations	of	
the	early	and	late	injury	repair	genes	showed	that	they	are	distinct	(Figure	3C).	We	combined	
the	early	and	late	injury	repair	response	genes	to	establish	a	general	Experimental	 Injury	
Repair	Profile,	consisting	of	2137	genes.	
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Figure 3. Identification of the Injury Repair Component of the PKD Signature
A:	injury	repair	progression	in	Wt	mice	injected	with	DCVC.	I-IV:	periodic-acid	Schiff	(PAS)	staining	on	formalin	fixed,	
paraffin	embedded	kidney	sections;	scale	bar	=	50	µm.	*Dilated	tubules	with	luminal	protein	inclusions;	normal 
brush	border.	I:	Wt	without	injury.	Normal	morphology	with	visible	brush	border.	II:	1	week	after	DCVC	injection	
damaged	and	slightly	dilated	tubules	with	luminal	protein	inclusions	were	observed.	III:	2	weeks	after	DCVC	the	
tissue	 is	almost	repaired	with	only	sporadic	protein	 inclusion	observable	but	some	 infiltrating	cells	present. IV: 
5	weeks	after	DCVC	injection	the	tissue	was	almost	completely	repaired	and	less	 infiltrating	cells	were	present.	
V:	blood	urea	(BU)	levels	(mmol/l)	at	different	time	points	after	DCVC	injection,	peaking	at	40	h	and	returning	to	
baseline	after	2	weeks,	when	the	tissue	 is	repaired.	B:	enrichment	(representation	factor,	y-axis)	of	each	 injury	
dataset	in	the	PKD	Signature.	Dataset	from	mice	(M)	or	rats	(R)	with	early	injury	response	(IRI,	black)	and	late	injury	
repair	response	(DCVC	treatment,	red)	were	all	enriched	in	the	PKD	Signature.	C: the	top	ten	enriched	terms	for	the	
early	injury	repair	(pink)	and	late	injury	repair	(green)	genes	based	on	MSigDB	Hallmark	categories	[false	discovery	
rate	 (FDR)	 <	 0.05].	 On	 the	 one	 hand,	 the	 early	 injury	 repair	 genes	 had	 apoptosis,	 hypoxia	 and	 inflammatory	
response	related	pathways	in	the	most	enriched	functions	identified	from	MSigDB	and,	on	the	second	hand,	the	
late	 injury	 repair	genes	had	 functions	 related	to	peroxisome,	glycolysis	and	 fatty	acid	metabolism	amongst	 the	
most	enriched	functions.	D:	comparison	of	the	experimental	(Exp.)	and	literature	(Lit.)	based	injury	repair	profiles	
and	their	overlap	with	the	PKD	Signature.	Approximately,	35%	(581/1,641)	of	the	PKD	Signature	genes	are	involved	
in	injury	repair	related	functions.	Representation	Factor	(RF)	denotes	the	level	of	enrichment	of	each	injury	repair	
profile	 in	the	PKD	Signature	(RF	of	Experimental	 Injury	Repair	=	2.0,	RF	of	Literature	Injury	Repair	=	2.0)	where	
values	greater	than	1	denote	strong	enrichment.	E:	a	clear	distinction	in	the	functional	profiles	of	the	injury	(red)	
and	non-injury	(green)	components	of	the	PKD	Signature,	as	represented	in	a	network	view	of	the	more	enriched	
terms	from	MSigDB	(FDR	<	1e-11)	for	each	of	the	two	components.
Literature Injury Repair Profile 
The	Literature	Injury	Repair	Profile	is	based	on	published	knowledge	of	genes	involved	in	
injury	 repair	processes	 in	PubMed.	We	set	our	 text-mining	algorithm	to	 retrieve	 the	 top	
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200	genes	that	are	most	associated	with	renal	injury	in	PubMed	abstracts	(Data	Set	4c).	In	
addition,	as	negative	controls,	we	retrieved	the	top	200	genes	most	associated	with	other	
conditions	that	we	believe	to	be	unrelated	to	PKD,	namely	fertility	and	Parkinson’s	disease.	
The	literature	renal	injury	repair	genes	were	significantly	enriched	in	the	PKD	Signature	(RF	
=	2),	contrary	to	the	two	negative	sets	(Fertility	RF	=	0.9,	Parkinson’s	disease	RF	=	1.1).	
Injury Repair processes in PKD
To	 find	 injury	 repair	 involvement	 in	 PKD,	 we	 compared	 the	 PKD	 Signature	 with	 the	
Experimental	Injury	Repair	Profile	and	the	Literature	Injury	Repair	Profile	(Figure	1C).	Our	
analysis	 revealed	 that	 both	 injury	 repair	 profiles	 were	 significantly	 enriched	 in	 the	 PKD	
Signature	(Figure	3D),	with	P	values	of	1.3	X	10-29	and	2.8 X	10-7 for	the	Experimental	and	
Literature	Injury	Repair	profiles,	respectively.	Of	the	total	PKD	Signature	genes,	35%	(581	
genes)	are	involved	in	injury	repair	processes	(Data	Set	5).	
We	extended	the	functional	analysis	that	we	performed	on	the	PKD	Signature	to	the	injury	
repair	and	non-injury	repair	genes	 in	PKD.	For	each	set	of	genes,	we	 identified	the	most	
enriched	functional	terms	from	MSigDB	with	stringent	FDR	cutoff	(<	1e-11).	Interestingly,	
22	 terms	were	 found	 to	be	more	enriched	 in	 the	 injury	 repair	 genes	and	only	1	 term	 is	
more	enriched	in	the	non-injury	repair	genes	when	compared	with	each	other	(Figure	3E,	
Data	 Set6).	 This	 demonstrates	 the	 cohesiveness	 of	 the	 injury	 repair	 genes.	Many	of	 the	
injury	repair	functions	are	related	to	NF-kB	signaling,	epithelial-to-mesenchymal	transition,	
inflammatory	 response,	 hypoxia,	 and	 metabolism.	 Although	 these	 functional	 terms	 are	
expected	in	a	well-defined	injury	repair	signature,	they	demonstrate	that	we	zoomed	in	on	
a	relevant	group	of	genes	(Table	3).	
Table 3. Top 5 annotations for genes in the injury repair PKD Signature component
Count	represents	the	number	of	genes	that	belong	to	a	functional	annotation	term	and	the	tested	PKD	Signature	
component.	FDR,	false	discovery	rate,	based	on	MSigDB.
 
Term Name Count FDR Genes (Gene Symbol) 
TNFA_SIGNALING_VIA_NFKB 43 1.9E-38 
CD44, GADD45B, RHOB, PLAUR, JUN, CYR61, CXCL1, TNC, MAFF, F3, 
KLF6, CSF1, MYC, NFIL3, PHLDA1, GCH1, CDKN1A, BTG2, HBEGF, SPHK1, 
TLR2, ICAM1, CCL2, KYNU, ETS2, PPP1R15A, BTG1, FOSL2, BIRC3, MCL1, 
PLK2, IER5, SOCS3, CXCL3, BCL3, CEBPB, JUNB, CXCL2, TGIF1, CEBPD, 
EGR1, PANX1, LITAF 
EPITHELIAL_MESENCHYMAL_TRANSITION 37 1.44E-30 
CD44, GADD45B, RHOB, PLAUR, JUN, CYR61, CXCL1, TNC, TIMP1, SPARC, 
FN1, FBN1, THBS1, SPP1, ITGA5, DCN, TGFBI, TNFRSF12A, SDC1, COL4A2, 
COL3A1, COL1A1, ITGB1, ITGB5, TAGLN, TPM2, COL1A2, LAMC2, FSTL1, 
BASP1, DPYSL3, LOXL2, MGP, PCOLCE, SFRP4, TPM4, VIM 
COAGULATION 25 3.65E-20 
TIMP1, SPARC, FN1, FBN1, THBS1, MAFF, F3, MEP1A, KLF7, ANXA1, CFH, 
MMP9, DUSP6, CAPN5, PF4, C3, CSRP1, FGA, FGG, MSRB2, CFI, APOC3, 
P2RY1, PROC, CAPN2 
INFLAMMATORY_RESPONSE 28 8.01E-20 
TIMP1, F3, MEP1A, PLAUR, ITGA5, KLF6, CSF1, MYC, GCH1, CDKN1A, 
BTG2, HBEGF, SPHK1, TLR2, ICAM1, CCL2, RGS16, TNFRSF1B, IL4R, 
TPBG, CD14, OSMR, TAPBP, BST2, RHOG, SLC7A1, PDPN, AXL 
XENOBIOTIC_METABOLISM 28 8.01E-20 
GCH1, KYNU, ETS2, GABARAPL1, AHCY, RETSAT, CROT, HSD11B1, 
ALDH9A1, TNFRSF1A, CAT, ACOX1, POR, APOE, FMO1, BPHL, PDK4, 
SLC6A12, TMBIM6, ESR1, SLC46A3, GSS, ARG2, MAN1A1, NDRG2, 
SLC12A4, NFS1, ENTPD5 
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Injury Repair in different PKD disease stages
We	evaluated	the	enrichment	of	the	genes	in	the	signature	at	the	different	phases	of	disease	
progression.	We	used	the	data	of	Menezes	et al26	that	included	mouse	samples	from	mild,	
moderate	and	advanced	PKD	disease	stages.	Injury	repair	and	non-injury	repair	PKD	genes	
are	enriched	in	all	stages	of	the	disease	(RF	>	1)	(Figure	4A).	However,	in	the	mild	phase	of	
the	disease,	 the	non-injury	repair	 is	 twice	as	enriched	 in	comparison	to	the	 injury	repair	
genes.	 In	 the	advanced	stage	of	 the	disease,	 the	opposite	 is	observed.	These	 results	are	
in	accordance	with	our	understanding	of	the	disease,	as	more	injury	repair	processes	are	
expected	with	disease	progression.	That	said,	injury	repair	genes	are	enriched	in	the	early	
phases	of	PKD,	and	appear	to	be	involved	in	cell	cycle,	extracellular	matrix	modulation	and	
growth,	 epithelial-to-mesenchymal	 transition	 and	metabolism	 (Data	 Set	 7b).	 In	 addition, 
several	cytokines	that	are	associated	with	kidney	injury	are	upregulated	in	the	early	phases	
of	PKD,	such	as	osteopontin	(OPN)	and	growth	differentiation	factor	15	(GDF15).	
Figure 4. Validation of Injury Repair processes in PKD Signature
A:	enrichment	analysis	(RF,	y-axis)	of	the	injury	repair	(blue)	and	non-injury	repair	(red)	components	of	the	PKD	
Signature	(PKD	S.)	in	the	different	phases	of	the	severity	of	PKD	disease	in	Pkd1cko mice38.	B:	bar	chart	showing	the	
strong	enrichment	of	different	macrophage	population	("CD11b+/Ly6Chigh",	"CD11b+/Ly6Cintermediate"	and	"CD11b+/
Ly6C low", Clements et al.11)	gene	signatures	activated	upon	injury	induction	in	mouse	models	in	the	injury	repair	
(blue)	and	non-injury	repair	(red)	components	of	the	PKD	Signature.	C:	the	enrichment	of	the	injury	repair	(blue)	
and	non-injury	repair	(red)	components	of	the	PKD	Signature	in	expression	profiles	from	other	kidney	diseases.	D: 
characterization	of	the	PKD	Signature	into	groups	based	on	the	overlap	with	renal	injury	repair	and	other	kidney	
diseases.	On	the	left,	a	pie	chart	showing	the	total	number	of	genes	within	each	of	the	four	groups	and	on	the	
right	a	bar	chart	reflecting	the	percentage	of	genes	that	matched	to	at	least	one	annotation	term	based	on	MsigDB	
Hallmarks	and	Reactome	pathway	database	after	running	the	enrichment	comparison	with	the	following	settings	
(FDR	<	0.05,	top	20	terms).
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Experimental validation of the injury component in independent samples
To	validate	our	results,	we	generated	an	independent	set	of	adult-onset	slow-progressing	
inducible	Pkd1-deletion	mice	as	a	PKD	model	not	 included	 in	 the	generation	of	 the	PKD	
Signature.	We	harvested	mice	at	five	different	time	points	(1,	2,	5,	and	10	weeks	after	injury	
and	at	kidney	failure)	(Figure	5A).	
These	samples	were	analyzed	by	Fluidigm	qPCR	chip	to	quantify	mRNA	levels	of	selected	
genes;	Inflammatory	response	(Pcdh7 and Stat3),	hypoxia	(Akap12 and Anxa2), epithelial-to-
mesenchymal	transition (Dpysl3 and Tnfrsf12a), TNF-α/NF-κB	signaling	(Socs3), coagulation	
(Fgg),	transcription	factor (Glis2) and	transporters	(Cp). Additionally,	we	have	included	an	
age-matched	set	of	mouse	samples,	i.e.	wild-type	mice	with	and	without	treatment	with	the	
nephrotoxic	compound	DCVC	to	reflect	the	injury	repair	component.	Normalized	Ct	values	
were	tested	for	statistical	significance	between	the	groups	(mutant	vs.	Wt,	and	Wt	+	DCVC	
vs.	Wt).	All	genes	from	the	PKD	Signature	were	significantly	dysregulated	between	mutant	
and	Wts		and	all	genes	we	classified	as	injury-repair	related	were	significantly	dysregulated	
between	(Wt	and	Wt	+	DCVC)	(Figure	5B).
Macrophages in Polycystic Kidney Disease
Macrophages	 have	 important	 roles	 in	 renal	 injury	 repair	 and	 PKD3,50,60.	 Having	 identified	
the	injury	repair	genes	of	the	PKD	Signature,	we	proceeded	to	identify	novel	macrophage-
related	molecular	pathways	 involved	 in	PKD	progression.	Using	data	of	Clements et al.11, 
which	contains	unique	expression	profiles	of	different	macrophage	populations	upon	renal	
injury	 induction. They	 identified	 three	 distinct	 macrophage	 populations:	 the	 "CD11b+/
Ly6Chigh"	population	associated	with	the	onset	of	renal	injury	and	increase	in	proinflammatory	
cytokines,	 the	 "CD11b+/Ly6Cintermediate"	 population	 that	 peaked	 during	 kidney	 repair,	 and	
the	"CD11b+/Ly6Clow"	population	that	emerged	with	developing	renal	fibrosis.	We	looked	
for	genes	that	are	up-regulated	in	the	PKD	Signature	and	uniquely	upregulated	in	each	of	
the	 three	macrophage	populations	by	 selecting,	 for	 each	population,	 the	genes	 that	 are	
upregulated	to	the	other	two	(logFC	≥	2,	P	<	0.05).	The	most	enriched	populations	in	PKD	
are	the	"CD11b+/Ly6Cintermediate"	and	"CD11b+/Ly6Clow"	populations,	both	are	two	times	more	
enriched	in	the	injury	repair	genes	when	compared	with	the	non-injury	repair	genes	(Figure	
4B).	As	these	are	macrophages	activated	upon	injury	induction,	stronger	enrichment	in	the	
injury	 repair	 component	 in	contrast	 to	 the	non-injury	 repair	 component	 is	expected	and	
observed.	
Using	these	datasets,	we	identified	several	novel	genes	that	are	involved	in	macrophage-
related	wound	healing	and	fibrosis	processes	in	PKD	(Data	Set	8a).	KEGG	pathway	annotations	
revealed	that	these	genes	are	involved	in	pathways	related	to	extracellular	matrix-receptor	
interaction,	focal	adhesion,	regulation	of	actin	cytoskeleton	and	cytokine-cytokine	receptor	
interaction	(Data	Set	8b).
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Figure 5. Validation of the PKD Signature in 
an adult onset iKsp-Pkd1del model and in a 
nephrotoxic injury model 
A:	 cyst	 progression	 in	 the	 adult	 iKsp-Pkd1del 
mice.	 I-III:	 PAS	 staining	 on	 formalin	 fixed,	
paraffin	embedded	kidney	sections,	 scale	bar	
=	 100	 µm.	 Mild	 tubular	 dilation	 at	 5	 (I),	 10	
weeks	 after	 gene	 disruption	 (II),	 and	 many	
cysts	at	kidney	failure	(III).	 IV:	BU	 levels	were	
used	to	assess	renal	failure	and	are	presented	
for	 individual	mice.	A	slow	progression	of	the	
disease	was	 observed,	 with	median	 duration	
until	 kidney	 failure	 of	 19	 weeks.	 B: genes 
selected	 randomly	 from	 the	 PKD	 Signature,	
were	 subjected	 to	 qPCR	 on	 the	 iKsp-Pkd1del 
mice	model	 described	 in	A and age-matched 
Wts	at	1,	2,	5,	10	weeks	after	gene	knockout,	
and	 at	 kidney	 failure.	 Normalized	 Ct	 values	
(cycle	 threshold	 values)	 are	 plotted	 (log2	
scale)	 for	 each	 gene	 separately	 across	 five	
measurement	 time	 points	 for	 three	 types	 of	
samples:	 wild-type	 mice	 treated	 with	 saline	
(WTPBS,	 red),	 iKsp-Pkd1del mice	 treated	 with	
saline	 (Pkd1cko,	 green)	 and	 wild-type	 mice	
treated	with	DCVC	 (WTDCVC,	blue).	 For	each	
time	 point,	 the	 significance	 of	 dysregulation	
in	RNA-levels	with	respect	to	WTPBS	mice	was	
tested	using	Student’s	t-test.	Grey	bars	below	
the	 x-axis	 are	 used	 in	 case	 of	 no	 significance	
(P ≥	0.01)	and	darker	shades	of	colors	 (green	
for	PKD	and	blue	for	injury)	are	used	to	denote	
stronger	dysregulation	(P <	0.01, P <	0.001, P <	
0.0001	for	the	three	different	shades	of	color).
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Comparison of the PKD Signature with other kidney diseases
We	compared	the	PKD	Signature	with	other	kidney	diseases,	for	which	expression	profiling	
studies	have	been	published	in	the	literature1,7,63,72	(Table	4).	The	Fh1	knockout	hereditary	
leiomyomatosis	and	renal	cell	 cancer	 (HLRCC)	model	 that	develops	 renal	cysts49, had the 
highest	enrichment	with	the	PKD	Signature	with	RF	of	3.3.	In	addition,	the	overlap	of	other	
kidney	 diseases	 such	 as	 glomerulonephritis63	 and	 diabetic	 nephropathy72,	 with	 the	 PKD	
Signature	 increases	as	 the	severity	of	 these	diseases	 increases,	evident	by	data	acquired	
from	4-	and	8-weeks-old	glomerulonephritis	mice	 (RF	of	1.7	and	2.9	respectively)	and	8-	
and	32-weeks-old	diabetic	nephropathy	mice	 (RF	of	1.8	and	2.8	 respectively).	Functional	
annotation	tests	of	the	genes	of	the	more	advanced	disease	stages	revealed	their	involvement	
in	 functions	 related	 to	 the	 immune	 system	 and	 epithelial-to-mesenchymal	 transition,	
suggesting,	 that	most	of	 the	overlap	of	 the	PKD	Signature	with	other	 kidney	diseases	 is	
related	 to	 injury	 repair	 and	 inflammation.	 To	 test	 this,	 we	 compared	 the	 enrichment	
of	each	disease	with	both	the	 injury	repair	genes	and	the	non-injury	repair	genes	of	 the	
PKD	Signature	 (Figure	4C).	 The	 results	 confirmed	 that	 the	overlap	with	 the	 injury	 repair	
component	of	PKD	was	twice	as	large	as	the	overlap	with	the	non-injury	repair	component.	
Utilizing	the	large	variety	of	datasets	that	we	have	compiled	and	compared	with	the	PKD	
Signature,	we	are	able	to	classify	the	PKD	Signature	genes	into	different	categories.	These	
categories	are	based	on	the	level	of	commonality	of	the	PKD	Signature	genes	to	other	kidney	
diseases	and	 injury	 repair	processes	 (Figure	4D).	 Interestingly,	 the	unique	PKD	Signature	
genes,	are	the	genes	with	the	least	known	functional	annotations	(<12%	of	genes	mapped	
to	annotation	terms)	(Figure	4D).
Table 4. Published Expression Profiling Studies used in the comparison of the PKD Signature to other diseases
HLRCC,	hereditary	leiomyomatosis	and	renal	cell	cancer;	ICGN	mice,	ICR-derived	glomerulonephritis.
 
 
 
 
Authors Organism Accession Disease Mouse Model 
Adam, J. et al.1 Mouse GSE10989 HLRCC Fh1 knock-out 
Braun, F et al.7 Mouse GSE3219 Aging kidney Aged wild-type mice 
Tamura K et al.63 Mouse GSE45005 Glomerulonephritis ICGN mice 
Yang et al.72 Mouse GSE20844 Diabetic nephropathy OVE26 mice  
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DISCUSSION
In	 this	 work,	 we	 have	 created	 a	 robust	 PKD	 Signature	 that	 would	 help	 in	 the	 ongoing	
translational	research	efforts	to	find	novel	treatments	for	PKD	patients.	We	followed	a	meta-
analysis	 approach	 that	 combined	 available	 PKD	 expression	 profiling	 studies	 with	 a	 new	
dataset	that	we	contributed.	Given	that	the	datasets	that	we	could	include	are	limited	and	
variable,	we	focused	on	creating	a	PKD	Signature	that	zooms-in	on	the	commonalities	of	the	
disease	and	included	genes	that	are	consistently	dysregulated	across	the	different	studies.	
Although	in	this	approach	we	do	not	guarantee	to	include	all	genes	involved	or	dysregulated	
in	PKD,	we	managed	to	include	highly	relevant	PKD	genes.	To	corroborate	this,	we	tested	
the	PKD	Signature	on	an	independent	PKD	dataset	that	was	not	used	in	the	making	of	the	
PKD	Signature.	This	analysis	revealed	that	the	PKD	Signature	genes	are	three	times	more	
enriched	in	an	independent	PKD	study	compared	with	the	PKD	genes	that	were	excluded	
from	 our	 PKD	 Signature.	 In	 addition,	 significant	 enrichments	 were	 observed	 in	 mild,	
moderate	and	advanced	stages	of	 the	disease,	 in	both	males	and	 females.	These	 results	
reveal	 the	 robustness	 of	 the	 PKD	 Signature	 and	 support	 the	 likelihood	of	 preserved	 key	
disease	mechanisms	between	genders.	We	also	experimentally	confirmed	the	dysregulation	
of	a	selection	of	genes	from	the	PKD	Signature	in	an	independent	PKD	model	using	qPCR.	
Our	functional	annotation	of	the	PKD	Signature	revealed	the	dysregulation	of	many	PKD-
linked	pathways,	such	as	epithelial-to-mesenchymal	transition8,	TGF-β	signaling	pathway8,17, 
cell	 cycle,	 JAK/STAT	 signaling	 pathway17,39,52 and	mammalian	 target	 of	 rapamycin	 (mTOR)	
signaling42,55,	in	addition	to	downregulated	genes	in	molecular	transport64	and	a	large	set	of	
genes	involved	in	metabolic	pathways5,53.
Being	motivated	by	the	rich	 literature	suggesting	a	strong	relationship	between	PKD	and	
injury	repair	processes,	we	went	on	to	characterize	the	injury	repair	involved	genes	in	the	
PKD	Signature.	We	used	a	novel	approach	to	combine	experimental	and	 literature-based	
renal	 injury	 repair	 profiles.	We	 also	 contributed	 a	 new	dataset	 of	 injury	 induced	mouse	
model	that	covers	the	late-injury	repair	response	phase.	Our	results	are	in	line	with	these	
suggestions,	where	we	were	able	 to	 link	35%	(581	genes)	of	 the	PKD	Signature	genes	to	
injury	repair	 response.	This	overlap	 is	 two	times	more	enriched	than	randomly	expected	
(RF=2).	 Interestingly,	 these	 injury	 repair	 genes	 are	 involved	 in	 more	 than	 65%	 of	 the	
functional	annotations	attributed	to	PKD.	The	most	enriched	functions	of	the	PKD	signature	
injury	 repair	genes	 include	epithelial-to-mesenchymal	 transition,	proliferation,	apoptosis,	
hypoxia,	 inflammatory	 response,	 TNF-α/NF-κB	 signaling	 and	 glycolysis.	 Furthermore,	we	
showed	that	the	injury	repair	genes	are	enriched	in	all	stages	of	the	PKD	disease	and	their	
enrichment	becomes	stronger	as	the	disease	progresses	towards	a	more	severe	state.	This	is	
in	accordance	with	our	understanding	of	the	disease.	As	PKD	progresses,	cysts	grow	in	size,	
putting	pressure	on	nearby	cells	and	giving	rise	to	new	cysts.	Oxidative	stress	increases	with	
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disease	progression	and	 injury	 repair	processes	become	significantly	evident	with	visible	
macrophage	infiltration	and	fibrosis	taking	place	at	the	cyst	site.	The	functional	annotation	
profiles	of	the	PKD	Signature	injury	repair	genes	reflect	this.	In	mild	and	moderate	phases	
of	the	disease,	injury	repair	genes	are	associated	with	cell	cycle-related	events	(i.e.	BIRC5, 
MCM2, MCM5, PLK1 and CDKN1A),	 genes	 involved	 in	 extracellular	matrix	 development	
and	morphogenesis	 (i.e. OPN, TPM4, TGFBI and TNFRSF12A),	genes	 involved	 in	transport	
of	 cations/anions	 and	 amino	 acids/oligopeptides	 (i.e. SLC25A10, SLC38A2, SLC6A12)	 and	
metabolism	 (i.e.	 CHPF and LGALS3).	 On	 the	 other	 hand,	 injury	 repair	 genes	 at	 the	 late	
phases	of	PKD	are	involved	in	the	negative	regulation	of	apoptosis,	hypoxia,	inflammatory	
response	and	TNF-α/NF-κB	signaling.	Additionally,	the	upregulation	of	renal	injury	markers	
Osteopontin	(OPN)	in	the	moderate	phase	and	Kidney	Injury	Molecule	1	(KIM-1 or HAVCR1)	
in	the	advanced	phase	of	PKD,	confirms	the	involvement	of	renal	injury	repair	processes	in	
disease	progression66.
Utilizing	 the	 data	 of	 Clements	 et al.11 we	 looked	 for	 PKD	 genes	 that	 are	 involved	 in	
macrophage-related	wound	healing	and	fibrosis	events	after	 injury	 induction.	Our	results	
revealed	that	macrophage-related	genes	activated	upon	injury	induction	are	more	enriched	
in	the	PKD	Signature	injury	repair	genes	than	the	non-injury	repair	genes.	This	is	especially	
evident	 in	 the	 macrophage	 populations	 "CD11b+/Ly6Cintermediate"	 and	 "CD11b+/Ly6Clow",	
suggesting	 a	 role	 for	 PKD	 injury	 repair	 genes	 in	macrophage-related	wound	healing	 and	
fibrosis	events.	Syndecan-1	(SDC1)36,	secreted	protein	acidic	and	cysteine	rich	(SPARC)48 and 
collagen	type	I	alpha-2	chain	(COL1A2)14 are	three	known	fibrosis	genes	found	in	the	injury	
repair	PKD	Signature	genes.	However,	it	remains	unclear	whether	these	genes	are	reflecting	
only	the	expression	in	macrophages	or	also	expression	in	the	epithelium.	As	macrophages	
are	known	to	contribute	to	PKD’s	pathology,	further	research	is	needed	to	determine	their	
clinical	significance	in	PKD	treatment.
We	validated	 the	PKD	Signature	genes	 in	a	 second	PKD	model	with	more	 sampling	time	
points,	using	a	Fluidigm	qPCR	chip.	We	also	included	Wt	and	Wt	+	DCVC	samples	at	matching	
time	points.	This	analysis	showed	that	our	classification	into	“injury	repair”	and	“non-injury	
repair”	groups	was	predictive.	For	instance,	Glis2,	an	important	gene	in	kidney	function22,26 
is	part	of	the	PKD	Signature	and	was	consistently	upregulated	in	all	qPCR	measured	time-
points	of	the	iKsp-Pkd1del.	Our	computational	analysis	did	not	include	it	as	part	of	the	injury	
repair	genes	in	the	PKD	Signature,	and	this	was	further	confirmed	in	the	qPCR	results	as	it	
did	not	respond	to	DCVC	injury	induction	in	Wt	mice.	Plk2, on the other hand,	is	upregulated	
in	the	early	PKD	time	point	and	in	the	injury	induced	mice,	confirming	our	classification	of	
Plk2	as	an	injury	repair	related	gene.	
In	conclusion,	our	computational	methodology	combined	by	our	experimental	validation	in	
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an	independent	mouse	model	identified	a	robust	expression	signature	of	PKD.	We	provide	
an	extensive	meta-analysis	of	PKD	transcriptional	profile	and	characterization	of	the	injury	
repair	genes	involved.	We	believe	that	this	study	can	be	used	to	improve	our	understanding	
of	 the	disease	and	how	altered	 injury	repair	processes	augment	 it	over	time.	Comparing	
the	PKD	Signature	 to	other	 kidney	diseases,	 revealed	 that	 the	 injury	 repair	 genes	 in	 the	
PKD	Signature	account,	in	large	part,	to	the	evident	overlap	between	PKD	and	other	kidney	
diseases,	revealing	the	significance	of	injury	repair	genes	and	pathways	in	the	development	
and	progression	of	kidney	diseases.	Novel	drug	targets	can	be	identified	from	the	profiles	
affecting	the	common	subset	of	injury	repair	processes	or	affecting	the	PKD-unique	targets.	
This	may	allow	for	drug	repurposing	between	renal	diseases	and/or	the	identification	of	PKD	
unique	agents	that	modulate	the	regenerative	process	in	PKD	patients	and	may	lead	to	the	
much	sought	after	treatment	for	PKD	patients.
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Abstract 
Autosomal	 Dominant	 Polycystic	 Kidney	 Disease	 (ADPKD)	 is	 the	 most	 common	 genetic	
renal	disease,	caused	in	the	majority	of	the	cases	by	a	mutation	in	either	the	PKD1 or the 
PKD2	 gene.	ADPKD	 is	 characterised	by	a	progressive	 increase	 in	 the	number	and	 size	of	
cysts,	 together	with	fibrosis	and	distortion	of	 the	renal	architecture,	over	 the	years.	This	
is	accompanied	by	alterations	in	a	complex	network	of	signalling	pathways.	However,	the	
underlying	molecular	mechanisms	are	not	well	 characterised.	Previously,	we	defined	 the	
PKD	Signature,	a	set	of	genes	typically	dysregulated	in	PKD	across	different	disease	models	
from	a	meta-analysis	of	expression	profiles.	Given	the	importance	of	transcription	factors	
(TFs)	 in	modulating	disease,	we	focused	in	this	paper	on	characterising	TFs	from	the	PKD	
Signature.	Our	results	revealed	that	out	of	the	1515	genes	in	the	PKD	Signature,	92	were	
TFs	with	altered	expression	 in	PKD	and	32	of	those	were	also	 implicated	 in	tissue	 injury/
repair	 mechanisms.	 Validating	 the	 dysregulation	 of	 these	 TFs	 by	 qPCR	 in	 independent	
PKD	and	 injury	models	 largely	confirmed	these	findings.	STAT3	and	RUNX1	displayed	the	
strongest	activation	in	cystic	kidneys,	as	demonstrated	by	chromatin	immunoprecipitation	
(ChIP)	followed	by	qPCR.	Using	immunohistochemistry,	we	showed	a	dramatic	increase	of	
expression	after	renal	injury	in	mice	and	cystic	renal	tissue	of	mice	and	humans.	Our	results	
suggest	a	role	for	STAT3	and	RUNX1	and	their	downstream	targets	in	the	aetiology	of	ADPKD	
and	indicate	that	the	meta-analysis	approach	is	a	viable	strategy	for	new	target	discovery	
in	PKD.
Key messages
• We	identified	a	list	of	transcription	factors	(TFs)	commonly	dysregulated	in	ADPKD
• Out	of	the	92	TFs	identified	in	the	PKD	Signature,	35%	are	also	involved	in	injury/repair	
processes
• STAT3	and	RUNX1	are	the	most	significantly	dysregulated	TFs	after	 injury	and	during	
PKD	progression
• STAT3	and	RUNX1	activity	is	increased	in	cystic	compared	to	non-cystic	mouse	kidneys
• Increased	expression	of	STAT3	and	RUNX1	is	observed	in	the	nuclei	of	renal	epithelial	
cells,	also	in	human	ADPKD	samples
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Introduction
Autosomal	Dominant	Polycystic	Kidney	Disease	(ADPKD)	is	a	genetic	disease	characterised	
by	the	formation	of	fluid-filled	renal	cysts.	Cyst	formation	and	cyst	growth	are	accompanied	
by	inflammation	and	fibrosis,	leading	to	kidney	failure.	In	the	majority	of	cases,	ADPKD	is	
caused	by	a	mutation	in	the	PKD1	gene	or,	less	frequently,	in	the	PKD2	gene.	Nevertheless,	
ADPKD	is	a	complex	disease	which	involves	the	dysregulation	of	many	different	signalling	
pathways1,	and	the	molecular	mechanisms	involved	in	disease	progression	are	not	entirely	
understood.	 Currently,	 the	 vasopressin	 V2	 receptor	 antagonist,	 tolvaptan,	 is	 the	 only	
approved	treatment	in	Europe	but	only	for	selected	patients.	More	generic	and	definitive	
treatment	is	still	missing.
Both	environmental	and	genetic	factors	can	be	considered	disease	modifiers	in	ADPKD1,2.	An	
important	one	is	renal	injury,	shown	to	accelerate	cyst	formation	and	expansion	in	different	
mouse models3,4.	 Recently,	 we	 showed	 that	 renal	 injury	 shares	 molecular	 processes	
with	 ADPKD	 progression.	 Using	 a	 meta-analysis	 approach,	 we	 identified	 a	 set	 of	 genes	
dysregulated	 in	a	variety	of	PKD	models	during	disease	progression,	which	we	called	the	
“PKD	Signature”.	About	35%	of	these	genes	were	found	to	be	also	implicated	in	injury/repair	
mechanisms,	confirming	the	strong	relation	between	ADPKD	and	injury5.
Transcription	 factor	 proteins	 (TFs)	 are	 master	 regulators	 of	 transcription,	 which	 control	
the	expression	of	genes	 involved	 in	 the	establishment	and	maintenance	of	cell	 states,	 in	
physiological	 and	 pathological	 situations.	 Dysregulation	 of	 TFs	 levels	 and/or	 activity	 can	
lead	to	the	development	of	a	broad	range	of	diseases.	Thus,	identification	of	a	TFs	profile	
in	ADPKD	could	help	to	better	understand	the	molecular	mechanisms	contributing	to	cyst	
formation.	For	this	reason,	in	this	study	we	focus	on	the	signature	of	TFs.	We	identified	new	
PKD-related	TFs,	and	we	validated	altered	expression	during	ADPKD	progression	and	injury/
repair	in	different	mouse	models.	For	two	of	the	identified	TFs,	STAT3	and	RUNX1,	we	also	
showed	increased	activity	in	mouse	cystic	kidneys,	as	well	as	altered	expression	in	human	
ADPKD	kidneys.	
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Materials and Methods
Identification of Transcription Factors in PKD
Identification	of	the	PKD	Signature	was	described	previously5.	Briefly,	in	the	previous	work	
we	performed	a	meta-analysis	of	PKD	expression	profiles	across	different	disease	models	
and	 identified	1515	genes	that	showed	consistent	dysregulation	across	the	different	PKD	
studies.	 We	 further	 identified	 genes	 involved	 in	 injury/repair	 processes	 from	 the	 PKD	
Signature	by	 firstly	 producing	 Injury	Repair	 gene	profile	 based	on	 several	 injury-induced	
animal	models	 and	 secondly	 intersecting	 the	 identified	 PKD	 Signature	 and	 Injury	 Repair	
Profiles	for	the	identification	of	overlapping	genes.	
In	 this	 publication,	 we	 used	 MSigDB’s	 collection	 of	 TFs	 based	 on	 Messina	 et al.6 and 
Moreland et al7	for	the	identification	of	TFs	involved	in	PKD.	Furthermore,	we	identified	the	
transcription	factors	that	are	involved	in	the	injury/repair	processes	of	PKD	based	on	the	
previously	identified	Injury	Repair	Profile5.
The	enrichment	of	TF	targets	in	the	PKD	Signature	was	based	on	the	target	collections	in	
the	 ChEA	 2016	 database8	 that	 includes	 TF	 targets	 based	 on	 experimental	 evidence.	We	
calculated	the	enrichment	using	the	representation	factor	method	described	below.	TFs	are	
considered	enriched	if	they	had	a	representation	factor	above	1.	The	representation	factor	
is	the	number	of	overlapping	genes	divided	by	the	expected	number	of	overlapping	genes	
drawn	from	two	independent	groups.	A	representation	factor	>	1	 indicates	more	overlap	
than	expected	of	two	 independent	groups,	and	a	representation	factor	<	1	 indicates	 less	
overlap	than	expected.	The	formula	used	to	calculate	the	representation	factor	is:	x	/	(n	*	
D)	/	N,	where	x	=	#	of	genes	in	common	between	two	groups;	n	=	#	of	genes	in	group	1	(the	
total	number	of	targets	calculated	per	transcription	factor	based	on	ChEA	2016	database);	
D	=	#	of	genes	in	group	2	(the	total	number	of	genes	in	the	PKD	Signature	up	(775)	or	down	
(740)	 regulated	 lists	 independently);	N	=	 total	 genes,	 in	 this	 case,	 the	10271	genes	with	
Entrez	IDs.
In silico functional annotation of gene lists
GeneTrail2	 v1.69	was	used	 to	 identify	 the	enriched/significant	pathways/functions	of	 the	
identified	 gene	 lists.	 For	 all	 analyses,	 we	 used	 Wikipathways	 as	 the	 primary	 source	 of	
annotation.	GeneTrail2	 v1.6	was	 run	with	 the	 following	parameters:	Over-representation	
analysis	(enrichment	algorithm);	FDR	adjustment	(adjustment	method);	significance	level	at	
0.05;	minimum	and	maximum	size	of	the	category	equal	to	2	and	700	respectively.
Gene expression and statistical analysis of the significance of results
Snap-frozen	mouse	kidneys	were	homogenised	using	Magnalyser	technology	(Roche).	Total	
RNA	was	isolated	using	Tri-Reagent	(Sigma-Aldrich).	cDNA	synthesis	was	performed	using	
Transcriptor	First	Strand	cDNA	Synthesis	Kit	(Roche),	and	qPCR	was	done	using	2×	FastStart	
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SYBR-Green	Master	(Roche)	according	to	the	manufacturer’s	protocol.	Alternatively,	it	was	
performed	at	GenomeScan	 (GenomeScan	B.V.)	using	 the	96.96	BioMark™	Dynamic	Array	
for	Real-Time	PCR	(Fluidigm	Corporation),	as	previously	described5.	Gene	expression	was	
normalised	to	the	geometric	mean	of	three	housekeeping	genes	(Rplp0, Hnrnpa2b1, Ywhaz)	
for	 Fluidigm	 data	 and	Hprt	 for	 SYBR-Green	 data. The	 output	 of	 the	 Fluidigm	 assay	was	
normalised and converted into Ct values	(cycle	threshold).	For	each	transcription	factor,	a	
two-way	ANOVA	was	conducted	to	compare	the	genotype	(PKD	vs	WT)	and	the	treatment	
(PBS	vs	DCVC)	effects	for	each	age-matched	time	points.	The	computation	was	made	using	
the Limma package10	in	R.	A	list	of	primer	sequences	and	TaqMan	assays	can	be	found	in	
Supplementary	Table	3.
Identification of Transcription Factors Binding Sites and primer design
For	 the	 TFs	 that	 were	 selected	 for	 our	 ChIP	 analysis,	 we	 identified	 the	 binding	 sites	 of	
each	TF	and	its	targets	by	screening	the	Cistrome	database11 and accessing all studies that 
performed	ChIP-Seq	experiments	on	our	selected	TFs.	We	looked	for	peaks	that	appeared	
with	an	 intensity	of	10	or	higher	 in	more	than	one	ChIP-Seq	study.	We	mapped	the	Mus 
musculus	mm10	genome	to	the	peaks	identified	using	Peak2Gene tool	that	is	part	of	the	
Cistrome	Galaxy	tools	to	 identify	genes	that	are	within	10000	base	pairs	of	both	ends	of	
the	peak.	The	peaks	 that	did	not	map	to	a	gene	target	 that	 is	part	of	 the	PKD	Signature	
were	eliminated.	Finally,	sorting	on	the	 intensity	 level	of	 the	peak,	we	visualised	the	top	
peaks	on	the	UCSC	Genome	Browser12	and	selected	the	peaks	that	had	sufficient	height	over	
noise	levels	for	qPCR	enrichment.	We	designed	primers	spanning	the	TFs	binding	sites	on	
their	putative	target	genes.	The	binding	sites	were	generally	overlapping	with	the	promoter	
region	of	the	target	genes.	As	a	negative	control,	we	designed	primers	binding	at	about	5kb	
from	the	promoter	regions	where	we	did	not	expect	to	find	any	TF	binding	activity.	A	list	
of	primers	can	be	found	in	Supplementary	Table	3.	Two-way	ANOVA	with	Tukey’s	multiple	
comparisons	 test	was	performed	comparing	 the	 input-normalised	binding-enrichment	of	
the	TFs	or	the	control	IgG	at	the	binding	site	and	at	the	non-binding	sites.
Animal Model
All	the	animal	experiments	were	evaluated	and	approved	by	the	local	animal	experimental	
committee	 of	 the	 Leiden	 University	 Medical	 Center	 (LUMC)	 and	 the	 Commission	
Biotechnology in Animals	of	the	Dutch	Ministry	of	Agriculture.	Kidney-specific	tamoxifen-
inducible	Pkd1-deletion	mouse	model	 (iKspPkd1del)	have	been	described	previously13.	We	
only	used	male	mice,	to	reduce	variability	in	disease	progression	as	female	mice	tend	to	have	
a	slower	and	milder	progression	of	the	disease	compared	to	male	mice14.	Wt	mice	have	only	
the	LoxP	sites	around	exons	2-11	of	the	Pkd1	gene	but	not	the	Cre	recombinase	(Pkd1loxlox).	
For	three	consecutive	days,	5	mg/kg	of	tamoxifen	was	administered	via	oral	gavage	when	
mice	were	13-14	weeks	old.	Inactivation	of	the	Pkd1	gene	at	this	age	leads	to	cyst	formation	
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in	 all	 the	 renal	 tubule	 segments.	A	week	 later	mice	were	 injected	 intraperitoneally	with	
15	mg/kg	of	the	nephrotoxic	compound	S-(1,2-dichlorovinyl)-L-cysteine	(DCVC)	or	vehicle	
(PBS)	as	a	control.	Kidney	function	was	evaluated	using	blood	urea	nitrogen	level	(BUN)	as	
previously	described4.	Renal	failure	is	defined	by	BUN	equal	or	higher	than	25mmol/l.	Mice	
were	sacrificed	at	1,	2,	5	and	10	weeks	after	DCVC	and	kidney	 failure.	The	experimental	
pipeline	has	been	presented	in	Formica	et al.15.	The	Wt	+	PBS,	Wt	+	DCVC	and	Pkd1	KO	+	
PBS	groups	have	also	been	used	in	Malas	et al.5.	At	the	sacrifice,	kidneys	were	collected	and	
weighed.	For	RNA	and	chromatin	extraction,	kidneys	were	snap-frozen	in	liquid	nitrogen.	For	
immunohistochemistry	 (IHC)	 staining,	 kidneys	were	preserved	 in	phosphate-buffered	4%	
formaldehyde	solution.	A	t-test	was	conducted	to	compare	median	survival	in	PBS	treated	
versus	DCVC	treated	mice	and	BUN	in	Wt	versus	iKspPkd1del	mice.
ChIP
Chromatin	was	isolated	from	mouse	inner	medulla	collecting	duct	(mIMCD3;	ATCC,	Rockville,	
USA)	cells	(about	5	X	106/ml).	Briefly,	cells	were	crosslinked	with	1%	formaldehyde	for	10	
minutes	at	RT,	then	lysed	with	buffer	with	protease	and	phosphatase	inhibitors	(Roche)	as	
described	on	Nature	Protocols	(ChIP	buffer)16.	
For	kidneys	chromatin	extraction,	snap-frozen	kidneys,	harvested	at	end-stage	renal	disease	
(ESRD)	from	Wt	mice	and	iKspPkd1del	mice	treated	with	DCVC	or	PBS,	were	cut	with	a	blade	
in	a	petri	dish	then	fixed	with	1%	formalin	(50	mg/ml)	rocking	for	12	minutes	at	RT.	Glycine	
(0.125M)	was	added	to	stop	the	reaction,	and	the	tissue	was	washed	with	PBS	with	serine	
protease	 inhibitor	 phenylmethylsulfonyl	 fluoride	 (PMSF).	 The	 tissue	was	 resuspended	 in	
cytoplasmic	lysis	buffer	and	moved	in	a	glass	tissue	grinder	(Kimble	Chase)	for	homogenisation	
and	 then	filtered	using	 a	 50	µm	filter	 (CellTrics®	 Sysmex).	 The	homogenate	was	washed	
and	then	lysed	with	ChIP	buffer	with	protease	and	phosphatase	inhibitors.	Chromatin	was	
sonicated	in	ChIP	buffer	using	a	Diagenode	Bioruptor®	Pico	(Diagenode)	30	sec	on/30	sec	off	
for	15	cycles.	Fragment	size	was	checked	by	gel	electrophoresis.	
For	 immunoprecipitation	60	μg	of	 chromatin	were	used	per	 reaction.	 Sepharose	protein	
A	alone	or	mixed	4:1	with	protein	G	(GE	Healthcare)	were	used	to	preclear	the	chromatin	
before	incubation	with	primary	antibodies	for	4h	at	4°C.	Primary	antibodies	used:	5	μg	rabbit	
anti-pSTAT3	(Cell	Signaling	#9145);	8	μg	mouse	anti-RUNX1	(Santa	Cruz	Biotechnology,	Inc.	
#sc-365644);	rabbit	anti-IgG	(Abcam	#ab37415);	mouse	anti-IgG	(Cell	Signaling	#5415S).	
20	μl	of	Sepharose	protein	A	(for	pSTAT3)	or	A/G	4:1	(for	RUNX1)	were	added	to	each	sample	
and	incubated	overnight	at	4°C.	Samples	were	collected	by	centrifugation	and	washed	with	
low	salt	wash	buffer	(150mM	NaCl,	20mM	Tris-HCl	pH	8.1,	2mM	EDTA,	0.1%	SDS,	1%	Triton	
X-100),	high	salt	wash	buffer	(500mM	NaCl,	20mM	Tris-HCl	pH	8.1,	2mM	EDTA,	0.1%	SDS,	1%	
Triton	X-100),	LiCl	wash	buffer	(10mM	Tris-HCl	pH	8.1,	1mM	EDTA,	0.25M	LiCl,	1%	NP-40,	1%	
sodium	deoxycholate)	and	twice	with	TE	wash	buffer	(10mM	Tris-HCl	pH	8.1,	1mM	EDTA).	
Cross-links	were	reversed	incubating	with	Chelex®100	resin	beads	(Bio-Rad	#142-1253)	at	
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99°C	for	15	minutes	on	a	shaking	block,	and	then	the	samples	were	diluted	1:1	with	MQ	
water.
IHC
Kidneys	fixed	in	formalin	and	embedded	in	paraffin	were	cut	at	4	μm	thickness.	Sections	
were	 stained	 with	 the	 primary	 antibodies	 used	 for	 ChIP:	 rabbit	 anti-pSTAT3	 (1:75;	 Cell	
Signaling	#9145);	mouse	anti-RUNX1	 (1:250;	 Santa	Cruz	Biotechnology,	 Inc.	 #sc-365644).	
Anti-rabbit	or	anti-mouse	Envision	HRP	(Dako)	was	used	as	the	secondary	antibody.
Renal	 tissue	 from	 ADPKD	 patients	 at	 end-stage	 renal	 failure	 was	 fixed	 in	 formalin	 as	
previously	described15.	Control	tissues	were	obtained	from	donor	kidneys	non-suitable	for	
transplant.	All	human	tissue	samples	were	collected	following	procedures	approved	by	the	
LUMC	medical	ethical	committee	(institutional	review	board).
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Results 
Transcription Factors in the PKD Signature
Using	a	meta-analysis	approach	of	published	PKD	expression	profiles	and	in-house	generated	
RNA-sequencing	data	on	our	Pkd1	mutant	mouse	model	(iKspPkd1del)	we	recently	identified	
1515	genes	that	are	commonly	dysregulated	across	several	PKD	disease	models,	hereafter	
referred	to	as	the	PKD	Signature5.
We	used	MSigDB	to	identify	the	TFs	that	are	part	of	the	PKD	Signature	(Figure	1a).	Out	of	
the	1515	genes	of	the	PKD	Signature,	we	identified	92	TFs	that	were	differentially	expressed	
and	could	be	involved	in	cyst	formation	and	PKD	development.	Among	the	92	TFs	identified,	
32	were	also	implicated	in	tissue	injury/repair	mechanisms	based	on	our	previously	defined	
Injury	Repair	Profile	(Supplementary	Table	1)5.	Several	of	the	herein	identified	TFs,	such	as	
STAT3	and	MYC	are	 known	players	 in	ADPKD	progression17,18.	Nevertheless,	many	others	
have	never	been	described	in	ADPKD	before.
Furthermore,	we	predicted	TFs	that	are	relevant	to	PKD	based	on	the	enrichment	of	their	
targets	in	the	PKD	Signature.	Using	the	ChEA	2016	database	of	TF	targets,	we	identified	TFs	
with	more	experimentally-verified	targets	(ChIP-chip	or	ChIP-Seq)	overlapping	with	the	PKD	
Signature	than	would	be	expected	by	chance	(Figure	1a).	The	TFs	E2F7,	TRIM28,	TP63	(two	
different	experiments	in	different	cell	lines),	EGR1	and	STAT3	were	most	significant	in	this	
analysis	 (Supplementary	Table	2a)	 since	 targets	of	 these	TFs	were	mostly	upregulated	 in	
PKD.	Five	TFs	were	both	in	the	list	of	TFs	identified	based	on	their	targets	and	among	the	92	
TFs	present	in	the	PKD	Signature:	EGR1,	ESR1,	STAT3,	FOXM1	and	KLF5.	Thus,	these	TFs,	as	
well	as	their	identified	direct	targets,	were	dysregulated	in	PKD	(Supplementary	Table	2b).	
Further	pathway	analysis	of	these	five	TFs	targets	uncovered	involvement	in	the	modulation	
of	TGF-β	signalling,	estrogen	signalling,	apoptosis,	oxidative	stress,	 interleukins	signalling,	
adipogenesis	and	cellular	metabolism	(Supplementary	Table	2c).
Validation of meta-analysis in independent samples
Our	 next	 step	 was	 to	 validate	 TFs	 identified	 in	 the	 meta-analysis	 in	 independent	
experimental	groups	of	mice	during	PKD	progression	and/or	the	nephrotoxic	injury/repair	
response15.	Briefly,	we	 induced	Pkd1	deletion	 in	adult	mice	via	 tamoxifen	administration,	
which	leads	to	a	slow	progression	of	the	disease.	Wild-type	(Wt)	mice	received	tamoxifen	
as	well.	A	week	after	tamoxifen	administration,	we	injected	both	genotypes	with	15	mg/
kg	of	DCVC,	a	nephrotoxic	compound,	or	PBS	as	a	control.	At	this	dosage,	DCVC	causes	a	
repairable	renal	injury	that	is	mostly	recovered	1	to	2	weeks	after	injection	but	accelerates	
cyst	formation	resulting	in	tubular	dilations	at	10	weeks	and	renal	failure	around	14	weeks	
of	age	(Supplementary	Figure	1).	Mice	were	sacrificed	at	1,	2,	5	and	10	weeks	after	DCVC	
and	at	kidney	failure.	Kidneys	harvested	at	these	time	points	were	used	to	evaluate	gene	
expression	of	selected	TF	using	the	Fluidigm	qPCR	chip	(Figure	1b).
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Out	of	the	92	TFs,	13	were	selected	for	further	analysis,	based	on	transcript	levels,	altered	
expression	in	the	injury/repair	response	and	involvement	in	multiple	molecular	pathways	
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Figure 1. Schematic representation of the workflow used for the identification and validation of TFs involved in 
PKD and injury/repair
(a)	MSigDB	was	used	 to	 select	 the	TFs	 in	 the	PKD	Signature.	ChEA	2016	was	used	 to	 select	 the	TFs	with	most	
dysregulated,	experimentally-verified	targets	in	the	PKD	Signature	(Note:	the	ChIP-chip	and	ChIP-Seq	experiments	
in	ChEA	2016	were	typically	from	cell	lines	not	necessarily	related	to	the	kidney).	The	TFs	identified	with	MSigDB	in	
the	PKD	Signature	were	intersected	with	the	Injury	Signature	generated	in	our	previous	work5	to	obtain	TFs	involved	
in	 injury/repair	mechanisms,	and	TFs	involved	only	 in	PKD	progression.	Fluidigm	assay	was	used	to	validate	the	
expression	of	selected	TFs	identified	by	this	analysis.	The	TFs	identified	based	on	their	target	genes	using	the	ChEA	
2016	database	were	intersected	with	the	TFs	identified	in	the	PKD	signature	to	identify	the	overlapping	TFs.	In silico 
pathway	analysis	was	performed	on	the	overlapping	TFs	and	their	target	genes	to	 identify	significant	pathways	
modulated	by	the	TFs.	(b)	Schematic	representation	of	the	workflow	used	to	identify	and	validate	selected	TFs.	The	
two	most	significant	TFs	identified	were	STAT3	and	RUNX1	which	were	further	investigated	in	cystic	kidneys	using	
chromatin	immunoprecipitation-qPCR	(ChIP-qPCR)	and	immunohistochemistry	(IHC)
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(Supplementary	Table	1).	In	our	Fluidigm	setup,	we	had	four	groups:	PBS	treated	Wt,	DCVC	
treated	Wt,	PBS	treated	iKspPkd1del, and	DCVC	treated	iKspPkd1del at	five	time	points	(1	wk,	
2	wks,	5	wks	and	10	wks	after	DCVC	treatment	and	at	kidney	failure).	Out	of	the	13	tested	
TFs,	11	were	significantly	different	 (P	<	0.05)	 in	PKD	samples	compared	to	Wt,	while	the	
involvement	of	Irf6 and JunB could	not	be	confirmed (Supplementary	Table	1,	Figure	2).	We	
also	evaluated	whether	expression	of	the	13	TFs	was	affected	by	injury,	by	comparing	DCVC	
versus	PBS	treated	animals	at	injury-related	timepoints	(1	wk,	2	wks	and	5	wks	after	DCVC	
treatment).	Of	 the	13	 selected	TFs,	8	were	part	of	 the	previously	 reported	 Injury	Repair	
profile,	while	5	were	not5.	We	confirmed	significant	injury-induced	dysregulation	(P	<	0.05)	
of	 6	 out	 of	 8	 TFs	 predicted	 to	be	 involved	 in	 the	 injury/repair	mechanism	by	 the	meta-
analysis,	while	we	did	not	see	any	significant	dysregulation	of	the	expression	of	3	out	of	5	
TFs	that	were	not	found	in	the	meta-analysis	(Supplementary	Table	1,	Figure	2)5.	Notably,	
the	expression	of	Runx1 and Stat3 was	most	significantly	affected	by	DCVC-induced	injury	
and	PKD	progression.
Expression of two selected TFs in mouse kidneys during ADPKD progression and after 
injury
To	further	support	the	utility	of	meta-analysis	approaches	to	new	target	discovery	in	ADPKD,	
we	chose	STAT3	and	RUNX1	for	additional	experimental	validation.
We	 performed	 immunohistochemical	 analysis	 for	 the	 active	 form	 of	 STAT3	 (pSTAT3)	
and	 RUNX1,	 and	 studied	 activation	 and	 subcellular	 localisation.	 In	 non-injured	 Wt	 and	
iKspPkd1del	mice,	pSTAT3	and	RUNX1	are	not	detectable,	except	 for	some	 interstitial	cells	
that	 show	nuclear	 staining.	 Interestingly,	 after	 injury	 (at	 1	wk	 after	DCVC)	 there	was	 an	
intense	nuclear	expression	of	pSTAT3	and	RUNX1	in	both	Wt	and	iKspPkd1del	mice	(Figure	3a	
and	Supplementary	Figure	2a).	
At	10	weeks	post-DCVC,	Wt	mice	have	fully	healed	the	renal	damage	and	have	largely	pSTAT3	
and	RUNX1	negative	kidneys,	comparable	to	the	Wt	treated	with	PBS.	Conversely,	iKspPkd1del 
mice,	which	already	developed	some	mild	cysts	at	this	time-point,	showed	expression	of	
pSTAT3	and	RUNX1	 in	the	cyst-lining	epithelial	cells	and	some	of	 the	surrounding	dilated	
tubules	(Figure	3b,	middle	panel	and	Supplementary	Figure	2b,	middle	panel).	iKspPkd1del 
mice	treated	with	PBS,	instead,	have	not	undergone	injury/repair	phase	nor	displayed	overt	
cyst	formation	at	this	time-point,	and	showed	almost	no	expression	of	pSTAT3	and	RUNX1,	
as	expected.
At	kidney	failure,	 iKspPkd1del	mice	present	severe	renal	degeneration	and	cyst	 formation.	
At	this	time-point,	the	expression	of	pSTAT3	and	RUNX1	is	markedly	increased	(Figure	3b,	
right	panel	and	Supplementary	Figure	2b,	right	panel).	Interestingly,	not	only	epithelial	cells,	
but	also	infiltrating	cells	stained	positive	for	these	TFs,	suggesting	that	pSTAT3	and	RUNX1	
might	be	important	in	the	regulation	of	signalling	pathways	in	other	cell	types	in	addition	to	
tubular	epithelial	cells	(Figure	3b,	arrowheads).
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Figure 2. Expression of selected TFs using Fluidigm assay 
TFs	selected	from	the	PKD	Signature	for	experimental	validation	were	subjected	to	qRT-PCR	on	RNA	isolated	from	
the	kidneys	of		iKspPkd1del	mice,	and	age-matched	Wt	mice	at	1,	2,	5,	10	weeks	after	DCVC	and	at	kidney	failure.	
On	the	Y-axis	normalized	Ct	values	(cycle	threshold	values)	are	plotted	for	each	gene	separately	across	the	five	
measurement	time	points	for	four	types	of	samples:	Wt	mice	treated	with	saline	(Wt	PBS,	salmon),	iKspPkd1del mice 
treated	with	saline	(iKspPkd1del	PBS,	light	green),	Wt	mice	treated	with	DCVC	(Wt	DCVC,	light	blue),	and	iKspPkd1del 
mice	treated	with	DCVC	(iKspPkd1del	DCVC,	light	purple).	The	analysis	was	based	on	comparing	Treatment	(DCVC	vs	
PBS)	and	Genotype	(iKspPkd1del	vs	Wt)	using	a	two-way	ANOVA	test.	The	resulting	P	values	are	shown	with	colour	
codes:	darkest	colour	shade,	P	value	<	0.0005;	medium	colour	shade,	P	value	<	0.005	and	low	colour	shade	at	P	
value	<	0.05.	P	value	≥	0.05	were	not	considered	significant	(grey	bars).	Each	dot	is	a	mouse	and	whiskers	reflect	
the mean ±	SD.	Expression	of	Glis2 and Stat3	in	Wt	PBS,	iKspPkd1del	PBS	and	Wt	DCVC	have	been	published	in	Malas	
et al. (2017)5.
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In	summary,	we	confirmed	that	pSTAT3	and	RUNX1	protein	expression	were	increased	in	the	
nuclei	of	tubular	epithelial	cells	after	injury	and	during	PKD	progression.
Figure 3. Expression of pSTAT3 and RUNX1 in Wt and iKspPkd1del mice after injury and during cyst progression
(a)	Representative	 immunohistochemistry	of	Wt	and	iKspPkd1del	kidneys	at	1	week	after	DCVC	(+	 injury)	or	PBS	
(-	injury).	Mice	without	injury	showed	only	sporadic	expression	of	pSTAT3	in	the	nuclei	of	tubular	epithelial	cells	
(asterisks);	after	injury,	the	expression	was	markedly	increased	both	in	Wt	mice	and	in	iKspPkd1del	mice.	RUNX1	
expression	in	non-injured	kidney	was	present	only	in	some	interstitial	cells	(arrowheads);	after	injury,	RUNX1	was	
visible	in	the	nuclei	of	the	epithelial	cells.	(b)	Representative	immunohistochemistry	of	Wt	and	iKspPkd1del	kidneys	
at	10	weeks	after	DCVC	(“10	wks”;	left	and	middle	panel)	showed	expression	of	pSTAT3	and	RUNX1	in	nuclei	in	cyst-
lining	epithelia,	in	the	epithelial	cells	of	surrounding	dilated	tubules	(arrows)	and	in	infiltrating	cells	(arrowheads)	
only	in	cystic	tissue.	Expression	of	pSTAT3	and	RUNX1	was	even	more	increased	at	kidney	failure	(“KF”;	right	panel)	
when	the	kidneys	are	severely	cystic.	Scale	bars	50	µm
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STAT3 and RUNX1 target genes were dysregulated during ADPKD progression and after 
injury
Although	 we	 demonstrated	 that	 pSTAT3	 and	 RUNX1	 expression	 were	 increased	 during	
ADPKD	progression	and	after	injury,	both	at	gene	and	protein	level,	we	do	not	know	if	this	
would	 translate	 into	 differences	 in	 their	 activity	 as	 transcriptional	 regulators.	 Thus,	 we	
quantified	the	expression	of	 their	 target	genes	during	PKD	progression	and	 injury/repair.	
To	find	TFs’	target	genes,	we	used	the	publicly	available	Cistrome	database.	For	both	TFs	
we	identified	ChIP-Seq	experiments	and	searched	for	peaks	(targets)	 identified	in	at	least	
two	ChIP-Seq	experiments.	Peaks	were	prioritised	based	on	1)	the	number	of	studies	they	
were	found	in,	2)	their	intensity	levels	(>10)	and	3)	whether	they	mapped	to	target	genes	
within	10	kb	distance.	For	both	TFs	 the	 top	putative	target	genes	were	crossed	with	 the	
PKD	Signature	genes	to	identify	targets	that	show	differential	expression	in	PKD.	Only	target	
genes	that	were	also	present	in	the	PKD	Signature	were	selected	for	further	analysis	(Figure	
4a).
The	final	targets	we	selected	are	Scp2, Kif22, Stat3 (autoregulation)	and	Socs3	for	STAT3,	and	
Runx1 (autoregulation), Tnfrsf12a and Bcl3	as	targets	for	RUNX1.	We	checked	the	expression	
of	 these	 targets	after	 injury	and	during	PKD	progression	 in	 iKspPkd1del	 and	Wt	mice.	We	
found	that,	 in	 iKspPkd1del	mice,	all	 targets	were	significantly	upregulated	except	for	Scp2, 
which	was	downregulated,	suggesting	an	inhibitory	effect	of	STAT3	on	Scp2	transcription.	
(Figure	2b	-	Stat3 and Runx1; Figure	4b	-	Scp2, Kif22, Socs3, Tnfrsf12a and Bcl3).
These	data	indicate	that	not	only	the	level	of	expression	of	the	selected	TFs	is	dysregulated	
during	 injury/repair	and	PKD	progression,	but	 likely	also	their	activity,	as	denoted	by	the	
dysregulated	expression	of	their	target	genes.
STAT3 and RUNX1 ChIP-qPCR in murine renal epithelial cells
To	confirm	that	STAT3	and	RUNX1	are	directly	 regulating	 the	expression	of	 the	 indicated	
target	genes	in	the	renal	epithelium,	we	performed	chromatin	immunoprecipitation	(ChIP)	
analysis	 followed	 by	 quantitative	 PCR	 (ChIP-qPCR).	 We	 first	 confirmed	 that	 STAT3	 and	
RUNX1	were	expressed	in	mIMCD3	cells	(Supplementary	Fig	3).	We	then	isolated	chromatin	
and	performed	ChIP-qPCR.	 STAT3	enrichment	at	 the	promoter	 region	of	 the	Scp2, Kif22, 
Stat3 and Socs3	 genes	 was	 significantly	 higher	 than	 at	 non-binding	 regions	 (Figure	 5a).	
Also,	RUNX1	showed	significant	enrichment	at	the	promoter	regions	of	 its	targets	Runx1, 
Tnfrsf12a and Bcl3	(Figure	5b)	compared	to	non-binding	regions.
Thus,	we	can	conclude	that	STAT3	and	RUNX1	are	actively	binding	the	selected	target	genes	
in	renal	epithelial	cells.
STAT3 and RUNX1 ChIP-qPCR in murine kidney tissue
We	then	investigated	whether	binding	of	STAT3	and	RUNX1	at	the	promoter	region	of	their	
target	genes	 is	 increased	 in	 cystic	kidneys	 compared	 to	non-cystic	kidneys.	 To	do	 so,	we	
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Figure 4. Identification of STAT3 and RUNX1 target genes
(a) STAT3	 and	RUNX1	emerged	 as	 two	 leading	 candidates	 for	wet-lab	 validation.	Using	 Cistrome	database,	we	
identified	ChIP-peaks	that	were	used	in	the	wet-lab	validation	process	and	led	to	the	identification	of	confirmed	
STAT3	 and	RUNX1	 targets. (b) Expression	 of	 STAT3	 and	 RUNX1	 targets	 during	 PKD	progression. Total	 RNA	was	
isolated	 from	kidneys	of	Wt	and	 iKspPkd1del	mice	 treated	with	PBS	or	DCVC	at	1,	2,	5,	10	weeks	and	at	kidney	
failure.	Expression	of	selected	STAT3	(Scp2, Kif22 and Socs3)	and	RUNX1	(Bcl3, Tnfrsf12a)	targets	was	evaluated	
using	a	SYBR-Green	based	qPCR.	On	the	Y-axis	normalised	Ct	values	(cycle	threshold	values)	are	plotted.	Data	were	
analysed	using	a	two-way	ANOVA	test	based	on	comparing	Treatment	(DCVC	vs	PBS)	and	Genotype	(iKspPkd1del 
vs	Wt).	 P	 values	 are	 reported	and	 classified	 into:	 high	 significance	 (darkest	 colour	 shade)	 at	 P	 value	<	0.0005,	
moderate	significance	(medium	colour	shade)	at	P	value	<	0.005,	and	acceptable	significance	at	(low	colour	shade)	
at	P	value	<	0.05.	P	value	≥	0.05	was	not	considered	significant	 (grey	bars).	Each	dot	 is	a	mouse	and	whiskers	
represent	mean	±	SD.
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Figure 5. ChIP validation of pSTAT3 and RUNX1 targets in mIMCD3 cells
(a)	ChIP	with	anti-pSTAT3	antibody	showed	significant	enrichment	at	the	promoter	region	of	Scp2, Kif22, Stat3 and 
Socs3	compared	to	a	negative	control	antibody	(rIgG)	and	a	non-binding	region	(Neg).	(b)	ChIP	with	anti-RUNX1	
antibody	showed	a	significant	enrichment	at	 the	promoter	 region	of	Runx1, Tnfrsf12a and Bcl3	 compared	 to	a	
negative	control	antibody	(mIgG)	and	a	non-binding	region	(Neg).	The	Y-axis	shows	the	input-normalised	binding-
enrichment	of	the	TFs	to	the	indicated	genomic	region.	Data	represent	the	mean	of	two	independent	ChIPs	±	SD;	
Two-way	ANOVA	with	Tukey’s	multiple	comparisons	test.	*	P	value	<	0.05;	**	P	value	<	0.01;	***	P	value	<	0.001
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performed	ChIP-qPCR	using	kidneys	from	iKspPkd1del	mice,	harvested	at	kidney	failure,	as	
well	as	age-	and	treatment-matched	Wt	kidneys.
As	expected,	we	observed	a	significantly	increased	abundance	of	STAT3	at	Stat3, Socs3, Scp2 
and Kif22	promoter	regions	in	iKspPkd1del	mice	compared	to	Wt	(Figure	6a	-	more	severe	
iKspPkd1del	+	DCVC	and	Supplementary	Figure	4a	-	milder	iKspPkd1del	+	PBS).
RUNX1	 enrichment	 in	 iKspPkd1del	 mice	 was	 not	 significantly	 higher	 than	 in	 Wt	 mice.	
However,	 RUNX1	 enrichment	was	 significantly	 higher	 compared	 to	 IgG	 at	 the	 promoter	
region	of	Runx1 and Bcl3	in	iKspPkd1del	mice	but	not	in	Wt.	A	similar	trend	is	observed	for	
Tnfrsf12a.	This	means	that	in	iKspPkd1del	mice,	RUNX1	binding	is	specific	while	in	Wt	it	is	not	
different	from	the	background	signal.	Thus,	RUNX1	 is	actively	binding	 its	 targets	 in	cystic	
kidneys	only.	(Figure	6b	-	more	severe	iKspPkd1del	+	DCVC	and	Supplementary	Figure	4b	-	
milder iKspPkd1del	+	PBS).
Overall,	 these	data,	 in	addition	to	the	altered	expression	 levels,	show	that	the	activity	of	
STAT3	and	RUNX1	is	increased	in	advanced	stages	of	PKD	in	mice.
Expression of TFs in kidneys of ADPKD patients
Lastly,	we	checked	the	expression	of	STAT3	and	RUNX1	in	human	kidney	sections	obtained	
from	ADPKD	patients	and	healthy	controls.	Comparably	with	what	was	observed	in	mice,	
in	healthy	controls,	we	found	only	sporadic	expression	of	pSTAT3	in	the	nuclei	of	tubular	
epithelial	cells	(Figure	7,	asterisks)	and	expression	of	RUNX1	in	some	infiltrating	cells	(Figure	
7,	arrowheads).	Conversely,	 in	ADPKD	patients	renal	tissue	the	expression	of	pSTAT3	and	
RUNX1	was	increased	in	the	nuclei	of	the	epithelial	cells	and	infiltrating	cells	(Figure	7,	right	
panel	and	Supplementary	Figure	5,	right	panel).
These	data	suggest	 that	 the	TFs	 identified	by	our	meta-analysis	using	 rodent	models	are	
relevant	for	human	ADPKD.
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Figure 6. Increased binding of STAT3 and RUNX1 to the promoter of target genes in cystic kidneys, shown by 
ChIP-qPCR
ChIP-qPCR	analysis	of	end-stage	renal	disease	iKspPkd1del	kidneys	or	Wt	kidneys	at	24	weeks	after	DCVC.	(a)	We	
confirmed	 an	 increased	 enrichment	 for	 STAT3	 binding	 at	 target	 genes	 in	 iKspPkd1del	 kidneys	 compared	 to	Wt	
kidneys.	(b)	RUNX1	enrichment	at	its	targets	is	not	detected	in	Wt	samples	(no	difference	between	RUNX1	ChIP	and	
IgG	ChIP)	but	detected	in	iKspPkd1del	samples.	Black	bars	pSTAT3	or	RUNX1	antibody,	grey	bars	isotype	IgG	control	
(rIgG:	rabbit	IgG;	mIgG:	mouse	IgG).	The	Y-axis	shows	the	input-normalised	binding-enrichment	of	the	TFs	to	the	
indicated	genomic	region.	Data	represent	the	mean	of	two	independent	ChIPs	±	SD;	Two-way	ANOVA	with	Tukey’s	
multiple	comparisons	test.	*	P	value	<	0.05;	**	P	value	<	0.01;	***	P	value	<	0.001
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Figure 7. pSTAT3 and RUNX1 expression in human kidneys with ADPKD
Representative	immunohistochemistry	of	human	kidneys.	In	healthy	patients,	the	expression	of	pSTAT3	and	RUNX1	
was	rarely	detected	(asterisks).	In	end-stage	cystic	kidneys	from	ADPKD	patients,	pSTAT3	and	RUNX1	localised	in	
the	nuclei	of	the	tubular	epithelial	cells	(arrows)	and	infiltrating	cells	(arrowheads).	Scale	bars	100	µm.
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Discussion
Previously,	we	identified	a	list	of	1515	genes	dysregulated	during	PKD	progression,	which	we	
defined	as	the	PKD	Signature.	We	also	showed	a	consistent	overlap	(about	35%)	of	the	PKD	
Signature	with	genes	normally	involved	in	injury/repair	mechanisms5.	Now,	we	have	put	this	
analysis	a	step	further	by	identifying	and	characterising	TFs	involved	in	ADPKD	progression.
Using MSigDB,	 we	 identified	 92	 TFs	 in	 the	 PKD	 Signature	 and	 again	 showed	 that	 about	
35%	of	these	genes	(32	out	of	92)	have	a	strong	injury-related	component.	This	 is	 in	 line	
with	a	substantial	body	of	 literature	 indicating	that	 injury	 is	a	significant	modifier	 in	PKD	
and	a	potential	trigger	of	cyst	formation.	 Indeed,	renal	 injury	causes	faster	cystic	disease	
progression	suggesting	that	events	activated	during	the	injury/repair	phase	are	also	crucial	
for	cyst	initiation	and	expansion3,4.	Moreover,	cyst	formation	per	se	is	a	source	of	injury	for	
the	surrounding	tissue	making	the	two	pathological	processes	challenging	to	dissect19.	
Among	these	92	identified	TFs	we	observed	known	players	in	PKD,	such	as	STAT317,20,	c-MYC18, 
SMAD221,	GLIS222,	c-JUN23	and	E2F124,	confirming	our	approach.	On	the	other	hand,	we	did	
not	find	TFs	such	as	PPARα,	which	has	been	described	to	play	a	role	in	PKD25.	This	is	likely	
due	to	the	high	stringency	used	for	the	definition	of	the	PKD	Signature,	which	allows	us	to	
get	specific	targets	while	possibly	losing	others5.	
Interestingly,	we	also	identified	many	other	TFs,	never	described	before	in	PKD.	Some	of	these	
TFs,	such	as	EGR1,	KLF5	and	FOXM1,	have	been	reported	in	literature	for	their	involvement	
in	injury/repair	mechanisms	or	pathways	dysregulated	during	PKD	progression	and	might	
be	interesting	candidates	for	future	studies.	Indeed, Egr1	is	an	early	growth	response	gene	
and	 is	downstream	of	 the	mitogen-activated	protein	 kinase	 (MAPK)	pathway,	 a	pathway	
dysregulated	in	PKD23.	EGR1	is	a	key	regulator	of	proliferation,	apoptosis	and	inflammation	
and	was	shown	to	be	involved	in	renal	injury	and	fibrosis.	Egr1	disruption	protected	mice	
from	renal	failure	in	a	model	of	tubulointerstitial	nephritis	and	resulted	in	lower	activation	of	
the	TGF-β	pathway26.	Moreover,	Egr1	can	be	downregulated	by	curcumin,	a	compound	able	
to	reduce	cyst	formation	in vivo17.	Also,	KLF5	was	shown	to	play	a	role	in	renal	inflammation	
and	fibrosis	since	unilateral	ureteral	obstruction	in	mice	haploinsufficient	for	Klf5 resulted in 
reduced	renal	injury,	fibrosis	and	infiltrating	cells27.	Thus,	modulation	of	KLF5	activity	might	
improve	the	pro-fibrotic	and	pro-inflammatory	phenotype	observed	especially	during	the	
more	advanced	phases	of	PKD	progression.	Foxm1	is	expressed	during	cell	proliferation	and	
is	critical	for	cell-cycle	progression.	In	adult	tissues,	Foxm1	expression	is	low,	but	after	injury	
its	levels	are	dramatically	increased.	In	particular,	FOXM1	can	control	the	expression	of	genes	
involved	in	the	G2/M	transition	phase.	Cell-cycle	arrest	 in	G2/M	phase	is	associated	with	
pro-fibrotic	cytokines	production	by	proximal	tubular	cells28.	Not	surprisingly,	these	three	
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TFs	are	involved	in	PKD	since	aberrant	extracellular	matrix	(ECM)	deposition	is	commonly	
found	in	PKD	patients	and	animal	models	of	PKD,	not	only	in	ESRD	but	also	in	early-stage29.	
This	suggests	that	increased	ECM	deposition	may	be	contributing	to	cyst	formation	and	not	
barely	be	a	consequence	of	it,	as	shown	for	laminin-alpha530	and	integrins-beta131,	which	
mutation	 could	 affect	 the	 cystic	 phenotype.	 Thus,	 modulation	 of	 pro-fibrotic	 processes	
could	be	a	valuable	strategy	to	modulate	PKD	progression.	
EGR1,	KLF5	and	FOXM1,	together	with	ESR1	and	STAT3,	were	also	among	the	significantly	
enriched	PKD	Signature	TFs	identified	based	on	their	target	genes	annotated	in	the	ChEA	2016	
database.	Pathway	analysis	of	the	targets	of	these	TFs,	using	Genetrail2	and	Wikipathways,	
revealed	enrichment	 for	pathways	known	 to	play	a	 role	 in	PKD	progression,	 such	as	 the	
TGF-β	pathway,	oxidative	stress,	cellular	metabolism,	interleukins	signalling,	adipogenesis,	
estrogen	 signalling	 and	 apoptosis21,32-35.	 Using	 this	 approach,	 we	 also	 identified	 TFs	 not	
directly	present	in	the	PKD	Signature.	Interestingly,	the	top	five	TFs	identified	based	on	their	
targets	were	all	described	in	literature	to	be	involved	in	the	progression	of	PKD	(STAT3)17,20,36, 
or	 in	processes	relevant	for	PKD	like	angiogenesis	 (E2F7)37,	DNA	damage	response	(E2F7,	
TRIM28)38,39,	 renal	 injury	 and	fibrosis	 (EGR1)26,	 epithelial	 cell	 proliferation,	 apoptosis	 and	
adhesion	 (TP63)40.	 Nevertheless,	 apart	 from	 STAT3,	 the	 TFs	 themselves	 had	 never	 been	
associated	with	PKD	before	and	therefore	could	be	interesting	subjects	for	future	studies.	
Surprisingly,	we	did	 not	 find	back	RUNX1	 in	 this	 list	 as	 the	 level	 of	 enrichment	was	 just	
below	the	significance	threshold	(data	not	shown).	Nevertheless,	we	confirmed	increased	
expression	 and	 activity	 of	 RUNX1	 during	 PKD	 progression	 in	 mice	 and	 human	 ADPKD	
kidneys.	Thus,	we	speculate	 that	 the	absence	of	RUNX1,	as	well	as	other	TFs	potentially	
involved	in	PKD,	is	due	to	limitations	related	with	the	ChEA	database,	such	as	the	source	of	
ChIP-data,	the	way	the	different	studies	have	been	analysed	and	the	actual	TFs	included	in	
the	database.
To	 further	 test	 and	 validate	 our	 approach,	we	 selected	 for	 additional	wet-lab	 validation	
STAT3	and	RUNX1	as	they	showed	the	most	significant	change	 in	expression	both	 in	PKD	
progression	and	injury. By	performing	ChIP-qPCR	for	STAT3	and	RUNX1	in	ADPKD-affected	
kidneys,	 we	 confirmed	 increased	 transcriptional	 activity	 in	 cystic	 kidneys	 for	 these	 TFs.	
Persistent	activation	of	STAT3	has	been	described	in	several	mouse	models	for	ADPKD	as	well	
as	in	human	cystic	tissues17,20,36.	STAT3	usually	is	not	active	in	adult	kidneys	but	is	abundantly	
present,	suggesting	that	it	can	be	readily	activated	at	needs,	such	as	after	injury36.	Indeed,	
STAT3	activation	has	been	shown	in	several	different	mouse	models	with	renal	 injury41,42.	
Thus,	the	fact	that	we	found	back	STAT3	and	several	of	its	putative	targets	in	our	signature	
proved	the	reliability	of	our	meta-analysis.
RUNX1	involvement	in	ADPKD	has	never	been	described	before.	RUNX1	is	one	of	the	Runt	
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domain	TFs,	 together	with	RUNX2	and	RUNX3.	RUNX2	expression	has	been	shown	to	be	
regulated	by	PC1	in	osteoblasts,	proving	the	existence	of	an	interaction	between	the	two	
proteins43.	Nevertheless,	expression	of	RUNX2	or	RUNX3	is	not	 increased	after	 injury	nor	
during	disease	progression	in	murine	(cystic)	kidneys	(RNA-Seq	data	identifier	E-MTAB-5319	
published	in	Malas et al., 20175).	In	contrast,	RUNX1	is	expressed	in	the	epithelium	of	several	
organs	during	development,	among	which	the	kidneys44.	It	participates	in	the	regulation	of	
cell	cycle,	cell	proliferation	and	apoptosis45,	and	has	been	described	in	several	models	for	
lung,	muscle	and	brain	injury46-48.	Recently,	a	study	was	published	suggesting	that	RUNX1	is	
an	important	regulator	of	TGF-β-induced	renal	tubular	epithelial-to-mesenchymal	transition	
(EMT)	and	fibrosis49.	As	mentioned	above,	TGF-β	signalling	is	involved	in	ECM	deposition	and	
cyst	progression	and	is	partly	responsible	for	the	EMT	observed	in	cystic	kidneys.	Modulation	
of	TGF-β-related	signalling	is	associated	with	amelioration	of	the	cystic	phenotype21.	Thus,	it	
is	plausible	that	RUNX1	might	play	a	role	in	ADPKD	progression.	In	fact,	inhibition	of	STAT3	
signalling	with	more	or	less	specific	inhibitors,	such	as	curcumin,	pyrimethamine	and	S3I-
201,	 has	 been	 proven	 to	 improve	 the	 cystic	 phenotype	 in	 different	mouse	models17,20,36.	
Similarly,	we	propose	that	targeting	RUNX1,	for	example	using	microRNAs	as	described	for	
prostate	cancer50,	or	other	molecular	or	pharmacological	approaches,	might	also	result	in	
amelioration	of	the	cystic	phenotype.	
We	 observed	 increased	 expression	 of	 STAT3	 and	 RUNX1	 also	 after	 injury	 in	 Wt	 mice,	
suggesting	 that	 these	 TFs	 orchestrate	 injury/repair	 mechanisms	 and	 that	 increased	
expression	is	not	necessarily	related	to	Pkd1	deletion.	Notably,	dissecting	PKD	progression	
and	injury	is	not	easy,	since	injury	can	speed	up	cyst	initiation/growth,	which	in	turn	causes	
injury	to	the	surrounding	tissue.	Therefore,	it	is	plausible	that	both	STAT3	and	RUNX1	are	
facilitating	PKD	progression	by	activating	injury/repair	pathways	normally	 inactive	in	fully	
developed	and	healthy	kidneys.		
To	 conclude,	 our	 comprehensive	 analyses	 identified	 a	 signature	 of	 TFs	 differentially	
expressed	 in	 PKD	 and	 to	 a	 certain	 extent	 also	 in	 injury/repair.	 Several	 of	 these	 TFs	 are	
involved	 in	processes	able	 to	support	cyst	 formation	and	progression,	nevertheless	were	
never	described	before	in	PKD,	suggesting	that	they	might	be	interesting	targets	for	therapy.	
Further	analyses	are	needed	to	identify	the	molecular	pathways	that	these	TFs	modulate	to	
contribute	to	PKD	progression	and	cyst	formation.	Additionally,	the	TFs	we	identified	are	a	
subset	of	the	TFs	involved	in	PKD	and	not	a	comprehensive	list.	This	is	due	to	limitations	in	the	
annotation	databases	we	used	and	RNA-Seq	technology. To	establish	a	comprehensive	list	of	
TFs	involved	in	PKD	and/or	injury,	further	studies	must	be	conducted	on	protein	levels	and	
protein	phosphorylation	status.	That	said,	our	approach	was	capable	of	robustly	identifying	
92	TFs,	and	additional	wet-lab	validations	confirmed	the	involvement	of	RUNX1	and	STAT3	
making	this	paper	a	starting	point	to	understand	the	role	of	TFs	in	PKD	progression.
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Supplementary Figure 1. ADPKD mouse model with kidney injury and PKD progression
Experimental	pipeline	and	data	partly	presented	in	Formica	et al.15 (a)	Experimental	pipeline.	Adult	mice	(around	
14	weeks	old)	were	treated	with	tamoxifen	to	induce	Pkd1	deletion.	One	week	after	gene	inactivation	mice	were	
injected	with	the	nephrotoxic	compound	DCVC	and	sacrificed	at	1,	2,	5,	10	weeks	after	DCVC	and	when	the	mice	
reached	end-stage	renal	disease,	indicated	by	blood	urea	nitrogen	level	(BUN)	over	25mmol/l.	(b) BUN	of	Wt	and	
iKspPkd1del	mice	showing	increased	BUN	at	40h	after	DCVC	injection	(t-test,	P	value	<	0.0001).	BUN	levels	are	back	
to	baseline	at	1	week	after	DCVC	and	remain	at	a	physiological	level	up	to	5	weeks	after	DCVC	injection	(t-test,	not	
significant).	Each	point	is	the	mean	of	6	mice	±	SD.	(c)	Representative	histology	of	Wt	and	iKspPkd1del	mice	before	
and	after	injury.	At	1	week	it	is	possible	to	observe	mild	tubule	dilation	in	both	Wt	and	iKspPkd1del	mice	which	are	
largely	resolved	at	2	weeks.	Scale	bar	50	µm.	(d)	In	Wt	mice	BUN	is	in	a	physiological	range	up	to	24	weeks	after	
DCVC	injection	when	the	mice	were	sacrificed.	The	iKspPkd1del	mice	injected	with	DCVC	(red	solid	line)	reach	end-
stage	renal	disease	earlier	compared	to	PBS	treated	mice	(light-blue	dashed	line).	Median	DCVC	group:	14	weeks;	
median	PBS	group:	19	weeks;	n=6,	Mann-Whitney	 test,	P	value	<	0.05.	 (e)	Representative	histology	of	Wt	and	
iKspPkd1del	kidneys.	At	10	weeks	after	DCVC,	iKspPkd1del	mice	show	tubule	dilation	and	small	cyst	spread	over	the	
kidneys,	which	are	absent	in	the	PBS	treated	group	or	in	the	Wt	mice.	At	kidney	failure,	iKspPkd1del kidneys	show	
evident	cyst	formation	while	the	Wt	kidneys	show	no	aberration	in	both	groups	with	or	without	injury.	Scale	bar	
1	mm.
CHARACTERISATION OF TRANSCRIPTION FACTOR PROFILES IN PKD
151
5
Supplementary Figures
CHAPTER 5
152
Supplementary Figure 2. Overview of pSTAT3 and RUNX1 expression in Wt and iKspPkd1del mice after injury and 
during cyst progression
(a)	Low	magnification	of	Wt	and	 iKspPkd1del	kidneys	at	1	week	after	DCVC	(+	 injury)	or	PBS	(-	 injury).	With	this	
magnification,	 it	 is	possible	to	appreciate	that	the	expression	of	pSTAT3	and	RUNX1	in	non-injured	kidneys	was	
present	mainly	 in	some	interstitial	cells	while	after	 injury	the	expression	was	clearly	visible	 in	the	nuclei	of	the	
epithelial	cells	(brown	nuclei).	In	particular,	tubules	in	the	cortico-medullary	region,	which	are	more	sensitive	to	
the	toxic	insult,	showed	the	most	staining.	(b)	Low	magnification	of	Wt	and	iKspPkd1del	kidneys	at	10	weeks	after	
DCVC	(“10	wks”;	 left	and	middle	panel)	and	at	kidney	failure	 (“KF”;	 right	panel)	when	the	kidneys	are	severely	
cystic.	With	this	magnification,	it	is	visible	that	Wt	and	normal-looking	tissue	in	mutant	mice	(mildly	cystic	kidneys	
at	“10	wks”)	showed	expression	of	pSTAT3	and	RUNX1	mainly	in	some	interstitial	cells	while	cyst-lining	epithelial	
cells,	epithelial	cells	of	surrounding	tubules	and	infiltrating	cells	showed	clear	nuclear	pSTAT3	and	RUNX1	staining.	
Scale	bars	100	µm.
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Supplementary Figure 3. Gene and protein expression of the TFs in cells
(a) Gene	 expression	 of	 Stat3 and Runx1	 in	 mIMCD3	 cells	 (n=3).	 On	 the	 Y-axis,	 we	 show	 the	 TFs	 expression	
normalised	on	the	geometric	mean	of	two	housekeeping	genes,	Ywhaz and Rplp0.	(b)	In	the	middle	panel,	western	
blot	showing	the	protein	expression	of	RUNX1	(about	50	kDa)	and	GAPDH	(about	37	kDa)	in	Jurkat	cells	(used	as	
a	positive	control)	and	two	renal	epithelial	cell	lines,	mIMCD3	and	PTEC.	In	the	right	panel,	quantification	of	the	
Western	blot	normalised	on	GAPDH	expression	is	shown.	Low	but	visible	RUNX1	expression	is	observed	in	both	
renal	epithelial	cell	lines.
Supplementary Figure 4. 
Enrichment of STAT3 and 
RUNX1 at their targets in Wt 
and iKspPkd1del mice treated 
with PBS
ChIP-qPCR	 analysis	 of	 end-
stage	 renal	 disease	 iKspPkd1del 
kidneys	(median	21	weeks	after	
PBS,	 equals	 age	 8	 months)	 or	
Wt	 kidneys	 (24	 weeks	 after	
PBS,	 equals	 age	 9	 months).	 (a) 
We	 confirmed	 an	 increased	
enrichment	 for	 STAT3	 at	 the	
promoter	 region	 of	 their	 target	
genes.	 (b) RUNX1	 enrichment	
at its targets is not detected in 
Wt	samples	but	show	a	trend	in	
iKspPkd1del	 samples.	 The	 Y-axis	
shows	 the	 input-normalised	
binding-enrichment	 of	 the	 TFs	
to	the	indicated	genomic	region.	
Data	 represent	 the	 mean	 of	
two	 independent	 ChIPs	 ±	 SD;	
Two-way	 ANOVA	 with	 Tukey’s	
multiple	 comparisons	 test.	 *	 P	
value	<	0.05;	**	P	value	<	0.01;	
***	P	value	<	0.001
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Supplementary Figure 5. Overview of pSTAT3 and RUNX1 expression in human kidneys with ADPKD
Low	magnification	 of	 healthy	 and	ADPKD	 affected	 human	 kidneys	 showing	 that	 the	 expression	 of	 pSTAT3	 and	
RUNX1	was	present	mainly	in	some	interstitial	cells	while	cyst-lining	epithelial	cells,	epithelial	cells	of	surrounding	
tubules	and	infiltrating	cells	showed	clear	nuclear	pSTAT3	and	RUNX1	staining	(brown	nuclei).	Scale	bars	100	µm.
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Supplementary Tables can be downloaded from
https://link.springer.com/article/10.1007/s00109-019-01852-3#Sec19
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Autosomal	 Dominant	 Polycystic	 Kidney	Disease	 (ADPKD)	 progression	 involves	 a	 complex	
interaction	of	different	molecular	pathways,	ultimately	leading	to	cyst	growth	and	loss	of	
kidney	function.	The	exact	mechanism	behind	cyst	formation	is	still	not	clearly	understood.	
Moreover,	 we	 know	 some	 of	 the	 molecular	 pathways	 involved	 in	 cyst	 initiation	 and	
progression,	but	we	do	not	know	at	which	stage	of	the	disease	they	play	a	role.
In	 this	 thesis,	 we	 investigated	 the	 molecular	 pathways	 involved	 in	 renal	 injury-repair	
mechanisms	and	ADPKD.	According	to	the	currently	available	 literature,	 injury-repair	and	
ADPKD	are	 two	extremely	 intertwined	mechanisms,	which	not	only	are	characterised	by	
activation	of	similar	molecular	pathways	but	are	also	able	to	influence	each	other.	In	fact,	
injury	is	able	to	accelerate	cyst	formation	and	progression,	and	cyst	growth	can	cause	injury	
to	the	surrounding	tissue.	Thus,	the	introduction	of	injury	in	the	context	of	ADPKD	can	help	
to	 characterize	 the	 steps	 of	 disease	 progression,	 particularly	 in	 the	 early	 phases	 of	 cyst	
initiation,	and	direct	future	research	to	new	possible	therapeutic	targets.
In chapter 2,	we	investigated	the	role	of	FJX1	in	PKD	and	injury.	We	showed	that	the	lack	of	
Fjx1 in Pkd1/Fjx1	double	KO	mice	was	able	to	limit	the	effect	of	injury	on	disease	progression.	
Indeed,	double	KO	mice	with	toxic	renal	injury	lived	significantly	longer	compared	to	single	
Pkd1	KO	mice	with	renal	injury.	Analysis	of	the	renal	tissues	revealed	that	differences	in	cyst	
initiation	and	progression	could	not	explain	this.	In	fact,	2	KW/BW	ratios	and	cystic	index	
at	mild	stages	of	disease	were	comparable	in	double	KO	and	Pkd1	KO	mice,	suggesting	that	
Fjx1	does	not	play	a	role	 in	cyst	 initiation	and	progression.	Consistently,	 the	examination	
of	the	two	Fjx1	downstream	pathways,	the	planar	cell	polarity	and	Hippo	pathways,	which	
are	believed	to	be	involved	in	cyst	progression,	did	not	show	significant	changes	in	the	two	
genotypes1-7.
Interestingly,	even	though	cyst	growth	was	comparable,	we	observed	reduced	injury	marker	
expression	and	fibrosis	 in	double	KO	mice	compared	with	Pkd1	KO.	Based	on	the	current	
knowledge,	cyst	growth	and	expansion	cause	compression	of	the	surrounding	tubules	and	
vessels	leading	to	local	injury,	ECM	deposition	and	activation	of	pathways	involved	in	ADPKD	
pathogenesis.	Consequently,	there	is	an	increased	likelihood	of	additional	cyst	formation	and	
accumulation	of	fibrosis,	which	ultimately	result	in	the	organ	function	decline8-12.	However,	
it	was	always	difficult	to	establish	whether	inflammation	and	fibrosis	are	responsible	for,	or	
just	a	consequence	of	cyst	formation.	In	chapter	2,	we	showed	a	separation	between	cyst	
progression	and	fibrosis	in	the	absence	of	Fjx1	expression.	Indeed,	we	confirmed	that	injury	
could	accelerate	cyst	formation	in	Pkd1	mutant	mice,	regardless	of	the	presence	or	absence	
of	 	Fjx1,	 suggesting	that	some	of	 the	pathways	 involved	 in	 response	to	 injury	are	crucial	
in	cyst	formation	and	progression.	At	the	same	time,	we	observed	that	the	inflammatory	
and	 fibrotic	 responses,	which	 follow	 the	 initial	 injury	 event	 and	 the	 chronic	 local	 injury	
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induced	by	 cyst	growth	and	compression,	are	 in	part	dependent	on	Fjx1	 expression	and	
do	not	 influence	 cyst	 formation	 significantly.	However,	 they	did	 impact	 the	 functionality	
of	 the	 cystic	 kidneys	 and	 the	 survival	 of	 the	animal.	Altogether,	 our	 results	 suggest	 that	
Fjx1	 regulates	pathways	related	to	the	fibrotic	response	and	that	these	are	critical	 in	the	
advanced	 stages	of	 the	disease,	more	 than	 in	 cyst	 initiation	and	expansion.	 Such	 results	
are	particularly	 interesting,	 as	 they	demonstrate	how	modulation	of	 the	 injury	 response	
can	help	mitigate	disease	progression	and	might	be	considered	as	a	part	of	a	therapeutic	
approach	in	PKD.		
Among	the	possible	pathways	that	might	be	responsible	for	the	reduced	inflammatory	and	
fibrotic	response	in	double	KO	mice,	TGFβ	and	WNT	pathways	are	particularly	interesting.	
TGFβ	and	WNT	pathways	have	been	extensively	described	for	their	role	in	renal	fibrosis13-16.	
We	found	reduced	expression	of	Tgfb1	and	three	targets	genes	(Pdgfb, Fn1 and Col1a117-19)	
in	double	KO	mice	compared	to	Pkd1	KO.	Similarly,	WNT	targets	Axin2, Cd44, Ccnd1 and Myc 
were	lower	in	double	KO	mice20-24.	Future	investigation	is	needed	to	define	the	mechanistic	
link	between	FJX1	and	the	TGFβ/WNT	pathway.	A	clarification	of	the	underlying	molecular	
mechanism	might	open	the	path	for	future	therapies	not	only	in	the	context	of	ADPKD	but	
also	of	other	chronic	kidney	diseases.
In chapter 3,	we	explored	the	option	of	modulating	one	of	the	FJX1	downstream	pathways,	
the	Hippo	pathway,	to	halt	PKD	progression.	In	particular,	we	decided	to	target	the	pathway	
effector	YAP,	as	we	observed	increased	nuclear	 localization	of	YAP	in	cyst	 lining	epithelial	
cells2.	The	advantage	of	our	approach	lies	in	the	use	of	a	mouse	model	that	develops	cyst	in	
all	the	kidney	segments	recapitulating	the	situation	in	humans	closely.	In	addition,	we	used	
Antisense	Oligonucleotides	(ASO)	as	a	therapeutic	strategy,	which	could	be	reasonably	easily	
translated	into	the	clinic.	Although	we	were	able	to	achieve	a	reduction	of	about	70%	of	Yap 
expression	in	the	kidneys,	we	did	not	see	any	improvement	of	the	cystic	phenotype.	Thus,	
our	 results	 suggest	 that	YAP	does	not	play	a	critical	 role	 in	cystic	proliferation.	However,	
we	could	not	exclude	that	TAZ	might	be	compensating	for	YAP	reduction,	leaving	open	the	
option	that	targeting	both	YAP	and	TAZ	might	be	a	better	approach	to	cyst	growth	inhibition.	
In vitro	experiments	revealed	that	Taz	KO	cells	did	not	show	altered	cyst	formation	and	cyst	
growth	 compared	 to	wild-type	 cells.	 In	 line	with	 our	 in vitro	 findings,	Taz	 deletion	mice	
developed	a	mild	cystic	phenotype,	even	in	the	absence	of	Pkd1	KO6,25.	Moreover,	TAZ	and	
Polycystin	1	(PC1)	can	directly	interact	and	participate	in	common	signalling	routes26.	Hence,	
reduction	or	depletion	of	TAZ	levels	might	worsen	disease	progression.	This	advises	against	
the	possibility	of	targeting	TAZ	in	PKD.
Another	 consideration	 is	 that	 YAP	 and	 TAZ	 have	 mostly	 overlapping	 yet	 also	 unique	
functions27.	 This	 is	 supported	by	 the	partly	distinct	expression	pattern	of	YAP	and	TAZ	 in	
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the	different	segments	of	the	kidneys	and	by	the	impossibility	to	generate	a	Taz	KO	line	in	
mIMCD3	cells,	suggesting	that	YAP	and	TAZ	dynamics	may	differ	in	different	segments	of	the	
nephron.	Nevertheless,	 the	modulation	of	YAP	 levels	might	affect	TAZ	 functions	and	vice 
versa.	Indeed,	it	has	been	reported	that	YAP	inversely	regulates	TAZ	protein	levels,	meaning	
that	reducing	YAP	levels	might	result	in	overactivation	of	TAZ28.	However,	such	dynamics	are	
not	completely	clear	and	should	be	addressed	in	future	research.
To	 complicate	 the	picture	 further,	 YAP	and	TAZ	are	at	 the	 crossroad	of	 several	 signalling	
pathways,	 such	 as	 TGFβ	 and	 WNT	 pathways.	 When	 phosphorylated,	 YAP	 and	 TAZ	 are	
restrained	in	the	cytoplasm	of	the	cell,	where	they	can	interact	with	SMADs	and	β-catenin	
and	 regulate	 their	 localization	 and	 transcriptional	 activity29.	 In	 our	 study,	 we	 observed	
increased	expression	of	some	of	the	downstream	targets	of	TGFβ	and	WNT	pathways	in	Yap 
ASO	treated	mice.	In	detail,	we	observed	a	significant	increase	in	the	expression	of	Myc in 
Yap	ASO	treated	mice,	and	a	similar	trend	for	Axin2,	both	WNT	pathway	targets.	Among	the	
TGFβ	pathway	targets,	we	found	increased	expression	of	alpha-smooth	muscle	actin	(Acta2)	
and	vimentin	(Vim);	we	also	observed	a	consistent	trend	for	collagen	1	alpha-1	(Col1a1),	
fibronectin	 (Fn1),	plasminogen	activator	 inhibitor-1	 (Pai1)	and	matrix	metallopeptidase	2	
(Mmp2).	Therefore,	our	results	show	that	reduction	of	YAP	results	in	increased	activation	
of	 the	WNT	pathway	 target	MYC,	 known	 to	 be	 a	 critical	 player	 in	 PKD30,31,	 and	 of	 some	
of	 the	TGFβ	 targets	 involved	 in	fibrosis,	 a	well-known	biological	process	 involved	 in	PKD	
progression32.	Since	activation	of	TGFβ	and	WNT	pathways	has	been	described	in	PKD33,34, the 
effect	of	YAP/TAZ	modulation	on	these	signalling	routes,	and	how	it	affects	PKD	progression,	
must	be	addressed	before	pursuing	this	line	of	therapy.
An	additional	critical	take-home	message	is	the	importance	to	use	the	right	set-up	in	the	
study	of	new	possible	targets	and	therapeutic	approaches.	For	example,		we	observed	that	
Yap	KO	in	cells	was	able	to	impair	cyst	formation	in	3D	cyst	assays.	This	may	suggest	YAP	as	
a	perfect	candidate	for	PKD	treatment.	However,	characterization	of	the	mutant	cell	lines	
revealed that Yap	 KO	 resulted	 in	 impaired	 expression	 of	 integrins,	 which	 are	 important	
for	 the	 interaction	of	 the	cells	with	 the	ECM	and	 the	correct	establishment	of	 the	cystic	
structures.	 As	 a	 consequence,	 Yap	 KO	 cells	 were	 able	 to	 form	 cysts	 only	 sporadically.	
However,	 the	 sporadic	 cysts	 could	 grow	 normally,	 suggesting	 that	 proliferation	 was	 not	
affected.	Consistently,	in vivo,	we	did	not	observe	any	effect	on	proliferation	after	Yap	ASO	
treatment.	
Although	our	findings	 cannot	exclude	 that	 the	Hippo	pathway	 is	 involved	 in	 cyst	 growth	
(possibly	via	YAP	independent	routes),	we	believe	that	a	therapeutic	intervention	for	PKD	
based	on	the	modulation	of	YAP	levels	might	not	be	feasible.	
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In chapter 4,	we	generated	a	robust	PKD	gene	expression	signature	using	a	combination	of	a	
meta-analysis	of	PKD	expression	profiles	mined	from	the	literature	and	our	newly	generated	
expression	 data.	 This	 approach	 allowed	 us	 to	 overcome	 single	 study	 biases	 related	 to	
experimental	or	technological	variations	and	to	come	up	with	a	list	of	genes	likely	involved	
in	PKD.	Moreover,	based	on	the	assumption	that	PKD	progression	and	renal	 injury-repair	
mechanisms	are	strongly	linked	together1,35-37,	we	characterized	the	overlap	between	injury-
repair	related	genes	and	the	PKD	signature	and	found	35%	overlap.	Even	more,	injury-repair	
genes	 were	 involved	 in	 65%	 of	 the	molecular	 functions	 connected	 to	 PKD	 progression,	
confirming	the	strong	link	between	PKD	and	injury-repair	mechanisms.
From	the	comparison	of	our	signature	with	an	independent	PKD	dataset	obtained	from	Pkd1 
mutant	mice	at	different	stages	of	the	disease38,	we	could	see	significant	enrichment	of	the	
PKD	Signature	genes	 throughout	disease	progression.	 Interestingly,	we	observed	a	major	
contribution	of	the	genes	involved	in	injury-repair	mechanisms	in	the	more	severe	stages	
of	the	PKD.	In	contrast,	the	genes	only	involved	in	PKD	and	not	in	injury-repair	were	more	
enriched	in	the	early	stages.	Therefore,	we	can	zoom	in	on	genes	consistently	dysregulated	
in	PKD,	and,	at	the	same	time,	obtain	insights	into	the	temporal	and	mechanistic	importance	
of	the	different	genes	identified.
Additionally,	 we	 compared	 our	 PKD	 Signature	 with	 a	 study	 focused	 on	 macrophage	
populations	 in	 renal	 injury,	as	macrophages	have	a	 critical	 role	 in	 response	 to	 injury	but	
also	in	PKD	progression39-42.	We	were	able	to	observe	enrichment	for	genes	related	to	the	
different	macrophages	populations	in	the	PKD	Signature,	with	a	larger	contribution	of	injury-
repair	genes	than	of	the	non-injury	ones.	Nevertheless,	we	could	not	discriminate	the	origin	
of	the	expression	between	the	macrophages	and	the	epithelial	cells	as	our	study	used	total	
kidney	lysates	to	generate	the	expression	profile.	In	the	future,	generation	and	integration	
of	datasets	from	single-cell	sequencing	in	cystic	kidneys	might	help	to	clarify	this	point	and	
gain	more	information	about	the	role	of	macrophages	and	other	cell	populations	in	PKD.
With	 this	 study,	 we	 provide	 an	 extensive	 analysis	 of	 expression	 profiles	 in	 PKD	 with	 a	
particular	focus	on	the	effect	of	renal	injury	in	the	progression	of	the	disease.	We	believe	
that	this	work	can	provide	a	proof	of	principle	on	how	to	use	this	knowledge	to	expand	our	
understanding	of	the	PKD	progression	and	discover	attractive	drug	targets	and	molecular	
processes	for	therapy.
In chapter 5,	we	further	explore	the	PKD	Signature	outlined	in	chapter	4.	Mainly,	we	decided	
to	focus	on	the	Transcription	Factors	(TFs)	 in	the	signature.	TFs	control	the	expression	of	
genes	involved	in	a	variety	of	biological	functions,	which	intervene	in	the	establishment	and	
maintenance	of	cell	states,	both	in	physiological	and	pathological	situations.	Dysregulation	
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of	TFs	activity	can	be	at	the	base	of	the	development	of	a	broad	range	of	diseases.	Using	
computational	 approaches,	 we	 interrogated	 the	 signature	 in	 different	 ways.	 First	 of	 all,	
we	 defined	 the	 list	 of	 TFs	 dysregulated	 in	 PKD	 using	MsigDB,	 and	 identified	 those	with	
an	 involvement	 in	 injury-repair.	Several	of	 the	TFs	 identified	were	already	known	 in	PKD,	
proving	 the	 validity	 of	 our	 approach.	 At	 the	 same	 time,	 we	 identified	 many	 other	 TFs	
never	described	 in	PKD	before,	which	might	be	 interesting	candidates	 for	 future	studies.	
Subsequently,	 employing	 the	 ChEA	 2016	 database	 of	 TFs	 targets,	we	 predicted	 TFs	 that	
are	 relevant	 to	PKD	based	on	 the	enrichment	of	 their	 targets	 in	 the	PKD	Signature.	This 
method	allowed	us	to	identify	TFs	that	were	missing	in	the	signature,	maybe	because	their	
expression	 level	 is	 not	 changed	 in	 PKD.	 Nevertheless,	 their	 activity	 is	 likely	 changed,	 as	
the	expression	of	 their	 targets	 is	altered	 in	PKD	progression.	At	 the	same	time,	knowing	
which	TFs	and	their	targets	were	deregulated	in	the	different	stages	of	the	disease,	gave	us	
insight	into	which	molecular	mechanisms	might	be	affected.	Finally,	pathway	analysis	of	the	
identified	TFs	using	Genetrail2	and	Wikipathways	revealed	enrichment	for	pathways	like	the	
TGF-β	pathway,	oxidative	stress,	cellular	metabolism,	 interleukins	signalling,	adipogenesis	
and	estrogen	signalling	and	apoptosis,	which	have	been	shown	to	be	involved	in	PKD43-46.
To	 validate	 our	 approach,	 we	 focused	 on	 two	 TFs	 for	 further	 wet-lab	 experiments.	We	
selected	 STAT3	 and	 RUNX1	 as	 they	 showed	 the	 most	 significant	 change	 in	 expression,	
both	in	PKD	progression	and	injury.	We	confirmed	that	the	expression	of	the	TFs	and	their	
putative	 targets	were	altered	 in	kidneys	 from	Pkd1	KO	mice	compared	 to	Wt.	Moreover,	
we	set-up	and	performed	a	ChIP	assay	and	confirmed	an	increase	in	the	binding	activity	of	
STAT3	and	RUNX1	to	the	promoter	region	of	their	target	genes	in	cystic	kidneys	compared	to	
Wt	kidneys.	Immunohistochemical	analysis	revealed	that	STAT3	and	RUNX1		are	virtually	not	
expressed	in	healthy	kidneys,	both	in	human	and	mice.	However,	their	expression	is	visibly	
increased	 in	 cystic	kidneys	and	after	 renal	 injury,	 confirming	our	 computational	 analysis.	
Increased	expression	of	STAT3	has	been	described	before	in	several	ADPKD	mouse	model,	
in	human	cystic	tissues	and	also	after	renal	injury47-49.	Indeed,	we	were	not	surprised	to	find	
it	back	in	our	analysis,	and	we	consider	it	a	proof	of	our	approach	reliability.	Additionally,	
previous	in vitro	evidence	suggested	that	STAT3	might	be	directly	activated	by	cleaved	PC1,	
although	the	exact	mechanism	linking	Pkd1	deletion	and	STAT3	activation	in	cystic	tubules	
was	still	elusive49,50.	A	recent	study	in	Pkd1	KO	mice	demonstrated	that	STAT3	activation	occurs	
after	macrophage	 recruitment	 by	 secretion	 of	 CCL2	 early	 after	 gene	 deletion.	 However,	
they	observed	that	tubular	STAT3	was	only	partially	responsible	 for	cyst	growth,	but	was	
central	in	the	establishment	of	a	feedback	loop	that	limits	immune	cells	infiltration	in	cystic	
kidneys51.	The	results	provided	in	this	work	denote	that	a	clear	mechanistic	evaluation	of	
interesting	targets	is	paramount	in	the	development	of	targeted	therapies	in	ADPKD.	RUNX1	
involvement	in	ADPKD	has	never	been	described	before.	Recently,	RUNX1	was	proposed	as	
a	regulator	of	TGF-β-induced	renal	tubular	EMT	and	fibrosis52.	TGF-β	signalling	is	involved	
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in	ECM	deposition	and	cyst	progression43,	making	 it	plausible	for	RUNX1	to	play	a	role	 in	
ADPKD.	Still,	we	need	to	obtain	more	 insight	 into	the	molecular	mechanisms	behind	the	
involvement	of	RUNX1	in	PKD	before	being	able	to	select	it	as	a	therapeutic	target.
With	this	work,	we	further	dug	into	the	PKD	Signature	and	showed	how	this	could	be	used	
to	 better	 understand	 the	 role	 of	 TFs	 in	 different	 steps	 of	 disease.	 Further	 analyses	 are	
needed	to	clarify	the	molecular	mechanisms	behind	the	contribution	of	these	TFs	to	PKD	
progression	and	cyst	formation.
Concluding remarks 
To	this	day,	the	scientific	literature	reports	a	variety	of	dysregulated	molecular	mechanisms	
in	ADPKD	progression.	However,	a	clear	hierarchical	overview	of	these	events	is	still	missing,	
thus	making	it	difficult	to	separate	the	early	effects	of	PKD	gene	disruption	on	cyst	initiation,	
from	the	secondary	effects	of	disease	progression	and	cyst	expansion.	Moreover,	we	need	
to	keep	in	mind	that	different	regions	of	the	kidney	might	be	experiencing	different	steps	of	
progression	at	any	time.	Inevitably,	we	need	to	deepen	our	knowledge	of	the	steps	of	disease	
progression	and	the	molecular	mechanisms	behind	them.	Our	functional	annotation	of	the	
genes	in	the	PKD	signature	allowed	us	to	identify	biological	targets	that	are	most	relevant	in	
the	different	phases	of	the	disease,	from	the	initial	moderate	phase	to	the	more	advanced	
and	severe	one.	The	knowledge	we	generated	is	just	a	starting	point	for	future	studies	that	
need	to	evaluate	in	detail	the	actual	significance	of	the	identified	mechanisms	in	PKD.
We	know	that	by	inducing	injury	and	the	subsequent	repair	phase,	we	can	accelerate	cyst	
initiation	 and	 growth.	However,	 I	 believe	 that	 injury-repair	must	 be	 considered	more	 as	
a	means	to	understand	the	 initial	phases	of	cystogenesis	more	than	a	possible	target	for	
therapy.	 Indeed,	even	 though	 injury-repair	mechanisms	are	 involved	 in	PKD	progression,	
some	 of	 the	 biological	 functions	 they	 control	 are	 actually	 employed	 to	 cope	 with	 the	
alterations	taking	place	during	disease	progression.	
In	my	opinion,	particular	attention	should	be	given	to	the	elucidation	of	 the	early	stages	
of	cyst	 formation.	However,	 this	 is	not	an	easy	 task.	At	 this	 stage,	 the	renal	tissue	 is	 still	
mostly	unaffected.	As	a	consequence,	the	major	input	to	all	kind	of	-omics	data	analysis	is	
coming	from	the	healthy	tissue,	while	the	signal	coming	from	the	diseased	tissue	is	lost	in	
the	noise.	Thus,	to	gather	information	about	these	early	stages,	we	need	to	employ	different	
models	and	more	sensitive	methodologies.	For	example,	organoids	(3D	cyst	assay	and	renal	
organoid)	might	offer	a	simplified	framework	to	study	the	early	events	that	occur	after	Pkd1/2 
inactivation.	 However,	 a	 significant	 limitation	 of	 these	 systems	 is	 that	 they	 cannot	 take	
CHAPTER 6
164
into	account	the	contribution	of	infiltrating	cells,	nor	that	of	the	fluid	flow,	both	extremely	
important	 in	 PKD.	 The	 implementation	of	 spatial	 transcriptomics	methods	 gives	 another	
possibility.	Single-cell	RNA	sequencing	is	a	powerful	technique	that	can	be	employed	to	get	
insight	into	the	contribution	of	the	different	cell	types	in	the	kidneys.	However,	since	cells	
need	to	be	dissociated	to	perform	this	technique,	the	information	relative	to	the	positions	
and	interactions	of	the	different	cells	is	lost.	A	possible	way	to	overcome	this	is	the	use	of	a	
newly	developed	technique	called	Slide-seq53.	With	Slide-seq,	the	RNA	can	be	transferred	
from	a	tissue	section	to	a	support	covered	in	barcoded	beads	allowing	to	generate	a	spatially	
resolved	gene	expression	profile.	This	kind	of	approach	might	be	extremely	useful	 in	the	
quest	to	understand	the	molecular	mechanism	of	ADPKD	progression.
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A
Nederlandse samenvatting
Autosomaal	 dominant	 overervende	 cystenieren,	 in	 het	 Engels	 Autosomal	 Dominant	
Polycystic	Kidney	Disease	(ADPKD),	is	een	systemische	ziekte	die	meestal	wordt	veroorzaakt	
door	een	mutatie	 in	het	PKD1	 of	PKD2	 gen.	Deze	genen	coderen	 respectievelijk	 voor	de	
eiwitten	Polycystine	1	(PC1)	en	Polycystine	2	(PC2).	Het	belangrijkste	kenmerk	van	ADPKD	
is	het	ontstaan	van	met	vocht	gevulde	cysten	in	de	nieren,	welke	de	normale	nierstructuur	
en	nierfunctie	aantasten,	wat	uiteindelijk	leidt	tot	nierfalen.	ADPKD	heeft	ook	enkele	extra-
renale	 ziektemanifestaties,	 zoals	 cystevorming	 in	 de	 lever	 en	 alvleesklier,	 en	 vasculaire	
afwijkingen.	Momenteel	 is	 er	 geen	medicijn	 dat	 ADPKD	 kan	 genezen,	 en	 daarom	 is	 het	
van	 groot	 belang	 om	 beter	 inzicht	 te	 krijgen	 in	 de	mechanismen	 die	 betrokken	 zijn	 bij	
cystevorming,	cystegroei	en	ziekteprogressie.
In	 patiënten	met	ADPKD	nemen	de	 cysten	 gedurende	het	 leven	 toe,	 zowel	 in	 aantal	 als	
in	grootte.	De	cellen	die	de	cystewand	bekleden	delen	actief,	en	scheiden	vloeistof	uit	 in	
het	 lumen	van	de	cyste,	wat	bijdraagt	aan	de	groei.	Cystegroei	en	expansie	veroorzaken	
mechanische	 stress	 in	 het	 omliggende	 weefsel.	 Dit	 gaat	 gepaard	 met	 de	 secretie	 van	
cytokines	 en	 groeifactoren,	 welke	 infiltrerende	 cellen	 aantrekken.	 Deze	 zorgen	 weer	
voor	 lokale	 schade	en	fibrose.	 Constante	proliferatie,	 ontsteking	 en	fibrose	 verstoren	de	
nierarchitectuur,	wat	uiteindelijk	leidt	tot	nierfalen.	Opvallend	is	dat	proliferatie,	ontsteking	
en	fibrose	ook	vaak	worden	waargenomen	na	acute	nierschade.	In	een	gezonde	nier	zorgt	
de	activatie	van	deze	mechanismen	voor	herstel	van	het	weefsel,	maar	 in	patiënten	met	
ADPKD	zorgt	de	activatie	van	deze	mechanismen	juist	voor	het	verergeren	van	de	ziekte.
In	de	literatuur	wordt	het	sterke	verband	tussen	de	schade-herstel	mechanismen	en	ADPKD	
progressie	 beschreven.	 Op	 basis	 van	 deze	 aanname	 is	 het	 doel	 van	 dit	 proefschrift	 om	
de	moleculaire	mechanismen	 betrokken	 bij	 zowel	 schade-herstel	 van	 de	 nier	 als	 ADPKD	
progressie	te	bestuderen,	om	zo	de	ontwikkeling	van	de	ziekte	beter	te	begrijpen	en	nieuwe	
inzichten	voor	toekomstige	studies	en	therapeutische	behandelingen	te	krijgen.
In hoofdstuk 1	 geven	 we	 een	 uitgebreide	 beschrijving	 van	 de	 huidige	 kennis	 over	 de	
moleculaire	mechanismen	betrokken	bij	nierschade-herstel	en	ADPKD	progressie.
In hoofdstuk 2	onderzoeken	we	de	rol	van	Four-jointed	box	protein	1	(FJX1)	in	nierschade	
en	ADPKD	progressie.	FJX1	is	een	eiwit	dat	betrokken	is	bij	de	regulatie	van	twee	belangrijke	
pathways	die	ontregeld	zijn	 in	ADPKD:	planar	cell	polarity	(PCP),	die	de	oriëntatie	van	de	
epitheelcellen	 controleert	 en	 Hippo	 signalering,	 die	 orgaangrootte	 controleert.	 In	 een	
eerdere	 studie,	 gedaan	 door	 onze	 groep,	 kwam	 FJX1	 afwijkend	 tot	 expressie	 gedurende	
zowel	de	nierschade-herstelfase	en	PKD	progressie	in	muizen,	wat	een	mogelijke	rol	voor	
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FJX1	 in	 cystevorming/groei	 en	 ziekteprogressie	 suggereert.	 Voor	 deze	 studie	 hebben	we	
Pkd1	knock-out	(KO)	muizen	(een	muismodel	voor	ADPKD)	gebruikt	om	te	onderzoeken	of	
het	uitschakelen	van	Fjx1	de	activiteit	van	de	PCP	of	de	Hippo	pathway	kon	beïnvloeden.	
Ook	hebben	we	onderzocht	of	dit	een	effect	had	op	ziekteprogressie,	mét	en	zonder	extra	
nierschade.	We	konden	geen	bewijs	vinden	voor	een	veranderde	regulatie	van	de	PCP	of	
de	Hippo	pathway.	 Echter,	we	 zagen	wel	 een	beschermend	effect	 van	Fjx1	 uitschakeling	
op	fibrose	en	de	 infiltratie	van	 immuuncellen.	Dit	zorgde	ervoor	dat	de	muizen	 langer	 in	
leven	bleven,	wat	suggereert	dat	de	modulatie	van	de	fibrotische	respons	kan	helpen	in	het	
controleren	van	de	ziekteprogressie.
In hoofdstuk 3	 doen	 we	 verder	 onderzoek	 naar	 de	 rol	 van	 de	 Hippo	 pathway	 in	 PKD	
progressie.	 De	 Hippo	 pathway	 is	 een	 sterk	 geconserveerde	 signaaloverdrachtsroute	 die	
orgaangrootte	reguleert.	Meerdere	moleculaire	mechanismen	die	door	de	Hippo	pathway	
worden	 gecontroleerd,	 zijn	 ook	belangrijk	 in	 cystegroei.	 In	 een	eerdere	 studie	 zagen	we	
inderdaad	een	verhoogde	expressie	van	één	van	de	downstream	effectormoleculen	van	de	
Hippo	pathway,	het	eiwit	YAP,	 in	de	kern	van	het	cyste-epitheel.	Daarom	veronderstellen	
we	in	hoofdstuk	3	dat	het	verlagen	van	de	hoeveelheid	YAP	in	Pkd1	KO	muizen,	mogelijk	
het	cysteuze	fenotype	kan	verbeteren.	We	besloten	een	strategie	te	volgen	gebaseerd	op	
antisense	 oligonucleotiden	 (ASO),	 waarmee	we	 specifiek	 de	 hoeveelheid	 YAP	 significant	
konden	verlagen	 in	de	nieren.	We	zagen	geen	effect	op	de	ziekteprogressie,	maar	 zagen	
wel	dat	het	vergelijkbare	eiwit	TAZ	sterk	ophoopt	 in	de	celkernen	van	nierepitheelcellen.	
Dit	 suggereert	dat	TAZ	het	verlies	van	YAP	kan	compenseren.	We	hebben	ook	het	effect	
van	het	uitschakelen	van	Yap of	Taz	op	cystevorming/groei	onderzocht	 in	3-dimensionale	
celkweken.	We	zagen	dat	het	uitschakelen	van	Yap		leidt	tot	een	verstoorde	organisatie	van	
de	cellen,	waardoor	de	cellen	geen	cysten	met	een	lumen	vormden,	maar	groeiden	als	een	
soort	tumor.	De	cellen	waarin	Taz	was	uitgeschakeld	lieten	daarentegen	geen	verstoringen	
zien.	Alles	bij	elkaar	genomen	concluderen	we	op	basis	van	onze	data	dat	het	moduleren	
van	YAP	geen	geschikte	benadering	is	om	ADPKD	te	behandelen.
In hoofdstuk 4	hebben	we	de	analyse	van	genexpressie	(RNAseq	analyse)	in	ons	diermodel	
voor	 ADPKD,	 gecombineerd	met	 genexpressieprofielen	 die	 openbaar	 beschikbaar	 zijn	 in	
de	literatuur,	om	zo	een	lijst	van	genen	te	identificeren	die	ontregeld	zijn	in	PKD	(de	‘PKD	
Signature’).	 Bovendien	 hebben	 we	 de	 link	 tussen	 PKD	 progressie	 en	 nierschade-herstel	
mechanismen	 onderzocht	 door	 de	 ‘PKD	 Signature’	 te	 vergelijken	met	 nierschade-herstel	
genexpressieprofielen.	 Tenslotte	hebben	we	 verschillende	ADPKD	muismodellen,	met	 en	
zonder	toxische	nierschade,	gebruikt	om	onze	bevindingen	te	valideren.
In hoofdstuk 5	bouwen	we	voort	op	het	werk	in	hoofdstuk	4.	We	concentreren	ons	op	de	
transcriptiefactoren	(TFs)	die	veranderd	zijn	in	zowel	PKD	progressie	als	nierschade-herstel.	
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TFs	zijn	eiwitten	die	de	transcriptie	van	genen	controleren,	en	dus	hun	expressie	reguleren.	
Na	het	selecteren	van	een	aantal	veelbelovende	TFs	door	middel	van	computeranalyses,	
hebben	we	 onze	 selectie	 gevalideerd	met	 laboratoriumexperimenten.	Met	 verschillende	
technieken	 hebben	we	 aangetoond	 dat	 twee	 TFs	 (STAT3	 en	RUNX1)	 actiever	 zijn	 tijdens	
nierschade	én	in	cystenieren,	vergeleken	met	normale	nieren,	in	zowel	muizen	als	patiënten.	
Ook	 hebben	we	 laten	 zien	 dat	 de	 expressie	 van	 een	 aantal	 voorspelde	 targetgenen	 van	
deze	TFs	verhoogd	is	na	nierschade	én	in	cystenieren,	wat	nogmaals	laat	zien	dat	de	twee	
gevonden	TFs	actiever	zijn	tijdens	nierschade	en	in	cystenieren.	
Tenslotte	worden	in	hoofdstuk 6	een	algemeen	overzicht	van	de	resultaten,	zoals	beschreven	
in	de	vorige	hoofdstukken,	en	suggesties	voor	verder	onderzoek	besproken.
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